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ABSTRACT 
Melatonin as a novel cardioprotective therapy in pulmonary hypertension 
Introduction: 
Pulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure which leads to 
right ventricular hypertrophy and failure. The mechanism involved in the pathophysiology of the 
disease remains unclear but it is suggested that oxidative stress may trigger cardiovascular dysfunction 
associated with the disease. To date, there is no efficient therapy against PH and novel therapies are 
urgently needed. Melatonin is a powerful antioxidant that can confer benefit against ischemia-
reperfusion injury and hypertension. We therefore hypothesised that melatonin may confer 
cardiovascular benefits against PH.  
Methods: 
Oxidative stress (plasma lipid peroxidation, antioxidant capacity and antioxidant enzyme activity) was 
assessed in healthy (n=10), in patients with PH (n=10), in Long Evans rats (n≥6) or in a rat model of PH 
induced 28 days after the injection of monocrotaline (MCT, 80mg/kg, subcutaneous) (n≥6). Melatonin 
(75ng/L, nutritional concentration), 4mg/kg or 6mg/kg (therapeutic dose) was given daily in the 
drinking water of rats, with the treatment started 5 days before the injection of MCT, on the day of 
the injection or 14 days after the injection of MCT. The development of PH was measured by assessing 
right ventricular hypertrophy, cardiac fibrosis, oxidative stress and cardiac function (via 
echocardiography and the isolated heart Langendorff perfusion model). 
Results: 
Plasma oxidative stress was increased in both patients and rats with PH compared with their 
respective controls. A chronic treatment with melatonin (75ng/L, 4mg/kg or 6mg/kg) starting on the 
day of the injection with MCT in rats with PH reduced right ventricular hypertrophy, cardiac 
dysfunction and plasma oxidative stress compared with control rats. Furthermore, the beneficial 
effect of melatonin (6mg/kg) could be observed when given as a preventive (5 days prior to the 
injection of MCT) or as a curative therapy (14 days after the injection of MCT). 
Conclusions: 
Our data demonstrate that chronic treatment of melatonin confers cardioprotection in a rat model of 
PH. As melatonin is inexpensive, safe (no reported side effects) and already available over the counter 
in many countries, we propose that melatonin should be considered as a novel preventive/curative 
therapy to limit cardiac dysfunction in patients with PH.
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SECTION A 
 
INTRODUCTION 
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1. The global burden of cardiovascular disease 
Noncommunicable diseases, including cardiovascular disease, are the leading cause of global 
mortality, accounting for more deaths annually than all other causes combined 1,2. In 2008, 
noncommunicable diseases were responsible for approximately 36 million deaths (63%) 2. 
Among these, cardiovascular disease, including heart attacks and strokes, were responsible 
for 17.3 million deaths, contributing to nearly a half of noncommunicable disease-related 
deaths 2. Furthermore, it is projected that the annual number of deaths due to cardiovascular 
disease will increase from 17 million in 2008 to 25 million in 2030 3. Despite major 
pharmaceutical developments, the largest proportion of noncommunicable disease-related 
deaths is still due to cardiovascular disease (48%), followed by cancers (21%), chronic 
respiratory diseases (12%), other noncommunicable disease (7.75%), digestive disorders 
(7.75%) and diabetes (3.5%) (Figure 1). Thus, the global burden of cardiovascular disease 
paints a grim picture and generates great concern for the public health sector. The 
prevention and management of cardiovascular disease is complicated by its divergent 
aetiologies including hypertension, atherosclerosis, obesity, and congenital defects, and in 
particular, pulmonary hypertension which is the main focus of this research study. 
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2. Pulmonary hypertension 
Though often referred to as a disease, pulmonary hypertension (PH) is more accurately 
described as a pathophysiological parameter defined by certain haemodynamic 
measurements, including pulmonary arterial systolic pressure ≥ 35 mmHg, mean pulmonary 
arterial pressure (mPAP) ≥ 25 mmHg at rest, pulmonary capillary wedge pressure ≤ 15 mmHg 
and a pulmonary vascular resistance (PVR) ≥ 3 woods units 4,5. PH is classified into various 
groups depending on the aetiology: group 1 (pulmonary arterial hypertension), group 2 (PH 
with left heart disease), group 3 (PH due to lung diseases/hypoxia), group 4 (Chronic 
thromboembolic PH) and group 5 (PH with indistinct, multifactorial mechanisms) 5. Due to 
the wide diversity of aetiologies with PH, the haemodynamic measurements which are used 
to make a diagnosis, are also diverse and dependent on which group of PH is present in a 
patient. PH develops due to endothelial damage and consequent pathological remodelling of 
the pulmonary vasculature, resulting in the narrowing of vessels in the lung. This causes 
increased blood pressure in the pulmonary vasculature, which is normally a low pressure 
system. Consequently, the right ventricular (RV) afterload increases and induces 
hypertrophic remodelling of the RV 6-8. PH is a heterogeneous disorder due to its aetiology, 
gender differences (in response to treatment) and variations in mortality/survival rates 8-12. 
Furthermore, it is associated with infectious diseases such as human immune virus/acquired 
immune deficiency syndrome (HIV/AIDS), schistosomiasis, and viral hepatitis, as well as 
chronic noncommunicable conditions including sickle cell disease, systemic sclerosis, 
congenital heart disease and chronic obstructive pulmonary disease (COPD) 6. 
 
2.1. Prevalence of pulmonary hypertension 
Currently, the prevalence of PH in general, remains elusive due to a lack in large 
epidemiological studies with appropriate diagnostic methods 13. Many studies that reported 
on the prevalence of PH, in any given patient population, based PH diagnosis on suboptimal 
measurements during echocardiography, such as tricuspid valve regurgitant jet velocity 
determined with Doppler echocardiography 5,14. MPAP is one of the main parameters used 
to diagnose PH and this is calculated from the tricuspid regurgitant velocity by the 
echocardiographer 14,15. An insufficient Doppler or tricuspid regurgitation jet is could be 
measured, which can results in an underestimated mPAP measurement 14,15. This may yield 
misleading results, usually with an underestimation of the prevalence of PH. Nevertheless, 
this can be addressed by confirming echocardiographic diagnosis with right heart 
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catheterization which is considered to be the “gold standard” for the diagnosis of PH 16. One 
should therefore be cautious when interpreting studies that investigate the prevalence of PH 
solely in one patient population, as this prevalence is likely to be true for that particular 
population but may not necessarily be extrapolated to other patient populations. From the 
literature, it is clear that there are no statistics for the overall prevalence of PH, either in a 
specific country or globally. In many publications, the prevalence of PH is often recorded for 
a specific patient population who have PH associated with diseases such as HIV/AIDS, 
congenital heart disease or COPD. 
 
Prevalence of pulmonary hypertension in human immune virus/acquired immune deficiency 
syndrome 
HIV/AIDS is an independent risk factor for PH, and in 2012 it was estimated that 35.3 million 
people were infected with HIV, with 70% of new HIV infections occurring in Sub-Saharan 
Africa 17. Furthermore, within this time period, the incidence of PH in HIV infected individuals 
was estimated to be approximately a thousand times higher than in the general population 
17. In 80% of cases, where PH is associated with HIV, the prevalence is 0.5% in patients with 
plexiform lesions 18. Nevertheless, the prevalence of PH in HIV infected individuals in African 
countries has been estimated to be 0.6% to 5% 19,20. However, considering the depressingly 
large percentage of HIV infected individuals and the impact of suboptimal diagnostic 
methods, the prevalence is likely to be much higher. 
 
Prevalence of pulmonary hypertension in congenital heart disease 
It has been estimated that worldwide approximately 600 000 babies are born annually with 
congenital heart disease and 50% or more will die of infection and heart failure during 
infantile development 21. Globally, three million children are at risk for the development of 
pulmonary vascular disease due to congenital heart disease 21. On the other hand, the adult 
congenital heart disease patient population is increasing and requires lifelong tertiary 
medical care, with approximately five to ten percent developing PH 22. In a retrospective 
longitudinal cohort study conducted by Lowe and colleagues, an adult patient population 
with congenital heart disease, was investigated from 1983 to 2005 23. A total of 38,430 adults 
(living with congenital heart disease in 2005) were included in the study and 2,212 were 
diagnosed with PH. This study calculated the prevalence of PH as 58 in a 1000 patients with 
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congenital heart disease 23. However, this prevalence is likely to differ for various countries 
and patient populations.  
 
Prevalence of pulmonary hypertension in chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality 
worldwide with PH considered as a major complication 24. The prevalence of PH in COPD is 
unknown due to a lack of large epidemiological studies 13. However, depending on which 
studies one looks at, most studies estimate the prevalence of PH in COPD to be approximately 
30% to 70% 13. In a study by Scharf et al, they evaluated 120 patients with severe COPD and 
defined PH as an mPAP > 20mmHg 25. These authors determined that 90.8% of patients had 
PH 25.  
The PH registry in France shows that the prevalence of PH from 2002 to 2003, was 15 cases 
per million and it varied among regions in France, from 5 to 25 per million 26. In South Africa, 
a clinical registry, the Heart of Soweto cohort study, was created to capture data from 5328 
de novo presentations of heart disease at the Cardiology Unit, Chris Hani Baragwanath 
Hospital in Soweto 27,28. There were more females than males in the study (379 versus 318), 
while more men presented with RV failure. The study was conducted from 2000 to 2008. 
There was a total of 2505 cases of heart failure (47% of total cohort) while 697 (28%) were 
diagnosed with RV failure. Possible pathways which could have caused the RV failure in these 
patients included chronic lung disease (26%) and PH (20%). Furthermore, women were 
almost two times more likely to present with PH and those with low levels of education and 
originating from Soweto were less likely to present with PH, compared with the rest of the 
cohort 27,28. The Heart of Soweto cohort study is a very unique study as it showed that PH in 
African communities is not such a rare disease as once thought. 
All these studies have shown the heterogeneous nature of PH and how this, together with 
insufficient diagnostic methods, can influence the estimated prevalence. Therefore, whether 
or not PH is truly as rare as once thought is unclear as not enough is known about the 
underlying pathophysiology and PH continues to be a fatal disorder which affects patients 
globally.  
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2.2. Pathophysiology of pulmonary hypertension 
It was previously thought that the development of PH was solely due to an imbalance of 
vasodilator and vasoconstrictor substances/responses which led to the pulmonary vascular 
remodelling observed in PH 29-31. However, this has been proved incorrect and we now know 
that with PH there are certain molecules (hypoxia, sheer stress and toxins) that trigger and 
initiate endothelial injury which leads to (i) increased/disorganized proliferation of 
endothelial cells and increased endothelial cells apoptosis, (ii) increased proliferation of 
pulmonary arterial smooth muscle cells (PASMC’s) and resistance of PASMC’s to apoptosis 
29,30.  
These proliferated cell masses, are better described as thickening of the muscle layers 
(intima, media and adventitia) of small pulmonary arteries, as well as intimal fibrosis, in situ 
thrombosis and plexogenic arteriopathy (plexiform lesions), as seen in severe forms of PH 
18,30,32,33. All of these proliferative processes embody the pathological remodelling of the 
pulmonary vasculature, evident by narrowing and obliteration of the vascular lumen (Figure 
2). 
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The pulmonary vascular remodelling in PH is exacerbated by biologically active inflammatory 
cytokines, growth factors, elastases and vasoconstrictors, such as thromboxane-A2, 
endothelin-1 and serotonin 18,30,33. Other contributing factors to this remodelling process 
include activated endothelial cell-colony forming cells, reduced circulation of vasodilators 
(such as prostacyclin, nitric oxide and vascular endothelial peptide) and bone morphogenetic 
protein receptor-2 (BMPR-2) mutations 30, 34, 45, 49, 50, 57 (Figure 3). 
 
 
 
Inflammatory cytokines in pulmonary vascular remodelling 
Inflammation has been defined as a complex series of interactions among soluble factors and 
cells that can arise in response to trauma, infection, ischemia, toxicity or autoimmune injury 
18. With PH, there is histological evidence of both innate and adaptive immunity involvement 
in the pulmonary vasculature and heart, as indicated by infiltration of mononuclear cells, B 
& T-cells, macrophages, dendritic cells, mast cells, cytokines and chemokines (such as 
interleukin-1β, interleukin-6, monocyte chemo attractantprotein-1 and chemokine ligand) 18. 
This may be evidence, that inflammation plays an integral role in the development of PH and 
RV remodelling. However, the exact mechanism of how inflammation contributes to the 
pathogenesis of PH is currently unknown 18,34 . 
Growth factors and elastases in pulmonary vascular remodelling 
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The balance of proteases and anti-proteases regulates the constant turnover of the cellular 
matrix and the availability of growth factors, including platelet- derived growth factor, 
epidermal growth factor, vascular endothelial growth factor and fibroblast growth factor 29,34. 
Various studies ascribed the changes in pulmonary vascular wall construction, to alterations 
in the circulating and tissue levels of growth factors and extracellular matrix molecules which 
control migration, proliferation and differentiation of endothelial cells, PASMC’s and 
fibroblasts, as well as regulate vascular branching morphogenesis 34. Furthermore, increased 
levels of platelet- derived growth factor have been found in blood and lung tissue samples of 
PH patients 35. It is known that, platelet- derived growth factor induces the Akt-mammalian 
target of rapamycin (Akt/mTOR) signalling pathway in order to bring about PASMC 
proliferation and pulmonary vascular remodelling ,36. 
On the other hand, elastase activity is increased in the isolated pulmonary arteries from the 
monocrotaline (MCT) and chronic hypoxia rat models of PH 37-39. It is an enzyme that degrades 
elastin and proteoglycans which serve as storage sites for growth factors such as fibroblast 
growth factor-2 and transforming growth factor-beta (TGF-β) 40,41. The sequence of events 
which precedes increased elastase activity is believed to be as follows: toxin and disease 
compromising the endothelial barrier and serum factors (such as apolipoprotein-A1) 
accumulation in the sub-endothelium 40,41. This sequence of events induces the expression of 
endogenous vascular elastase in vascular smooth muscle cells by binding to elastin on the 
PASMC surface 40,41. Elastin binds to elastin binding protein and increases the activity of 
elastase, which is also associated with activity of mitogen-activated protein kinase and focal 
adhesion kinase 40,41. This augmented elastase activity has been linked to the induction of 
PASMC proliferation via association with the glycoprotein, tenascin 40,41. The importance of 
elastase has been proven by the experimental model of elastase-induced pulmonary 
emphysema and its ability to attenuate cigarette smoke-induced remodelling of lung vessels 
in guinea pigs 42,43. It is therefore clear, that growth factors and elastase play a key role in 
pulmonary vascular remodelling observed in PH.  
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Vasoconstrictors: Thromboxane-A2, endothelin-1 and serotonin in pulmonary vascular 
remodelling 
Thromboxane-A2 is generated by thromboxane-synthase, stimulates vasoconstriction and 
platelet aggregation 44. Thromboxane-A2 levels are increased in lung tissue of PH patients 45. 
Endothelin-1 is elevated in circulation and lung tissue of patients with PH associated with 
chronic thromboembolic disease and COPD 46-48. It is a well-known endothelium derived 
vasoconstrictor peptide that stimulates PASMC proliferation and vasoconstriction upon 
activation of its receptors 30,33,44. In the MCT and chronic hypoxia rat models of PH, circulating 
levels of endothelin-1 have also been shown to be increased 30,33. Lastly, serotonin, also 
known as 5-hydrotryptamine, is reportedly reduced in platelets and plasma of patients with 
PH 30. It is a vasoconstrictor that promotes PASMC hyperplasia and hypertrophy 30. 
Collectively, this suggests that increased levels of these vasoconstrictors may contribute to 
pulmonary vascular remodelling in PH. 
 
Activation of endothelial cell-colony forming cells in pulmonary vascular remodelling 
Endothelial cells are normally quiescent, but injury, inflammation and hypoxia can initiate 
angiogenesis via mobilization of pro-angiogenic cells from the bone marrow and proliferation 
of local endothelial cells 49. These pro-angiogenic cells are myeloid in origin, found in the 
pulmonary vessel wall and known as endothelial cell-colony forming cells 49. They reside 
among pulmonary artery endothelial cells and possibly contribute to angiogenesis via cell 
proliferation, but it is unclear whether they are unipotent or multipotent stem cells or fully 
undifferentiated with high proliferative potential 49. More research is required to elucidate 
their exact function in PH as this may be instrumental in delineating our understanding of the 
disease pathogenesis. Nevertheless, these cells may be a contributing factor in the 
development of pulmonary vascular remodelling in PH.  
 
Reduced production of vasodilators: Prostacyclin, nitric oxide and vascular intestinal peptide 
in pulmonary vascular remodelling 
Prostacyclin is generated by prostaglandin-I-2 synthase which is expressed in pulmonary 
vascular endothelium, where it relaxes smooth muscle and inhibits platelet aggregation 44. In 
patients with PH, there is a decrease in prostacyclin levels and the production of prostacyclin-
I2 synthase in the small- and medium- sized pulmonary arteries 45. On the other hand, nitric 
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oxide is produced by endothelial nitric oxide synthase, is a vasodilator and an inhibitor of 
platelet activation and PASMC proliferation 30,50,51. With vascular endothelial injury, nitric 
oxide synthase produces nitric oxide via the activation of soluble-guanalate-cyclase 51. 
Subsequently, guanosine-triphosphate is converted to cyclic-guanosine-monophosphate 
which acts as a second messenger and induces smooth muscle relaxation or vasodilatation 
51.  
In the pulmonary vasculature of PH patients, endothelial nitric oxide synthase expression has 
been shown to be decreased 52. However, its expression is increased in plexiform lesions 
where it is thought to promote pulmonary vascular endothelial cell proliferation 30,34,52. 
Impaired nitric oxide synthesis and vasodilatation have been observed in an animal model of 
chronic hypoxia-induced PH and this was associated with impaired cyclic-guanosine 
monophosphate dependent mechanisms 34. Vascular intestinal peptide is a neuropeptide 
that act as a vasodilator and has the ability to reduce mPAP and pulmonary vascular 
resistance 53. Patients with PH have decreased serum levels of vascular intestinal peptide 
which is thought to also influence remodelling 54-56. Thus, it is evident that an imbalance 
between vasoconstrictor/vasodilator responses has merit as a contributing factor to the 
development of PH. This gives more value to the current understanding that vascular 
remodelling in PH is most probably due a combination of factors and pathological pathways. 
 
Mutations in the gene encoding for bone morphogenetic protein receptor-2 in pulmonary 
vascular remodelling 
PH also occurs in a rare idiopathic form with a prevalence of 90% for sporadic PH and 10% 
for familial PH 34. A mutation in the gene encoding for BMPR-2 is associated with 60% of 
familial cases of PH, while 80% of family members who carry the mutation, never present 
with the PH phenotype 34. BMPR-2 is highly expressed on the endothelium of pulmonary 
arteries 57. It is also expressed at a lower level in PASMC’s and fibroblasts and possibly 
contributes to PH, pulmonary fibrosis and COPD 58. It has been shown that, lung samples of 
patients with PH have mutations in genes encoding for BMPR-2 59-62. BMPR-2 forms part of 
the TGF-superfamily of proteins where TGF-β signalling is initiated by signals transmitted 
from small mothers against decapentaplegia (Smad)-molecules that facilitate the binding of 
TGF-β ligands to the TGF-β-receptor 63-65. Subsequently, Smad 2, 3 or Smad 1, 5, 8 are 
phosphorylated and co-localize with Smad 4 which translocate to the nucleus where it 
modulates transcription of target genes (Figure 4).  
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The general understanding is that, signalling via TGF-β/Smad 2, 3 induce PASMC proliferation 
and resistance to apoptosis, whereas BMPR-2/Smad 1, 5, 8 induce the opposite effects 63,64. 
This means that neither BMPR-2 nor TGF-β act independently, but form part of the TGF-β/ 
BMPR-2/Smad signalling axis, which controls apoptosis and PASMC proliferation 63,64. Studies 
in the animal model of MCT-induced PH have shown that the expression of TGF-β receptor-
activin-A receptor-like kinase-1 and Smad 3, 4, is reduced in the lungs. In the MCT model, the 
toxin induces PH by initiating endothelial injury in the lung and smooth muscle cell 
proliferation which leads to narrowing of the pulmonary arterioles 165, 324. This was associated 
with a decreased expression of the full BMPR-2 gene in the lungs of these rats 63,64. This may 
indicate that TGF-Smad and BMPR-2 signalling is impaired in PH and contributes to 
remodelling via PASMC proliferation and resistance to apoptosis.  
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2.3. Pulmonary hypertension and cardiac alterations 
General overview of the right ventricle: before and after pathology 
Under normal circumstances, the RV is structurally, geometrically and mechanically distinct 
from the left ventricle (LV) 6,7. It has a thinner wall than the LV and is half-moon shaped which 
reflects the low pressures in the pulmonary circulation (See figure 4). The RV also has a 
greater compliance compared to the LV and has an ability to adapt to changes in volume load 
more rapidly 66. Furthermore, the RV is different from the LV with regards to (i) its highly 
trabeculated endocardial surface, (ii) presence of the moderator band and (iii) lower oxygen 
requirement at rest/during exercise 67. When the RV, as in the case of PH, is exposed to the 
increased afterload and possibly even decreased coronary perfusion, it undergoes 
hypertrophy (Figure 5). This is also known as adaptive RV remodelling, as the heart attempts 
to adapt to the higher RV afterload and increased wall stress based on Laplace’s principle 6. 
However, if the increased afterload persists, the RV will eventually dilate and fail to pump 
blood to the lungs for oxygenation (i.e. RV failure) 6,68.  
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RV dysfunction also occur in progressed RV remodelling (hypertrophy and dilatation) and is 
the main determinant of prognosis of PH patients and a strong predictor of mortality 66,69,70. 
However, the relationship between RV function and afterload is complex. This is often seen 
in patients with idiopathic PH who have low load or low pressure, but yet have a worse 
prognosis compared to patients with congenital heart disease with high load or high pressure 
and, yet, often have a better prognosis 66,69,70. Therefore, it is not the load per se which causes 
death in PH but the RV failure after prolonged RV hypertrophy 69. On the molecular level, RV 
hypertrophy is achieved by increased protein synthesis and increased cell size, whilst the 
progressive process from RV hypertrophy to RV failure is potentially modified by a variety of 
contributing factors 6,66. These factors include (i) neurohormonal activation, (ii) increased 
reactive oxygen species (ROS) production, (iii) infiltration of inflammatory cells and disturbed 
balance of cell loss (apoptosis) and new cell formation (due to cardiac stem cells inherent to 
the myocardium), (iv) degradation of the extracellular matrix, (v)alterations in contractile and 
regulatory proteins, (vi) alterations in ion channels and (vii) mitochondrial defects (Figure 6) 
6,69.  
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Neurohormonal activation in right ventricular remodelling 
In ventricular failure (LV or RV) neurohormonal pathways are activated due to reduced tissue 
perfusion caused by decreased cardiac output to compensate for depressed cardiac function 
6,69,71,72. This may very well be the case in PH-induced RV failure when neurohormonal 
activation (via angiotensin-II, aldosterone, and atrial natriuretic peptide and brain natriuretic 
peptide) may attempt to maintain blood pressure and renal perfusion 6,69. Furthermore, the 
renin-angiotensin-system has been shown to be involved in the RV remodelling process in 
the pulmonary artery banding animal model of pressure overload-induced RV remodelling 
73,74. This is in line with current knowledge, that with heart failure, the renin-angiotensin-
system (angiotensin-II) is upregulated and directly affects cardiomyocyte growth and 
proliferation, myocardial fibrosis and contractile dysfunction 6. Thus, the initial activation of 
neurohormonal pathways may be beneficial but eventually lead to ventricular remodelling 
and decreased cardiac function 6.  
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Increased reactive oxygen species production in right ventricular remodelling 
It is known that all cells in the heart can produce reactive oxygen species (ROS) in the absence 
and presence of pathology 75,76. In ventricular remodelling, ROS damages (i) proteins 
important for cardiac excitation-contraction coupling, (ii) mitochondrial deoxyribonucleic 
acid, as well as (iii) activity of hypertrophic signalling kinases, transcription factors and matrix 
metalloproteases 77. These adverse effects of ROS cause cardiomyocyte apoptosis, 
remodelling of the extracellular matrix and impaired cardiac contractile function 77. 
Furthermore, in ventricular failure, ROS suppresses enzymes involved in excitation-
contraction coupling and poly-nitrosylates ryanodine receptors which also contribute to 
cardiac dysfunction 6. Therefore, ROS plays an instrumental role in RV remodelling and 
dysfunction associated with PH.  
 
Disturbed balance of cell loss and new cell formation in right ventricular remodelling 
Cardiomyocyte apoptosis is increased in the RV of rats that underwent pulmonary artery 
banding-induced RV remodelling 73. This has also been proven in animal models of heart 
failure due to mechanisms involving mechanical stretch, increased ROS production, pro-
inflammatory cytokines and angiotensin-II release 6,73. A rather interesting development in 
cardiac research is the evidence that the mammalian heart harbours clonogenic, multipotent 
cardiac stem cells that are able to differentiate into cardiomyocytes 6. The mere fact that the 
heart has these cells suggests an inherent ability to balance cell loss with de novo cell 
production 6. It is also possible, that, with ventricular remodelling, there may be an imbalance 
between apoptosis and the formation for new cells 6. However, although an interesting 
notion, this area of research is still highly experimental. Other factors that contribute to RV 
remodelling include excessive degradation of the extracellular matrix via matrix metallo 
protease activity, alterations in contractile and regulatory protein expression, alterations in 
enzymes and ion channels involved in cardiomyocyte excitation-contraction coupling, as well 
as the modification of cardiomyocyte energy metabolism 6. 
  
40 
 
Degradation of the extracellular matrix in right ventricular remodelling 
In PH-induced RV remodelling, there is an increase in mast cells which activates matrix 
metalloproteases by secreting tumour necrosis factor-alpha, tryptase and chymase that is 
linked to TGF-β signalling 78-80. This leads to degradation of the extracellular matrix and 
increased collagen content which may exacerbate ventricular remodelling 6,78,80.  
 
Alterations in contractile and regulatory protein expression in right ventricular remodelling 
In the rat model of MCT-induced PH, it has been shown that sarco (endo) plasmic reticulum 
calcium-ATPase and phosphorylated phospholamban levels are increased and total-
phospholamban levels decreased 81. This was associated with impaired intracellular calcium 
handling. Another contributor to ventricular remodelling is alterations in the expression of 
transcription factors including GATA-4, Nkx-2.5/Csx, MEF-2 and the HAND family (eHAND and 
dHAND) 7. In patients with idiopathic PH there is a decrease in the cardiac expression of α-
myosin heavy chain and an increase in β-myosin heavy chain which is regulated by GATA-4 7. 
This is part and parcel of the phenomenon called the recapitulation of the foetal gene pattern 
7. The β-myosin heavy chain isoform has lower adenosine triphosphatase activity compared 
to α-myosin heavy chain and, therefore, the increase in the expression of β-myosin heavy 
chain impairs systolic RV function 6. These alterations in the expression of proteins, which are 
imperative for myocardial function, play a key role in ventricular remodelling 6.  
 
Alterations in ion channels in right ventricular remodelling 
It has been reported, that in cardiac pathology there are alterations in the messenger 
ribonucleic acid expression of transient outward ion channels (such as the voltage gated 
potassium channels-4.2 and 4.3 and the sodium-hydrogen-exchanger-1 or NHE-1) 82. These 
channels are involved in cardiomyocyte excitation-contraction coupling and the 
downregulation of their expression contributes to RV dysfunction in the rat model of MCT-
induced PH, representative of group 1 PH. 82. This is supported by data showing that cardiac 
remodelling is associated with stage dependent changes in the transient outward current 
and L-type calcium channel current 83. LV remodelling is known to be dependent on sodium-
hydrogen-exchange, in particular the activity of the NHE-1 84-86. In MCT-induced PH, the RV 
has increased expression of NHE-1 84. Collectively, this suggests that alterations in the 
expression of ion channels play an important role in RV remodelling. 
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Cardiomyocyte energy metabolism in right ventricular remodelling 
In cardiomyocytes, phospholipids are situated in the mitochondrial membrane which is 
essential for mitochondrial biogenesis and optimal mitochondrial activity 87. In PH, there is a 
reduction in the levels of these phospholipids and thus defective mitochondrial activity 87. 
Cardiac tissue samples from animal models and patients with PH have increased glycolysis in 
RV remodelling, as opposed to fatty acid oxidation under normal circumstances 88,89. This 
choice of fuel to generate energy is insufficient to maintain the increased RV energy 
requirement (as with RV hypertrophy) and results in impaired RV contractility 88,89.  
Some of the multiple factors that possibly contribute to the development of pulmonary 
vascular remodelling and RV remodelling in PH have now been discussed. Furthermore, there 
are some other factors that also play a role in PH and these factors should be taken into 
consideration. These include: diagnosis of PH when the disease may already be in a far 
progressed stage, differences in aetiology that possibly precede or modulate PH, differential 
response to treatments, gender differences and varying mortality rates (Figure 7). All these 
factors accompany PH, perhaps varying in the extent to which they contribute, but together 
they prove PH to be a very complex disorder. However, the exact mechanistic interplay of 
these factors is not fully elucidated and the complete understanding of the pathophysiology 
of PH appears to evade experts at present. Therefore, due to the incomplete understanding 
of PH in general, fully effective treatments are also currently non-existent. Sadly, PH remains 
a fatal, global health threat without any cure or effective treatments. 
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3. Current treatments for pulmonary hypertension 
Overall treatment for PH includes the primary treatment (digoxin, supplemental oxygen 
therapy, diuretics and anticoagulants) and targeted treatment (endothelin-1 receptor 
antagonists, prostacyclin analogues and phosphodiesterase type-5 inhibitors) 90-92. As 
mentioned earlier, the pathophysiology of PH is complex as it arises due to the culmination 
of various pathological pathways and treatment of PH thus comprises of a variety of 
treatment modalities 90-92. 
 
3.1. Primary treatments 
The first step in the treatment of PH is the baseline assessment of the severity of PH, followed 
by treatment directed at the underlying cause of the PH and this is usually referred to as 
primary treatments 90. Primary treatments include supplemental oxygen therapy, diuretics 
and anticoagulants 90. 
 
Supplemental oxygen therapy 
In a study with 203 patients with PH and hypoxemic COPD, supplemental oxygen therapy was 
shown to be beneficial with minimal improvements in the severity of PH at rest or during 
exercise 95. In this particular study, the pulmonary vascular resistance (PVR), mPAP and stroke 
volume-index were improved after continuous oxygen therapy. Improved PVR was 
associated with improved cardiac function as displayed by an increase in the baseline and 
exercise stroke volume-index. However, the response of pulmonary haemodynamics to 
oxygen therapy did not allow the authors to make predictions regarding the long-term effects 
of supplementary oxygen therapy on patient survival 95. Furthermore, right heart 
catheterization was performed in 16 patients with severe hypoxemic COPD before and after 
nineteen months of supplemental oxygen therapy 96. This long term oxygen therapy, 
decreased mPAP and for two years after therapy, a similar decrease was observed annually. 
Lastly, short term supplementary oxygen therapy during right heart catheterisation in 104 
patients with PH reduced heart rate, cardiac output, mPAP and PVR 97. The heart rate in 
response to the short term oxygen therapy was associated with a better prognosis in patients 
with PH associated with chronic thromboembolism and chronic lung disease.  
Collectively all these studies show that supplemental oxygen therapy has a favourable effect 
on pulmonary haemodynamics and a modest impact on survival in patients with PH 
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secondary to COPD. However, there is a lack of randomized studies that test the efficacy of 
long-term oxygen therapy in PH and, even though oxygen therapy is advised to correct 
hypoxemia, it may increase the risk of aggravated pulmonary vasoconstriction 90-92.  
 
Diuretics and anticoagulants 
Diuretics diminish hepatic congestion and peripheral oedema and are useful in treating fluid 
retention in patients with PH and RV failure 90. It also improves cardiac contractility via 
reduction of RV preload and dilatation and is therefore an important component of primary 
therapy for PH 98-100. On the other hand, anticoagulation therapy such as warfarin is often 
recommended to prevent thrombosis and stroke in patients with PH associated with chronic 
thromboembolic disease 92. These patients are prone to thromboembolism due to tardy 
pulmonary blood flow, dilated RV, venous insufficiency and physical inactivity 92. 
Anticoagulation therapy is crucial in such patients and has also been shown to prolong life in 
patients with idiopathic PH 92,101. Apart from treating the underlying cause of PH, targeted 
treatment should be started promptly. Very often patients with idiopathic PH either don’t 
respond to primary treatment or the PH may already be too severe. In such cases targeted 
treatment is mandatory (Figure 8). 
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3.2. Targeted treatments 
Targeted treatments are the second step in treating PH, when PH is either unresponsive to 
primary treatment or present at a severely progressed stage. These treatments include 
endothelin-1 receptor antagonists, prostacyclin analogues, and phosphodiesterase type-5 
inhibitors) on which ample of research has been done over the years 90-92. 
 
Endothelin-1 receptor antagonists  
Endothelin-1 is a peptide that regulates vascular tone by modulating signalling via endothelin 
receptor-A and B which are located on PASMC’s 44. Activation of receptor-A cause PASMC 
proliferation and vasoconstriction while activation of receptor-B induces nitric oxide and 
prostacyclin production from pulmonary endothelial cells 99,100,102. Both PASMC proliferation 
and vasoconstriction play a key role in PH, therefore endothelin-1 receptor antagonists have 
been developed as a treatment for patients with PH 33,90,99,103. There are various endothelin-
1 receptor antagonists, including bosentan (a dual receptor antagonist), ambrisentan and 
sitaxentan (which are selective receptor antagonists) 33,99,103,104. In a retrospective data 
analysis in 82 PH patients with end-stage heart failure, 54 received oral bosentan treatment 
twice a day (for a period of fifteen months), while the remaining 28 patients received 
standard medical treatment 105. Bosentan reduced mPAP and PVR compared to the control 
patients. Interestingly, the authors noted that after one year of treatment, the survival was 
approximately 20% higher in the bosentan-treated group 105.  
In a randomized placebo-controlled study by Channick and colleagues, 33 PH patients were 
randomly assigned to placebo or bosentan treatment 106. The starting dose of bosentan was 
62.5mg twice daily for four weeks, which was then up titrated to 125mg twice daily for twelve 
weeks. Patients who received bosentan treatment displayed a dramatic increase of 76 
metres walking distance during the six-minute walk test (a measure of exercise capacity and 
severity of PH). This was associated with improved cardiac output, PVR and mPAP 106.  
Furthermore, in a one-year follow up study, 213 PH patients received bosentan treatment at 
a dose of 62.5mg twice daily for four weeks and thereafter 125mg or 125mg twice daily for 
one year 107. Bosentan increased the walking distance during the six-minute walk test to 44 
metres and improved the time to clinical worsening 107. In a recent publication, bosentan 
displayed similar benefit with longevity of benefit for up to 4 years after treatment 108. All 
these studies show that bosentan treatment is effective in improving cardiopulmonary 
haemodynamic parameters and endpoints such as the six minute walk distance.  
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The selective endothelin receptor antagonists include ambrisentan and sitaxentan 99. 
Ambrisentan increased the six minute walk distance and decreased circulating brain 
natriuretic peptide levels in 224 patients with PH associated with various diseases 109. Which 
was corroborated by data that ambrisentan provided modest benefit in patients with 
idiopathic PH 109. In two randomized, double- blind, placebo-controlled studies, the so called 
ARIES-1 and ARIES-2 trials, ambrisentan treatment was tested in 202 and 192 patients with 
PH 104. In the ARIES-1 study, patients were assigned to placebo or oral ambrisentan treatment 
respectively (5 or 10mg) and in ARIES-2 study, doses were 2.5 or 5mg daily for 12e weeks. 
The six minute walk distance increased in all ambrisentan treated groups, with approximately 
20 metres. Further improvements were seen in the functional class, dyspnoea score and 
natriuretic peptide-type B levels. Thus, ambrisentan modestly improved the exercise capacity 
of these patients 104. Furthermore, in a single centre cohort study with 17 patients with PH 
associated with congenital heart disease, ambrisentan improved exercise capacity but had 
no convincing effect on functional class 110. Lastly, D'Alto and colleagues conducted a single 
centre, non-placebo controlled study during which they investigated the long term effects of 
ambrisentan treatment in patients with PH 111. Ambrisentan treatment for 12 months 
improved the six minute walk distance, functional class and cardiopulmonary 
haemodynamics. These improvements were associated with a reduction in the pro-
natriuretic peptide type-B levels 111. It is thus clear, that ambrisentan provides 
cardiopulmonary benefit similar to bosentan however, the other selective endothelin 
receptor antagonist, sitaxentan, generated very interesting results.  
Sitaxentan is a very potent endothelin receptor antagonist with a long duration of action 112. 
In a study by Barst, patients with idiopathic PH were randomized to placebo, oral sitaxsentan 
100mg or oral sitaxsentan 300mg once daily for 12 weeks 113,114. Both the 100mg and 300mg 
dose increased six minute walk distance; functional class, cardiac index and PVR, compared 
to placebo 113,114. Similar results were generated in other studies that tested the effects of 
sitaxentan in patients with PH 115-120. However, in the study by Barst et al, they noticed that 
the incidence of elevated aminotransferase values were three times higher than normal and 
this appeared to be dose dependent 113,121. Although this finding was not given much thought 
at the time, in retrospect, it was a subtle indication of liver toxicity associated with sitaxentan 
treatment. In 2012, Chin and colleagues published a case report of a 61-year old female with 
sitaxentan-induced acute liver failure 122. This was further corroborated by evidence of a 
similar toxic effect of sitaxentan in 7 cases of severe hepatitis-type drug reactions associated 
with sitaxentan 114,123-126. Consequently, sitaxentan was withdrawn from the market.  
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Prostacyclin analogues 
Epoprostenol was the first prostacyclin analogue used in the treatment of PH 127. In a 
randomized, open label, controlled trial, intravenous epoprostenol treatment (12 weeks) 
improved exercise capacity, haemodynamics, functional class and dyspnoea scores in 
patients with moderate/severe PH 128. In a separate study, patients with primary PH received 
poprostenol infusion for 3 months and those with a history of RV failure, persistent functional 
class two/three and the absence of a decrease in the PVR were all associated with poor 
survival 107. In these studies, epoprostenol improved certain endpoints but it has a very short 
life and thus treprostinil has been considered as a better option 129.  
In a study by Gomberg-Maitland, 27 patients were switched from intravenous epoprostenol 
to intravenous treprostinil over 24 to 48 hours, for a period of 12 weeks 129. At week 12, the 
six minute walk distances and dyspnoea scores were maintained with intravenous 
treprostinil. These results were associated with decreased PVR, mPAP and cardiac index. This 
suggested that the transition from intravenous epoprostenol to intravenous treprostinil is 
safe and effective 129,130. The bulk of data indicate that treprostinil may be a first line 
treatment for patients with PH 130. Similar success has been shown with other prostacyclin 
analogues such as beraprost and iloprost 131,132.  
 
Phosphodiesterase type-5 inhibitors 
One of the most well-known phosphodiesterase type-5 inhibitor is sildenafil and its efficacy 
in PH well documented, for its both oral and intravenous forms 133,134. In a double-blinded, 
placebo-controlled study of 278 idiopathic PH patients, oral sildenafil treatment (20, 40, or 
80mg, three times daily for a period of 12 weeks) increased six minute walk distance, reduced 
mPAP and improved functional class 135. Furthermore, in an open label pilot study 14 children 
with primary and secondary PH were assigned to oral sildenafil treatment at a dose of 0.25 
to 1mg/kg four times daily 136. After treatment, the mean distance walked increased, while 
both the mPAP and PVR decreased 136. Similarly, oral sildenafil (75mg/day for 12 weeks) 
increased the six minute walking distance and improved dyspnoea scores; functional class 
and cardiopulmonary haemodynamics 137.All of these studies corroborate the efficacy of 
sildenafil as treatment for PH.  
Another phosphodiesterase type-5 inhibitor is tadalafil 138. In a double-blind, 52 week, 
uncontrolled extension study, 293 PH patients received tadalafil treatment at doses 20mg or 
40mg 138. Long term tadalafil treatment improved the six minute walk distance and functional 
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class. Aggarwal and colleagues conducted a prospective study with thirteen PH patients 
treated with tadalafil (10mg for ten weeks and thereafter up titrated to 20mg for two more 
weeks) 139. After 4 weeks of therapy, all patients had improved exercise capacity, functional 
class, haemodynamic parameters and mPAP. The PVR and pulmonary blood flow were also 
improved. Lastly, in a 16 week, double-blind, placebo controlled study, 405 patients with 
idiopathic PH were randomized to placebo or oral tadalafil treatment at doses of 2.5, 10, 20, 
or 40mg once daily 16. Tadalafil increased the six minute walk distance in a dose dependent 
manner while the highest dose of tadalafil (40mg) improved the time to clinical worsening, 
incidence of clinical worsening and quality of life. Tadalafil appears to be an effective and a 
safe treatment for patients with PH by improving exercise capacity, clinical status, 
haemodynamic parameters and quality of life 140.  
 
3.3. Efficacy of current treatments against pulmonary hypertension 
Despite a plethora of research displaying positive results and the significant advancements 
that have been made in the treatment of PH in the last 12 years, the disease remains fatal 
141,142. As seen in the above mentioned studies, all the targeted treatments strategies, with 
the exception of tadalafil, show modest improvement in endpoints such as clinical status and 
patient survival, together with cardiopulmonary haemodynamic benefit. Therefore, current 
treatments are only successful to a certain extent but do not provide a permanent reduction 
of mPAP or reversal of pulmonary vascular remodelling 143-147. Furthermore, there is a lack of 
adequately powered, multicentre studies that show the effects of treatment on patient 
survival, after long term treatment and for these reasons there is a great need for either an 
improvement of current PH treatments or a cure 6,148. In the last decade, there has been an 
increasing amount of research studies which, if carefully studied, display certain trends in 
treatment strategies. These trends comprise various ways to improve the limited impact of 
current treatments on PH and patient survival.  
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3.4. Novel trends pulmonary hypertension treatment research 
3.4.1. Combination therapy 
One of the most prominent trends in PH research is the combination of various existing PH 
treatments. The first rationale for combination therapy is based on the hope of achieving 
greater and longer lasting benefit with PH treatment 16. The second is based on the fact that 
several pathological pathways are involved in the pathogenesis of PH and, thus, combination 
therapy has the benefit of targeting multiple pathways simultaneously 16. Many studies have 
emerged that support this concept of combination therapy. One such study is the so called 
BREATHE-2 trial (bosentan randomised trial of endothelin antagonist therapy for PH trial-
two) 99,104,149. 
The BREATHE-2 trial was a randomized, double-blinded, placebo-controlled study that 
investigated the effects of combined of bosentan and epoprostenol in patients with severe 
PH 99. In this trial, 33 patients received epoprostenol treatment at doses of 2ng/kg/min 
(starting dose), up to 14ng/kg/min (at week sixteen). Patients were then randomized for 
bosentan treatment (62.5mg twice daily for 4 weeks and thereafter 125mg) or placebo. Thus, 
there were two groups; one group that received the placebo plus epoprostenol and another 
group that received bosentan combined with epoprostenol. After 16 weeks, the exercise 
capacity, haemodynamics and functional class improved in both groups. The group that 
received the combination therapy showed a trend for a greater improvement in all measured 
haemodynamics but this was not statistically significant. The BREATH-2 trial data gave some 
indication of a possible greater clinical benefit with combination therapy although not 
statistically significant at the time 99. Other smaller studies, which were not blinded or 
placebo controlled, corroborated this notion.  
In one such retrospective, single centre study, 7 patients with PH received continuous 
inhalation of nitric oxide (10ppm) and iloprost (10μg) 150. Combined treatment decreased 
PVR and mPAP which was associated with an improvement in RV function. In a study by 
Hoeper, a combination of bosentan and sildenafil improved the six minute walk distances in 
9 patients with severe idiopathic PH 151,152. However, this was not sustained and, after 12 
months, the walk distance declined. At this point, sildenafil was administered in addition to 
bosentan treatment. After an additional 3 months, the six minute walk distances increased 
and patients remained stable for the following 9 months 151,152. Similar success was reported 
with a combination of prostacyclin and tadalafil 153. However, in another study, PH patients 
who underwent valvular heart surgery did not show any improvement after combination 
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therapy with oral sildenafil and beraprost 154. In this particular study, combination therapy 
was administered 15 minutes prior to heart surgery and resulted in loss of pulmonary 
selectivity and no additional pulmonary vasodilation or favourable perioperative 
haemodynamics. Nevertheless, in retrospect, the concept of combination therapy is 
plausible but needs to be corroborated by larger, randomized, placebo-controlled, 
multicentre studies 155-157.  
 
3.4.2. Complementary cardioprotective strategies for pulmonary hypertension 
Another trend in PH treatment research is the investigation of possible cardioprotective 
treatments that may protect the RV in PH. In theory, such a cardioprotective strategy can be 
given complementary to existing PH treatments and may further improve the quality of life 
and survival of patients with PH (See figure 8) 6,7,69,158. This type of cardioprotective or RV 
protective treatment is even more relevant, as RV function is the main predictor of mortality 
in patients with PH 66,69,70. 
Many studies indicate that RV remodelling in PH is similar to that of the LV with regards to 
energy substrate utilization, beta-adrenergic receptor density and cardiomyocyte growth 
response 88,159-162. Therefore, because RV remodelling potentially shares certain 
pathophysiological mechanisms with LV remodelling it can, in theory, be treated with 
therapies that have been successful in treating LV remodelling 67,69,163. However, more 
research is needed before such treatments can officially be implemented in patients with PH-
induced RV remodelling 67,69,70.  
Unfortunately, due to such a small number of studies that investigate complementary 
cardioprotective strategies, one is obliged to revisit data from LV remodelling studies and 
constantly draw parallels between RV protective treatments and those for LV remodelling. 
Based on our current knowledge of LV remodelling, a variety of signalling pathways are 
activated to initiate this remodelling process 164,165. These pathways are well studied in LV 
pathology, but whether they are involved in RV remodelling, to the same extent, is not 
completely elucidated 7,70. There are a number of possible cardioprotective treatments or 
therapeutic targets including cardiomyocyte apoptosis, epigenetic control of cardiac gene 
transcription, cardiac gene expression and micro-RNA’s (miRs), nuclear factor kappa-B 
modulation of notch signalling, energy metabolism of RV cardiomyocytes, the sodium-
hydrogen-exchanger-1 and cardiac resynchronization therapy (Figure 9).  
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Inhibition of cardiomyocyte apoptosis 
With LV failure, cardiomyocyte apoptosis is increased which is triggered by activation of G-
protein-coupled receptors, cytokines and increased ROS 165. Because of the regulated and 
ordered nature of apoptosis, it is possible to intervene at an early stage and prevent it 165,166. 
Many proteins are implicated in apoptosis with caspases being the most prominent and 
important 166 ,167. Z-Val-Ala-Asp (Ome)-CH2K (ZVAD-fmk) is a tripeptide inhibitor of the 
caspase-interleukin-1β-converting enzyme family of cysteine proteases 166 . In a rat model of 
ischemia/reperfusion injury, ZVAD-fmk (3.3mg/kg) reduced myocardial ischemia/reperfusion 
injury associated and partially attenuated cardiomyocyte apoptosis 166 .  
Another apoptosis targeting agent is aurintricarboxylic acid, an inhibitor of endonucleases 
which is situated downstream in the apoptotic pathway and facilitates DNA strand breaks 
168,169. Aurintricarboxylic acid has been shown to reduce the number of necrotic cells in the 
perinecrotic region of the damaged myocardium in a dog model of ischemia/reperfusion 
168,169. Furthermore, mitofusion-2, a factor that is a major determinant of oxidative stress, 
mediates cardiomyocyte apoptosis and is thought to be beneficial in overt heart failure 170. 
In a rat model of MCT-induced PH and right ventricular remodelling, rat hearts have been 
shown to have increased RV cardiomyocyte apoptosis 171. Ecarnot-Laubriet, showed that in 
the same model, the RV is vulnerable to apoptosis with concomitant activation of the cell 
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cycle 162. In this study, RV cardiomyocyte apoptosis was evident with an increased expression 
of caspase-3 and down regulation of the anti-apoptotic protein B-cell lymphoma-2 (bcl-2) 162. 
Taken together, these data suggest that inhibition of various steps in the apoptotic signalling 
pathway may be a therapeutic target in developing a RV protective treatment in PH as 
apoptosis play an important role in ventricular remodelling.  
 
Interference with the epigenetic control of cardiac gene transcription 
A fairly novel approach in PH research is the pharmacological inhibition of histone 
deacetylases (HDACs) 141,172,173. HDACs are enzymes that add acetyl groups to histone proteins 
and cause relaxation of the chromatin structure, enhances the accessibility of histone 
proteins to DNA binding as well as transcription 172,174. HDACs have a regulatory function in 
ventricular remodelling and can be suppressed with HDAC inhibitors (such as trichostatin-A 
and valproic acid) to attenuate LV remodelling 172,175. Bogaard et al investigated whether 
interference with the epigenetic control of gene transcription, by means of HDAC inhibitors, 
may also attenuate RV hypertrophy 148.  
Male rats were subjected to pulmonary artery banding surgery to constrict the main 
pulmonary artery; increase RV afterload and cause RV hypertrophy 69,88,148. Four weeks after 
surgery, when RV hypertrophy was evident, trichostatin-A treatment was initiated (450µg/kg 
intraperitoneal, 5 times per week for a period of 2 weeks). Interestingly, trichostatin-A was 
ineffective in attenuating RV dysfunction and decreased the mRNA expression of 
phosphorylated protein kinase-B, vascular endothelial growth factor, angiopoeitin-1 and 
insulin-like growth factor-1. Furthermore, trichostatin-A significantly decreased the 
endothelial nitric oxide synthase gene expression 148. The authors did not know the reason 
for this but speculated that the rats developed RV dilatation after the pulmonary artery 
banding surgery that was associated with capillary rarefaction. This may have caused RV 
ischemia and hypoxic stabilization of hypoxia inducible factor-1-alpha expression 148. 
Another HDAC inhibitor, valproic acid, has been shown to block RV hypertrophy in both the 
pulmonary artery banding and monocrotaline models of RV failure 176. However, valproic acid 
is a nonspecific inhibitor of HDACs and with a wide range of pharmacological actions such as 
regulation of ion channels, expression of glycogen synthase kinase-3β and mitogen activated 
protein kinases 177. Therefore, due to the nonspecific nature of valproic acid, these results 
should be taken with caution 177. On the other hand, selective class-1 inhibition of HDAC’s 
attenuates RV hypertrophy in the chronic hypoxia model of PH 173. Benzamide, a selective 
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HDAC inhibitor (MGCD0103) decrease caspase-3/7 activity; interleukin mRNA expression (IL-
1β, IL-2) and reduce RV hypertrophy 173. However, HDAC inhibitors need further investigation 
as potential RV protective treatments but remain attractive targets for RV remodelling in PH. 
 
Gene expression and micro ribonucleic acids 
Micro-RNA’s (miR’s) are short, noncoding ribonucleic acids that regulate gene expression at 
posttranscriptional level 165,178. They are activated by cellular stress signals and their 
regulatory function is achieved by inhibiting protein translation or promoting the 
degradation of target messenger-RNA’s 165,178-180. MiR’s are highly conserved and involved in 
biological processes such as cardiovascular development and pathology 165,178-181. More 
specifically, they have important functions in the regulation of cardiomyocyte apoptosis, 
differentiation and proliferation 182. In heart failure, a number of miR’s are either up or down 
regulated, including miR-17, miR-20a and miR-24 165,178,182,183. In 2007, Care at el, published a 
study where they elegantly showed the instrumental role of miR’s in 3 different models of LV 
hypertrophy, including transverse aortic constriction, transgenic mice with selective cardiac 
overexpression of Akt kinase 184. Here, overexpression of miR-133 inhibited LV hypertrophy 
while antagomir-133 caused sustained LV hypertrophy. This was suggestive of the regulatory 
role of this specific miR in LV remodelling. Furthermore, In vivo antagomir silencing of miR-
24 were done in mice with LV hypertrophy after aortic constriction 185. MiR-24 silencing 
prevented the transition to decompensated cardiac hypertrophy. In the chronic hypoxia 
(representative of group 2 PH) and MCT models of PH (representative of group 1 PH), 
inhibition of miR-17 with the antagomir-17 improved lung and heart function 182. 
Furthermore, antagomir-20a significantly reduced RV hypertrophy in a mouse model of 
chronic hypoxia induced pulmonary vascular remodelling and RV hypertrophy 186. 
Understandingly, the miR’s gained much attention as novel therapeutic targets for 
cardiovascular disease due to their cardiac specific nature and therefore they may also be 
applicable in the development of RV protective treatments for PH 165,181. 
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Nuclear factor kappa-B modulation of notch signalling 
Nuclear factor kappa-B (NFκB) is a key modulator of the notch signalling pathway and has 
been shown to be involved in the development of PH 187. This is a complex juxtacrine 
signalling pathway initiated by interaction between the notch transmembrane receptors 
(notch1-4) and their ligands (jagged-1 and 2) 188,189. Notch signalling is widely implicated in 
cardiovascular development and pathology 188-191. In a study by Gude et al, mice were 
subjected to coronary artery ligation and an adenoviral vector expressing notch intracellular 
domain, was injected into the myocardium after coronary artery ligation 190. This improved 
haemodynamic function of infarcted mice hearts with enhanced Akt-signalling, induced by 
notch activation 190. 
The NFκB /notch signalling pathway has been shown to be involved in RV remodelling in 
transgenic mice over expressing a cardiac specific dominant-negative-IκB gene 187. These 
mice were in subcutaneously injected with MCT (60mg/kg) and transgenic over expression 
of the IκB gene inhibited myocardial NFκB activation 187. The inactivation of NFκB prevented 
RV hypertrophy despite the presence of PH 187. This was associated with a reduced activation 
of NFκB genes, restoration of the expression of bone morphogenetic protein (BMP) signalling 
molecules and alteration in notch and smad signalling 187. These changes were observed in 
cardiac and in lung tissue. Activation of NFκB, decreased the expression of notch-3, BMP-2 
and BMPR-2, inhibitory of differentiation (Id), Smad-2 & 8, increased Smad-4 expression, as 
well as RV hypertrophy 187. These observations were abolished in the transgenic mice with 
inhibited cardiac NFκB activation 187. Collectively, these studies suggest that pharmacological 
modulation of the NFκB /notch signalling axis may be useful in developing a RV protective 
treatment for PH. 
 
Cardiomyocyte energy metabolism  
When cardiomyocytes are exposed to decreased oxygen levels they shift their energy 
metabolism from oxidative phosphorylation to glycolysis and reverse this shift when oxygen 
levels return to normal 159,192-195. In response to pressure overload, cardiomyocytes develop 
a metabolic phenotype known as the glycolytic shift characterized by increased glycolysis 
88,196. The general concept holds that increased glucose oxidation might ameliorate cardiac 
function 159,192-195. In 2000, Wambolt, subjected rats to suprarenal abdominal aortic 
constriction in order to induce cardiac hypertrophy 197. The hearts were isolated and 
subjected to 20 minutes of global ischemia and 60 minutes reperfusion. Throughout the 
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perfusion protocol, the hearts were perfused with a buffer containing dichloroacetate. In this 
study, dichloroacetate improved the function of the hypertrophied hearts.  
Furthermore, Piao et al, showed that promotion of glucose oxidation with dichloroacetate 
partially prevented RV hypertrophy in the MCT and pulmonary artery banding animal models 
88. Dichloroacetate treatment increased the expression of glucose transporter-1, pyruvate 
dehydrogenase and restored the expression of the voltage gated potassium channels (Kv1.5 
and Kv4.2) 88. This led to increased RV glucose oxidation, cardiac work, improved RV 
repolarisation and RV function 88. It has also been shown that partial inhibition of fatty acid 
oxidation with trimetazidine and ranolazine increased cardiac output and exercise capacity 
in the pulmonary artery banding model 198. However, although these pharmacological 
treatments are effective, one should bear in mind that they are not cardiac specific and may 
have widespread systemic effects 196. Nevertheless, these studies suggest that 
dichloroacetate, trimetazidine and ranolazine may be cardioprotective targets in PH induced 
RV remodelling. 
 
Inhibition of the sodium-hydrogen-exchanger-1 
The sodium hydrogen exchanger-1 (NHE-1) is an integral membrane glycoprotein, 
ubiquitously expressed in mammalian cells and responsible for the removal of intracellular 
protons at the expense of the sodium ions 85,86,199. It is regulated by hormonal, 
paracrine/autocrine regulators, ribosomal-S-6-kinase and mechanical stretch 181,199,200. The 
involvement of NHE-1 in the cardiac hypertrophic response is thought to be initiated by 
mechanical stretch that stimulates NHE-1 activity via the activation of kinases such as 
phoshokinase-C or mitogen activated protein kinases 199. The pro-hypertrophic activity of 
NHE-1 also involves calcineurin, calmodulin-dependent-kinase-II and ROS 199. Furthermore, 
the inhibition of phosphorylation dependent NHE-1 activation in cardiomyocytes has been 
shown to occur via increased dephosphorylation by the catalytic subunit of protein 
phosphatase-2-A 199,201. 
NHE-1 has been implicated in cardiac remodelling and evidence suggests that inhibitors of 
NHE-1 are beneficial against cardiac pathology 85,86,199. Such inhibitors include cariporide, 
amiloride & zoniporide and have been widely tested in LV remodelling 202,203. Seven days after 
left coronary artery ligation in female rats, cariporide treatment was commenced and 
continued for 52 days 204. Interestingly, cariporide treatment did not affect hypertrophy post 
infarction but did improve cardiac contractility. In another study, rabbits were subjected to 
57 
 
myocardial infarction and received cariporide treatment for nine weeks 205. Here cariporide 
improved LV dilatation and improved cardiac function. The anti-hypertrophic effects of 
cariporide treatment were more outspoken in a study where it attenuated LV hypertrophy 
and improved cardiac function in aortic constriction mice 206.  
Seven days of pre-treatment with cariporide in the MCT model of RV failure attenuated RV 
hypertrophy compared to the hearts of MCT treated rats 84. Cariporide also reduced the 
cardiac response to pulmonary vascular damage and the beneficial cardiovascular effects 
were independent of the pulmonary vascular system 84. In general, the cardioprotective 
effects of this form of NHE-1 inhibition are thought to be based on two mechanisms, 
including the prevention of cytosolic sodium and calcium overload and the prevention of 
mitochondrial permeability transition pore opening 207. However, even though the exact 
mechanisms are not fully elucidated, the bulk of evidence suggests that inhibition of the NHE-
1 has therapeutic potential in RV protection in PH.  
 
Cardiac resynchronization therapy 
Increased RV afterload prolongs RV contraction which eventually leads to uncoordinated 
contraction and RV systolic dysfunction 208. Cardiac resynchronization therapy is a well-
established treatment for LV dyssynchrony related to LV failure in patients 209. Follow-up 
examinations in patients with LV remodelling/systolic dysfunction revealed that cardiac 
resynchronization therapy reduced morbidity and mortality 209. Handoko et al, investigated 
whether RV pacing would resynchronize the generation of pressure across the septum and 
thereby improve RV systolic function in the MCT model 208. Rats were injected with MCT and 
subjected to RV pacing that was achieved by direct stimulation of the RV free wall with an 
electrode 208. Pacing improved RV systolic function and resynchronized the time of RV and LV 
peak pressure. It had no detrimental effects on LV function or coronary perfusion. Although 
this technique is not of pharmacological nature, it can also be seen as a candidate treatment 
for the adverse effects of PH on the RV. However, further experimental testing is required. 
In retrospect, it is clear that taking advantage of the similarities between the LV and RV may 
help to elucidate the mechanisms involved in PH induced RV remodelling and to develop RV 
protective treatments. A number of studies have shown benefit by targeting various aspects 
of the ventricular remodelling process. However, in the few available experimental studies, 
the benefit seen with some RV protective treatments may be due to a dual effect on both 
the heart and pulmonary vasculature and possibly other organs.  
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3.4.3. Targeting oxidative stress as a potential treatment for pulmonary hypertension 
Another trend in PH treatment research is targeting oxidative stress, which is a very 
important factor in the pathogenesis of PH 30,210,211. Oxidative stress is characterized by the 
increased production of oxidants such as ROS (including superoxide anion radical, hydrogen 
peroxide and hydroxyl radical) and/or decreased levels of antioxidants or antioxidant 
enzymes (including superoxide dismutase, catalase and glutathione peroxidase) 210. It is well 
known that diseases such as PH enhance the production of ROS and diminish antioxidant 
activity which results in oxidative damage to crucial cell components such as DNA, proteins 
and lipids 211. Oxidative damage elevates the breakdown products of these oxidative 
processes which can be detected in plasma, serum or urine samples of patients with PH 211. 
Breakdown product includes malonic dialdehyde, F2-isoprostane, 8-hydroxyguanosine, 
protein carbonyl content and nitrotyrosine (Figure 10). 
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In PH, oxidative stress is believed to be involved in the initial “trigger” stages of the disease 
development where it causes endothelial injury in the pulmonary vasculature 30,210,211. It has 
also been reported that all cells in the lung can generate ROS and this production is directly 
mediated by alveolar macrophages via nicotinamide adenine dinucleotide phosphate-
(NADPH)-oxidase 212. Therefore, oxidative stress is an integral part of the development of PH, 
as evident in both animal models of PH and patients with PH 211,213-216.  
 
Oxidative stress in animal studies 
Rats with MCT-induced PH and left pneumonectomy have increased NADPH-oxidase-4 and 
oxidative stress-induced lipid peroxidation as seen in the elevated plasma levels of malonic 
dialdehyde and nitrotyrosine (which are breakdown products of lipid peroxidation) 217. 
Interestingly, the levels of the antioxidant enzyme, catalase, were decreased while 
superoxide dismutase and glutathione peroxidase-1 were elevated 217. Authors speculated 
that these findings suggested possible accentuated attenuation of the biological antioxidant 
defence system 217. In another study, Mohammadi, showed that MCT rats have decreased 
plasma levels of catalase, superoxide dismutase and glutathione peroxidase and increased 
malonic dialdehyde levels 218.  
Furthermore, MCT rats also have increased levels of other markers of oxidative stress (such 
as hydrogen peroxide and thioredoxin reductase activity) in the RV, but not the LV 219. These 
results were challenged when Leichsenring-Silva and colleagues showed that oxidative stress 
was increased in the LV of rats injected with MCT 71. It is possible that the contradictive results 
of these studies may be due to the doses of MCT (80mg/kg versus 50 mg/kg) or the site of 
injection (subcutaneous versus intraperitoneal). It is known that pathological remodelling of 
the RV also affects the LV with regards to contractility and ejection fraction 220. Furthermore, 
in both the LV and RV it has been shown that during ventricular remodelling, ROS production 
was increased, which led to the generation of nitrotyrosine residues in tissue inhibitor of 
metalloproteinases and activation of matrix metalloproteinases 221. All these studies suggest 
that oxidative stress is increased in animal models of PH. Demarco 
Mitochondria are major sites for the production of ROS and particularly mitochondria from 
endothelial, smooth muscle, and adventitial cells. 211, 222 They modulate the oxygen demand 
of cells because they consume approximately 90% of cellular oxygen 222. In brief, 
mitochondrial energy substrates (such as fatty acids) are catalysed to acetyl coenzyme-A, 
which is further reduced to reducing equivalents nicotinamide adenine dinucleotide and 
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flavin adenine dinucleotide-2. These reducing equivalents function as carriers of electrons 
while oxygen serves as a terminal electron acceptor in the electron transport chain. The 
electron transport chain is situated in the inner mitochondrial membrane and consists of four 
protein complexes and is a major means to producing energy in the cell. During the process, 
ROS are generated and this contributes to oxidative stress 222. Iqbal et al, isolated and 
assessed mitochondria from the lungs of male broiler chicks with PH 214. These mitochondria 
showed increased oxidative stress, decreased levels of glutathione and impaired respiratory 
function. These data support the role and involvement of mitochondria in the production of 
highly toxic and ROS.  
Some patients with hereditary haemorrhagic telangiectasia have mutations in the endoglin 
gene which is an underlying cause in this type of slow onset PH. Consequently, in a mouse 
model of slow onset PH, lung tissue levels of superoxide were increased 223. The study 
supports data from a study by Grobe et al, who established a lamb model that mimics a 
congenital heart defect with increased pulmonary blood flow using in utero placement of an 
aorta-to-pulmonary artery vascular graft 215. These lambs had increased mPAP with clinical 
and pathologic sequelae similar to children with congenital heart defects associated with PH. 
Although congenital heart disease is not considered hereditary, it is, in fact, associated with 
a genetic component. In this lamb model analysis of lung tissue revealed increased oxidative 
stress, as reflected by increased nicotinamide adenine dinucleotide phosphate-oxidase 
expression and superoxide production 215. These studies highlight the involvement of 
oxidative stress in the development and progression of PH associated with hereditary or 
congenital causes. 
 
Oxidative stress in human studies 
There are currently only 2 studies that examined oxidative stress in tissue samples from 
patients with PH 210,224. In a study done by Bowers et al, lung tissue from patients with both 
primary and secondary PH were analysed by microarray gene expression profiling 210. These 
tissue samples had increased oxidative stress as displayed by elevated levels of breakdown 
products from oxidative damage to deoxyribonucleic acid and proteins. Breakdown products 
included nitrotyrosine, 8-hydroxy guanosine and 5-oxo-eicosatetraenoic acid. The tissue 
samples also had reduced activity of superoxide dismutase 210. Furthermore, Masri et al, 
showed that lung tissue samples from patients with idiopathic PH had deficient superoxide 
dismutase and glutathione peroxidase activity 224.  
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A number of studies assessed oxidative stress in plasma and serum samples of patients with 
PH 213,225-229. In one such study, electron spin resonance spectroscopy revealed that plasma 
samples from patients with idiopathic PH have increased xanthine oxidase activity 225,226. In 
16 patients with primary PH, erythrocyte glutathione peroxidase levels were decreased and 
plasma malonic dialdehyde levels were increased 213. These findings support data published 
in another study where serum samples of COPD patients with PH displayed increased malonic 
dialdehyde levels and decreased erythrocyte glutathione peroxidase activity 230.  
Urine samples from patients with PH had increased levels of isoprostaglandin F2-type III 
(which is an F2-isoprostane and marker of oxidative stress) 227. Collectively, these studies 
suggest that PH is associated with elevated oxidative stress in lung tissue which is also 
reflected in plasma, serum and urine. With this set of evidence, it is clear that oxidative stress 
is an intrinsic part of PH and RV remodelling, which builds a strong case for the potential use 
of an antioxidant as a RV protective treatment in PH. A number of studies investigated the 
effects of various antioxidants in animal models of PH. 
 
3.4.4. Antioxidant treatments in animal models of pulmonary hypertension 
EUK-134 
EUK-134 is a superoxide dismutase and catalase mimetic 219 . In the MCT model of PH, EUK-
134 treatment was commenced at a dose of 25mg/kg (once every two days), ten days after 
MCT injection (80mg/kg for an additional 22 days) 219. EUK-134 attenuated RV hypertrophy, 
oxidative stress and prevented interstitial fibrosis. The fact that antioxidant treatment was 
commenced on day ten of the MCT model suggests that antioxidant treatment administered 
fairly late in the disease progression may still be effective. These results were corroborated 
by Ahmed et al, who showed that mice overexpressing extracellular superoxide dismutase 
and subsequently exposed to hypoxia for ten days (10% fraction of inspired oxygen) lower 
lung tissue levels of xanthine oxidase and ROS as well as improved RV hypertrophy 231.  
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Resveratrol 
Resveratrol is a polyphenol compound with strong antioxidant, anti-inflammatory and 
endothelial protective properties 232. Resveratrol pre-treatment (for one day; 25 mg/kg/day 
intraperitoneal) in MCT rats attenuated RV remodelling as well as oxidative stress levels in 
lung tissue, after 21 days 232. In a study done by Yang et al, intragastric resveratrol treatment 
(10 and 30mg/kg twice daily for 21 days) improved PH and RV remodelling in MCT-induced 
PH (50mg/kg intraperitoneal) 233. This was accompanied by a reduction in cardiomyocyte 
apoptosis. Oral resveratrol treatment (3mg/kg) also attenuated MCT-induced PH and RV 
remodelling 234. What makes the latter study so crucial is the fact that resveratrol treatment 
was commenced on day 28 after the MCT injection (50mg/kg intraperitoneal). This is 
important because at this time point the disease is fully progressed and supports the notion 
that antioxidant treatment in already progressed PH and RV remodelling may be effective. 
The authors of both these last two studies did not directly measure markers of oxidative 
stress but it is appropriate to speculate that the beneficial effects of resveratrol may be 
largely due to its antioxidant properties 75,76.  
 
Allopurinol 
Allopurinol is an inhibitor of the enzyme xanthine oxidase and inhibits ROS production 235. In 
heart failure, allopurinol treatment effectively increases myocardial contractile efficiency but 
also generated some concern of possible renotoxicity 236. Nevertheless, allopurinol has been 
shown to attenuate pulmonary vascular remodelling in rats that were exposed to chronic 
hypoxia (13% fraction of inspired oxygen, for 14 days). Allopurinol treatment (50mg/kg/day 
intraperitoneal) significantly reduced xanthine oxidase derived superoxide anion production 
235. Thus, allopurinol proves to have merit as a potential antioxidant treatment in PH.  
It is worth mentioning that even though oxidative stress is detrimental in the pulmonary 
vasculature and cardiac remodelling, its actions in the heart are somewhat complex 75,76. 
Literature indicates that ROS play two major roles in the heart including its ability to cause 
injury to cell components and involvement in cell signalling pathways and antioxidant 
defence 75,76. Piantadosi et al, showed that ROS plays a crucial role in antioxidant-induced 
cardiac mitochondrial biogenesis by liberating, stabilizing and translocation of nuclear 
respiratory factor-2 to the nucleus 237. Upon activation by ROS, nuclear respiratory factor-2 
subsequently binds to multiple antioxidant-response-element motifs which regulate 
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mitochondrial biogenesis, in conjunction with peroxisome proliferator-activated receptor-
gamma coactivator-1-alpha 237.  
This suggests that ROS enable cardiomyocytes to “sense” ROS-induced damage, employ its 
inherent antioxidant systems and counteract the damage as an adaptive response. 76, 237 
Furthermore, ROS have been shown to trigger the activation of rat sarcoma protein or Ras, 
which induces the recruitment of phosphatidylinositol-3’-kinase to Ras 238. This ROS triggered 
activation of Ras is required for the activation of cardioprotective prosurvival, downstream 
signals such as Akt and mitogen activated kinases 238. Therefore, experts believe that 
although antioxidant therapy in experimental PH and RV remodelling is strikingly beneficial, 
this presents a challenge, as ROS also play an important physiological role in health and 
disease 75,76. This physiological balance or ROS related functions should be kept in mind when 
ROS scavenging or antioxidant treatments are administered, as complete depletion of ROS 
may be detrimental.  
Clinical trials employing antioxidant therapy in humans with cardiovascular disease were 
disappointing and this may be due to the fact that the biological function of ROS is not 
completely understood 75,76,239. In the MRC/BHF Heart Protection study (Heart Protection 
Study Collaborative Group, 2002), 20,536 adults were studied for a period of five years 240. 
These patients had coronary artery disease, other occlusive arterial disease or diabetes and 
were randomly divided in three groups that received daily oral supplementation with 
antioxidant vitamins (600mg vitamin-E, 250mg vitamin-C, and 20mg beta-carotene) or 
matching placebo. Primary outcomes were, major coronary events and fatal or nonfatal 
vascular events with assessments of cancer and other major morbidities. In this patient 
population, antioxidant treatment was shown to be safe but did not cause any significant 
reduction in the five year mortality from any type of vascular disease, cancer or any other 
major disease 240. 
Palumbo et al, conducted a randomized controlled, open trial and investigated the effects of 
vitamin-E supplementation (300mg/day for twelve weeks) on clinic and 24 hours ambulatory 
blood pressure in 142 treated hypertensive patients 241. After the treatment period, 
ambulatory blood pressure measurements showed no change in either patients treated with 
vitamin-E or controls. Clinic blood pressure measurements were lower whether or not the 
patients received the vitamin-E supplementation. The authors concluded that chronic 
vitamin-E supplementation has no clinically relevant effect on blood pressure in hypertensive 
patients 241. Similar outcomes were seen in a study by Kim et al, who investigated the effect 
of chronic vitamin-C treatment (50 and 500mg daily for five years) on blood pressure of 439 
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cancer and stroke patients 242. In this study, long term vitamin-C supplementation had no 
effect on either blood pressure or mortality 242.  
Despite the overwhelming success of antioxidant therapy in animal studies, the dismal failure 
of antioxidant therapy to impact human disease left a great sense of disappointment 75,76,239. 
However, this obstacle may be overcome by treatments that specifically targets major 
cellular producers of oxidative stress in particular mitochondria 239,243. The doses of 
pharmacologically administered antioxidants should be carefully controlled to match 
physiological levels of ROS. Another antioxidant that has been tested and shown to be 
effective against oxidative stress and cardiovascular disease in both animal studies and 
clinical trials is melatonin.  
 
4. Melatonin and its role as an antioxidant 
4.1. Biosynthesis of melatonin, circulating levels and its effect on sleep 
Melatonin is an idoleamine hormone synthesized by the pineal gland in the brain, is lipophilic 
and able to cross cell membranes 244-247. Besides being produced in the pineal gland it is also 
secreted by entero-endocrine cells in the upper gastrointestinal tract 248. Melatonin is not 
only produced in the body but also in plants, fruits, during the process of milk production and 
the fermentation of wine 249 250 . It is predominantly synthesized at night time, as day light 
has an inhibitory effect on its production and secretion 251,252. The secretion of melatonin is 
synchronized with a day and night or circadian cycle, during which, night time or darkness is 
sensed by the retina. This light pathway, modulates the activity of the suprachiasmatic 
nucleus which leads to the activation of neurons, from the suprachiasmatic nucleus to the 
paraventricular nucleus in the pineal gland. Here, rate limiting enzymes control the synthesis 
of melatonin from its precursor, the amino acid tryptophan 251,252. During the biosynthesis of 
melatonin, the first rate-limiting enzyme, arylakylamine-N-acetyltransferase convert 
serotonin to N-acetylserotonin, while the second rate-limiting enzyme, hydroxyindole-
methyltransferase, transform acetyl-serotonin into melatonin 248. After melatonin is 
synthesized, it is released into the blood and can reach peak, night time serum levels of 
approximately 10-10 to 10-9 mol/L or 50-140pg/L, while during the day levels can be as low as 
20pg/L 253,254. This pattern of melatonin synthesis and release, led to many studies showing 
the ability of melatonin to reset the biological clock and increase time to sleep onset in 
people with jet-lag, shift workers or children with neurodevelopmental disorders 255-257. In 
2012, Appleton et al, performed a study that included 146 children (3 years to 15 years), with 
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a whole range of neurological and developmental disorders and a severe sleep problems 258. 
Immediate release melatonin or placebo capsules were administered 45 minutes before bed 
time for a period of 12 weeks. All children started with a 0.5mg capsule, which was increased 
to 2mg, 6mg, and 12mg depending on their response to treatment. In this study, melatonin 
increased the total sleep time by 22.4 minutes and reduced sleep onset latency measured by 
sleep diaries. Melatonin treatment was also associated with earlier waking times than 
placebo 256. These data suggest that melatonin is very efficient in resetting the biological clock 
and to regulate the sleeping pattern. However, despite its efficacy in regulating the sleeping 
pattern, its bioavailability has been drawn into question 259. 
 
4.2. Bioavailability of melatonin 
Although melatonin is a highly effective antioxidant, is has a relatively short half-life and 
undergo extensive first-pass metabolism 260,261. Circulating melatonin is metabolised in the 
liver where the first step is hydroxylation at the C-6 position by cytochrome-P450-mono-
oxygenases (isoenzymes CYP1A2, CYP1A1 and to a lesser extent CYP1B1) 262-264. These 
isoenzymes catalyse the formation of 6-hydroxymelatonin, which undergoes further 
conjugation with either sulphate or glucoronic acid. During these steps, melatonin’s highly 
antioxidant by-products, N-acetyl-N-formyl-5-methoxy-kynuramine and N-acetyl-5-
methoxy-kynuramine are formed 262,263,265. However, the majority of orally administered 
melatonin is lost due to the first-pass effect and is excreted in the urine as unchanged 
melatonin 262-264,266.  
A number of studies, investigated the bioavailability of melatonin after oral administration in 
humans 259,260,267,268. In a study by DeMuro et al, oral melatonin at doses 2-4mg had a 
bioavailability of approximately 15%, as only so much of the administered dose, managed to 
reach systemic circulation 259. Due to this low bioavailability, Bartoli et al, developed an oral 
melatonin emulsion spray, administered it sublingually to healthy individuals and compared 
this to the bioavailability after drinking a melatonin pill 260. This spray is absorbed via the oral 
mucosa and avoids the first-pass effect associated with metabolism of melatonin in the liver. 
In this study, the amount of melatonin that reached systemic circulation was twice as high as 
with the pill form, even though the dose of melatonin was the same for both the spray and 
the pills (5mg). Similar work was done by Mao et al, who prepared starch microspheres 
(particle size of 30-60µm) for intranasal administration of melatonin, by an emulsiﬁcation-
crosslinking technique 269. In this study, the entrapment ratio of melatonin in the 
microspheres was 11.0% and melatonin was released from the microspheres in a sustained 
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manner in vitro. The absorption rate was rapid (7.8 min) and the absolute bioavailability was 
as high as 84%. These studies, are important as they develop new ways to increase the 
bioavailability of melatonin in order to increase its efficacy in long-term treatment 270. 
Not undermining the importance of these studies, one need to carefully evaluate the data. 
In the study by DeMuro et al, after oral melatonin administration (pills of 2-4mg), 85% of 
melatonin was lost due to first-pass metabolism 259. However, despite the low bioavailability 
of 15%, the mean concentration of melatonin in the serum of these individuals, reached peak 
values of approximately 4000-5000pg/mL after melatonin administration. These serum 
concentrations are much higher than physiological peak levels and could therefore be the 
reason why, in most studies, the melatonin is still highly effective in scavenging free radicals 
and modulating pathology 250,271-273. Furthermore, apart from its well-known effects, such as 
scavenging free radicals and regulation of the sleeping pattern, melatonin has been shown 
to have many others effects including anti-inflammatory, anti-thrombotic, anti-lipidemic, and 
anti-cancer 244-246,253,254,274. 
 
4.3. Melatonin as a multifunctional molecule 
In 2010, Borazan et al, assessed the efficacy of melatonin as a preoperative medication to 
improve postoperative analgesia in patients undergoing elective prostatectomy 275. In this 
study, 6mg melatonin given orally the night before surgery and one hour post-surgery, 
reduced pain scores in addition to improving quality of sleep of these patients.  
In work by Rosales-Corral et al, melatonin treatment reversed the adverse effects of an 
intracerebral injection of amyloid-Aβ, in an animal model of Alzheimer’s disease 276. Here, 
melatonin reversed the mitochondrial dysfunction and reduced oxidative stress in the brains 
of these animals.  
Furthermore, the anti-cancer effect of melatonin was demonstrated when Ehrlich ascites 
carcinoma cells, were exposed to melatonin 277. Melatonin, reduced the vitality and cell 
volume of these cancer cells and induced apoptosis. These anti-cancer effects of melatonin 
was believed to be mediated via the inhibition of the cell cycle in cancer cells. Also, melatonin 
has been shown to reduce plasma levels of total cholesterol, very low density lipoproteins 
and low density lipoproteins in hypercholesterolemic rats 278. These findings were 
corroborated by Dominguez-Rodriguez et al, who showed that in patients with myocardial 
infarction, nocturnal elevated serum levels of oxidised low density lipoproteins are 
associated with reduced circulating melatonin levels 279. Taken together these studies 
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strongly suggest melatonin as multifunctional molecule with great potential to improve 
various pathologies and their adverse consequences on health. Furthermore, this wide range 
of physiological functions include its potent antioxidant and anti-hypertensive properties.  
 
4.4. Melatonin as an antioxidant and anti-hypertensive agent 
There is a plethora of research proving melatonin to be up to a hundred times more effective 
in scavenging free radicals compared to vitamin E 280,281. Melatonin has its antioxidant effects 
by either directly scavenging ROS or by indirectly stimulating the synthesis/activity of 
antioxidant enzymes 282. These direct antioxidant effects are believed to be receptor 
independent 247,278. Almost more than twenty one years ago, the first report was published 
that melatonin neutralises the highly toxic hydroxyl radical 283. These was corroborated by 
others who by means of a computational study showed that this interaction of melatonin 
with hydroxyl radical is when melatonin chemically binds hydroxyl radical to the C-2 position 
of its indole ring 284. Similarly, melatonin can also interact with hydrogen peroxide and form 
by-products such as water and N-acetyl-n-formyl-5-methoxy-kynuramine (AFMK) 285. An 
interesting fact of melatonin is that during most of these oxygen free radical scavenging 
reactions, melatonin’s by-products including AFMK or 3-hydroxymelatonin also have 
antioxidant abilities 286 282. This was shown by Tan et al, that AFMK reduces oxidative damage 
to lipids and DNA in cells exposed to hydrogen peroxide, glutamate or amyloid-beta 285,287. 
Therefore, the potent antioxidant effects of melatonin are not just due to its own actions but 
also its daughter molecules.  
The indirect effects of melatonin are usually achieved via its membrane bound G-protein 
coupled receptors, melatonin receptors (MT-1, 2 and 3) 282. These receptors of melatonin 
have been shown to be present throughout the cardiovascular and the pulmonary vascular 
systems 247. In particular, the melatonin receptors 1 and 2 have been found to be present on 
cardiomyocytes of the human heart and coronary arteries 253,254. Upon binding to its 
receptors (MT-1 and MT-2), melatonin can activate various signalling pathways including the 
cAMP/PKA pathway which could inhibit the cAMP-response element binding protein or 
activation transcription factor (CREB-ATF) 288,289. This could modulate immediate early gene 
transcription and gene transcription regulation of antioxidant enzymes. Other pathways 
regulated by melatonin include the ERK/JNK pathway and the phospholipase-C/PKC/NFkB 
pathway, which could also modulate antioxidant enzyme gene expression (Figure 11).  
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Melatonin also has antihypertensive properties either by increasing plasma levels of L-
arginine, which is a substrate used by endothelial nitric oxide synthase to produce nitric oxide 
251,252. Furthermore, melatonin also reduces circulating levels of the natural inhibitor of nitric 
oxide, asymmetric dimethyl arginine, or intracellular calcium levels, and elevate cyclic-GMP 
in order to cause vasodilation 290 (Figure 11). Melatonin has been shown to be beneficial in 
various pathologies including atherosclerosis, ischemia/reperfusion injury, cardiac 
hypertrophy as well as hypertension 244-246,273,291. Evidently, both the antihypertensive and 
antioxidant effects of melatonin have been well substantiated in animal models of 
cardiovascular pathology. 
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4.5. Indications that melatonin could be a potential treatment for pulmonary hypertension 
According to our knowledge, there are currently no studies that tested melatonin as a 
possible treatment against PH. However, both its antioxidant and antihypertensive 
properties makes it a likely option for a cardioprotective treatment that can be given as a 
complimentary treatment in PH. The cardioprotective effects of melatonin have been 
confirmed in the literature where melatonin treatment, at the concentration found in red 
wine, could protect against ischemic/reperfusion injury 250. Similarly, chronic melatonin 
treatment, in a rat model of diet induced obesity, was found to be cardioprotective 273. There 
is no scientific evidence that melatonin has been tested as a treatment in PH but there are 
some indications that melatonin could be a potential cardioprotective treatment in PH. These 
indications are found in studies performed in both animal models that display oxidative stress 
or hypertensive cardiomyopathy in humans with systemic hypertension.  
 
4.5.1. Melatonin in animal models: Antioxidant and antihypertensive effects 
Gosh and colleagues investigated the effects of melatonin in a rat model of triiodo-L-
thyronine-induced cardiac hypertrophy 292. Melatonin was administered intraperitoneally 
(2mg/100g body weight) one hour before triiodo-L-thyronine treatment and after 15 days 
the rats were sacrificed. Triiodo-L-thyronine resulted in cardiac hypertrophy, which was 
reduced by the melatonin pre-treatment. Melatonin also suppressed lipid peroxidation and 
hydroxyl radical levels and prevented the inhibition of superoxide dismutase in the 
hypertrophic hearts 292. This was a striking finding, as it showed melatonin’s ability to have 
beneficial effects even in such a short period of pre-treatment. In rats injected with 
melatonin (10mg/kg intraperitoneally) and subsequent exposure to intermittent hypoxia, 
cardiac, kidney and lung lipid peroxidation was decreased, with no effect on liver 
peroxidation. It is important to note that in the first study, the heart was the organ that had 
the pathology (triiodo-L-thyronine-induced cardiac hypertrophy) while in the second study it 
was the lung that was directly exposed to the pathological insult by means of hypoxia. These 
studies suggest that melatonin, has the ability to protect the biological site that is directly 
under “attack” as well as to those affected indirectly. This is an important point as, in the 
case of PH, the lung is the main site of pathology but the heart is indirectly affected. Thus, 
the antioxidant effect of melatonin may be of real benefit in PH with regards to both the lung 
and the heart. 
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Tain et al, assessed the effect of melatonin on blood pressure in spontaneous hypertensive 
rats 293. The rats were caged for 4 weeks to allow hypertension to fully develop and in the 
following 8 weeks, they received melatonin treatment (0.01% in the drinking water). Both 
the systolic and diastolic blood pressures were decreased in the rats treated with melatonin. 
Melatonin also reduced the plasma levels of asymmetric dimethyl arginine, which is a natural 
inhibitor of nitric oxide. Furthermore, it also restored plasma levels of L-arginine (a substrate 
for the production of nitric oxide) and reduced oxidative stress as displayed by the levels of 
8-hydroxydeoxyguanosine.  
Here, melatonin attenuated hypertension by restoring the nitric oxide pathway and 
attenuating oxidative stress 293. This study corroborates data by Girouard, who also 
investigated the effects of melatonin treatment (30mg/kg for four weeks) on blood pressure 
in spontaneous hypertensive rats 294. Melatonin treatment reduced mPAP, systolic and 
diastolic pressures. In this study, vasorelaxation was induced with a calcium ionophore, in 
mesenteric artery beds isolated from spontaneous hypertensive rats. Melatonin improved 
vasorelaxation as well as sensitivity of the nitric oxide pathway. It is suggested by others that 
this melatonin-induced sensitivity of the nitric oxide, may occur via the increase in cyclic 
guanosine monophosphate levels and decreased cytosolic calcium in smooth muscle cells 
251,252. Another possible mechanism for the effect of melatonin on blood pressure may be 
nitric oxide-induced vasodilation and antioxidative properties (See figure 10). Overall, 
melatonin proved to be a molecule with surprising ability and its striking efficacy in 
attenuating cardiovascular disease in animal models created great hope for similar 
therapeutic success in humans. There were in fact some studies that investigated the 
antioxidant and antihypertensive effects of melatonin. 
 
4.5.2. Melatonin in humans: Antioxidant and antihypertensive effects 
Healthy volunteers were randomly divided into two groups: one group that received oral 
administration of melatonin (6mg) for two weeks and the other group that received no 
melatonin treatment 295. Blood samples were collected before melatonin administration, on 
the seventh and fourteenth day of melatonin treatment and on the tenth day after the last 
dose of melatonin. Blood samples were assessed and plasma antioxidant ferric reducing 
ability was increased and lipid/deoxyribonucleic acid peroxidation was decreased in the 
melatonin treated group.  
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Furthermore, investigators noticed that these beneficial effects of melatonin were 
maintained even 10 days after discontinuation of melatonin treatment 295. This study is a 
clear indication that melatonin can increase the antioxidant ability of the plasma even in the 
absence of pathology. In another study, melatonin treatment before a major event such as 
surgery has been shown to decrease pain scores, the use of pain medication and subjective 
analgesic efficacy during the postoperative period 275. Umbilical arteries from healthy 
pregnant women who delivered between 37 and 39 weeks of gestation were cut into small 
sections 296. These artery sections were pre-treated with melatonin (10-8M to 10-6M) and the 
effect of hydrogen peroxide on the response of the segments to external calcium was 
determined. Melatonin pre-treatment significantly suppressed the contractile response to 
external calcium and thus the vaso-spastic effect of hydrogen peroxide on umbilical arteries. 
This effect of melatonin was attributed to the scavenging of the hydroxyl radical 296. All these 
studies suggest that pre-treatment with melatonin may have beneficial effects but one 
should keep in mind that excessive use of antioxidants may be detrimental. 
In a randomized, double blinded, placebo controlled, crossover trial in sixteen men with 
untreated hypertension, repeated oral doses of melatonin (2.5mg/kg for three weeks) 
reduced systolic and diastolic blood pressure 297. In another study where normotensive and 
hypertensive women were treated with melatonin (3mg/kg) for three weeks, investigators 
observed a significant reduction in the nocturnal systolic diastolic and mean arterial pressure 
298. It is known that systolic and diastolic blood pressures fluctuates in humans with 
hypertension and is at its highest during the day and lowest at night 244-246. Patients who do 
not display a lower blood pressure at night are at a higher risk for cardiovascular mortality 
299. Therefore, these two studies are very crucial as they show that melatonin has the ability 
to reduce nocturnal blood pressure in hypertensive patients which in theory should reduce 
their risk of cardiovascular mortality.  
Lastly, in a randomized, double blinded, placebo controlled study on 36 patients with 
clinically stable moderate to severe COPD, melatonin treatment (3mg capsule, once a day 
before bedtime for 3 months) reduced oxidative stress and improved dyspnoea but had no 
significant effect on exercise capacity or lung function 300. It appears that melatonin has the 
ability to reduce oxidative stress in COPD which is also a well-known risk factor for PH 300. The 
latter study elicited my interest into whether anyone investigated the ability of melatonin to 
affect oxidative lung damage or lung injury. 
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4.5.3. Melatonin in animal models: Its effect on oxidative lung damage and lung injury 
In rats subjected to aortic occlusion for 30 minutes and reperfusion for 12 hours, 
ischemia/reperfusion injury was present in the lungs with concomitant low survival 301. 
Melatonin pre-treatment (2mg/kg intraperitoneally) one hour before surgery, reduced 
oxidative stress (in particular, malonic dialdehyde levels). In another study, rats received a 
single injection of melatonin (10mg/kg intraperitoneally) and were exposed to hyperbaric 
oxygen (100% oxygen at four atmospheres) for 90 minutes 302. Here, melatonin prevented 
the increase in lipid peroxidation (malonic dialdehyde levels) as observed in the control group 
and maintained reduced oxidative stress at levels similar to that of the control rats.  
In rabbits exposed to cigarette smoke in a glass chamber for one hour daily (for one month), 
melatonin (1mg/kg intraperitoneal) reduced oxidative stress and damage in the bronchioles 
303. These data are supported by the work of Pedreira and colleagues who showed that pre-
treated with melatonin (10mg/kg intraperitoneally), decreased lung injury oedema, 
haemorrhage and infiltration of inflammatory cells, in a mouse model of ventilator-induced 
lung injury 304. These studies collectively suggest that melatonin is effective in improving lung 
damage associated with either oxidative stress or damage of a mechanical cause. There are 
currently no reports of the effects of melatonin in animal models of PH. However, the studies 
which are available highlight important aspects of melatonin and support it as a potential 
treatment for PH. These available studies mostly investigate the effects of melatonin on 
isolated pulmonary arteries. 
 
5. Concluding remarks 
The evidence that melatonin may be of benefit in PH is copious and there is a whole range of 
reasons to support this notion: (i) other antioxidants have failed in altering cardiovascular 
pathology when tested in clinical trials, while melatonin has been successful in doing this, (ii) 
melatonin is strikingly effective in attenuating hypertension in both animals and humans. In 
brief, various mechanisms which underlie these effects have been proposed and include 
suppression of circulating catecholamines, relaxation of smooth muscle in the peripheral 
blood vessels due to its antioxidant activity or receptors present on peripheral blood vessels 
244-246. More reasons in support of the notion that melatonin may be of benefit in PH, are that 
(iii) melatonin treatment is not associated with toxic or adverse effects in either animals or 
humans and (iv) circulating melatonin levels has been shown to be decreased in patients with 
hypoxic/destructive lung disease as well as cardiovascular disease which are risk factors for 
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PH 305-308. Therefore, based on the bulk of the evidence presented here, the antioxidant and 
antihypertensive effects of melatonin makes it an attractive therapeutic target for the 
protection of the heart and possible treatment of PH. Melatonin is investigated in this PhD 
study for its potential as a possible complementary cardioprotective treatment for PH. 
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SECTION B 
HYPOTHESIS AND OBJECTIVES 
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PH is a fatal disorder that currently has no cure and only palliative therapy with limited health 
benefits. It is a global health threat with increasing disease burden and patients with PH have 
a poor prognosis and quality of life. In Sub-Saharan Africa, in particular South Africa, PH has 
become a depressing reality as a considerable number of patients with HIV/AIDS, chronic 
obstructive lung disease and congenital heart defects often develop PH 145. There is a wide 
range of drugs available to limit the negative outcomes of patients with PH including 
endothelin-1 receptor antagonists, prostacyclin analogues, and phosphodiesterase type-5 
inhibitors (e.g. sildenafil). Sadly, sildenafil is the only drug currently available in South Africa 
and is unfortunately very expensive 145. All of this paints a grim picture for South African 
patients living with this dreadful disease, but it also highlights the need for new treatments. 
There are various mechanisms involved in the development of PH, in particular oxidative 
stress caused by highly ROS 29,30,210,211. A very promising novel therapeutic drug target, 
melatonin, has been shown to provide protection against cardiovascular disease. Melatonin 
is a powerful antioxidant, shown to be up to a hundred times more potent than vitamin E 
and it also presents anti-hypertensive properties 281,285. The use of melatonin in humans has 
no reported side effects, it is relatively inexpensive and available in many countries. 
Melatonin levels are disrupted in certain cardiovascular pathologies such as myocardial 
infarction, and exogenous melatonin has been proven to be beneficial against ischaemic and 
hypertensive heart disease, most probably due to its antihypertensive properties 250,273. 
 
1. Hypothesis 
We therefore hypothesise that melatonin may be used as an effective treatment in 
pulmonary vascular diseases, providing beneficial effects on the pathophysiological outcome 
of experimental PH.  
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2. Objectives: 
To test this hypothesis the following objectives will be pursued: 
a) Assess oxidative stress in South African patients with PH by measuring blood plasma 
levels of lipid peroxidation (a marker of oxidative stress), plasma antioxidant capacity 
(oxygen radical absorbance capacity), antioxidant enzymes catalase and superoxide 
dismutase activities (Section C). 
b) Validate an experimental model of PH by injection in Long Evans rats a toxin called 
monocrotaline (MCT) (80mg/kg subcutaneous). This model has never been induced 
in this particular rat strain and therefore we need to first validate whether the Long 
Evans rat strain will recapitulate the characteristics of PH, 28 days after the injection. 
We will also establish whether oxidative stress is present in the blood plasma of these 
rats, with assays that were performed in the blood plasma of patients. We will also 
collect heart samples for histological analyses of interstitial fibrosis (Section D). 
c) Test various doses of melatonin, to see whether melatonin can confer 
cardioprotection and to ascertain the most efficacious dose against PH. To assess this 
hypothesis we will measure cardiac function with echocardiography and the isolated 
heart perfusion apparatus in rats with/without PH and treated daily with melatonin 
from the day of the injection with MCT. In addition we will measure biometric 
parameters, collect blood plasma samples and perform blood plasma assays to 
assess lipid peroxidation, plasma antioxidant capacity and activities of catalase and 
superoxide dismutase. We will also collect and prepare heart samples from all 
treatment groups to do histological staining in order to assess cardiac interstitial 
fibrosis. The first concentration of melatonin will be 75ng/L (oral) which corresponds 
to the concentration of melatonin absorbed via nutrition 250. The other doses of 
melatonin (4mg/kg and 6mg/kg, oral) are comparable to the pharmacological doses 
of melatonin absorbed by taking tablets 273,309 (Section E).  
d) Administer melatonin treatment either as a therapeutic intervention given daily 
(given fourteen days after the induction of experimental PH) or as a preventive 
intervention (given five days before the induction of experimental PH). Hereafter, we 
will assess cardiac function and blood plasma oxidative stress and antioxidant 
capacity as described above. Heart samples will also be collected and used for 
histological staining for cardiac interstitial fibrosis (Section F).  
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SECTION C 
MATERIALS AND METHODS 
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1. Evaluation of oxidative stress in a patient population with pulmonary hypertension 
1.1. Patient recruitment and clinical assessments 
Patients were referred from a primary to a secondary cardiac clinic at GF Jooste hospital 
(Cape Town, South Africa) if they had symptoms including shortness of breath, fatigue, 
peripheral oedema, and persistent cough at night (tuberculosis was excluded at primary care 
level). Ten of these patients underwent clinical investigation which comprised medical 
history, clinical examination, chest X-ray, electrocardiogram and echocardiography (where a 
RV systolic pressure of above 35 mmHg confirmed the diagnosis of idiopathic-PH). The 
patients were also required to do a six minute walk test, to determine their capacity to do 
exercise and then blood samples were collected and stored for later experimentation. 
Furthermore, blood samples were collected from ten healthy individuals and used as 
controls. All the blood samples were used for the determination of the overall antioxidant 
capacity of the blood plasma, as well as the activity of antioxidant enzymes; a marker of 
oxidative stress, catalase and superoxide dismutase. All experimental protocols were 
approved by the faculty of health sciences human research ethics committee, university of 
Cape Town (241/2011).  
Systolic and diastolic blood pressure was measured using conventional Korotkof sounds. 
Blood pressure was measured at the right arm three times, with a five minute rest between 
each measurement. Patients were weighed without shoes and in light clothing on a standard 
beam balance. Height was measured to the nearest centimetre using an anthropometric 
plane, with patients not wearing shoes or headgear. Body mass index was calculated as 
kg/m2. All subjects also had 12-lead electrocardiogram performed by a trained technician 310. 
Echocardiography was performed using a commercially available ultrasound system (IVIS-
60). Subjects were examined in the left lateral decubitus position using standard parasternal, 
short-axis, and apical views. Measurements were performed according to the guidelines of 
the American Society of Echocardiography 311. The LV measurements included 
interventricular septal thickness at end-diastole (IVSd), the posterior wall thickness at end-
diastole (PWTd), and the LV internal dimensions at end-diastole (LVIDd) and end-systole 
(LVIDs). The LV systolic function was calculated by Teichholz’s formula and by volumetric 
analysis when a regional wall motion abnormality was detected. The LV flow velocities were 
measured using pulsed-wave Doppler from the apical four-chamber view with sample 
volume located between the tips of the mitral valve leaflet during ventricular diastole. Peak 
velocity of early rapid filling (E), peak velocity of late filling caused by atrial contraction (A), 
and the interval from peak E wave to its extrapolation to the baseline or deaccelaration time 
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(DT) were measured. LV filling was classified into normal filling (E/A ¼ 1–2 and eDT ¼ 130–
220 ms), impaired relaxation (E/A .1 and DT 220 ms), restrictive filling (E/A .2 and DT, 130 ms) 
and pseudonormal filling (E/A ¼ 1–2 and DT 220 ms). The right heart function was measured 
according to standard criteria 311. Right-sided heart failure or PH was defined as heart failure 
secondary to right-sided pathology with increased jugular venous pressure and liver size, 
tricuspid regurgitation, and/or elevated RV systolic pressure ≥ 35 mmHg 312.  
 
1.2. Blood sample collection 
Blood samples were collected from the median cubital vein and the nurse or physician used 
a scalp vain infusion set (23Gx3/4”) (Lasec, South Africa) that was connected to a blood 
collecting tube (BD-vacutainer, containing EDTA as anticoagulant) (Lasec, South Africa). The 
tube was gently tilted twice and immediately placed on ice. The tubes were transferred to a 
precooled (4°C) bench centrifuge (Eppendorf Centrifuge 5804R) and centrifuged for ten 
minutes at 2500rpm (revolutions per minute). Centrifugation separated the blood into two 
phases with the plasma phase on top. The plasma was transferred with a pipette (Lasec, 
South Africa) into 2mL Eppendorf tubes in aliquots of 300μL each. These tubes were marked 
with the number of the patient, the date and whether the patient was part of the control or 
PH group. Plasma aliquots were stored at -80°C until used for the various assay analyses. 
 
1.3. Thiobarbituric reactive substance assay 
The thiobarbituric acid reactive substance (TBARS) assay measures malonic dialdehyde, 
which is a reactive compound formed during lipid peroxidation caused by ROS (also known 
as oxidative stress) 313. Lipid peroxidation occurs during various diseases, including 
cardiopulmonary vascular disease. During this assay, blood plasma samples are mixed with 
thiobarbituric acid and malonic dialdehyde, formed during lipid peroxidation within the 
sample, forms a pink coloured adduct with thiobarbituric acid. This pink colour is measured 
at a certain wave length and used as an indication of the level of TBARS produced. 313 The 
darker the pink colour, the higher the level of TBARS. The levels or concentrations of TBARS 
were measured by a spectrophotometric method (SPECTRAmaxPLUS-384).  
Concentrations were calculated using the appropriate molar extinction coefficients and 
standards. Fifty microlitres of the blood plasma (sample) was mixed with 6.25µL butylated 
hydroxytoluene (4mM, in ethanol) (Sigma, South Africa) and 50µL of ortho-phosphoric acid 
(0.2M) (Sigma, South Africa) in an Eppendorf tube. The tube was vortexed for ten seconds 
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after which, 6.25µL of TBA or thiobarbituric acid reagent (Sigma, South Africa) was added and 
the tube was vortexed for another ten seconds. 
The samples were microfuged (Spectrafuge 16M, Labnet) for two minutes at a speed of 
3000rpm, at 4°C to collect the volumes at the bottom of the tubes. The samples were placed 
on a heating block, pre-set at 90°C for 45 minutes. Subsequently, the samples were placed 
on ice for two minutes and left at room temperature for five minutes. Five hundred 
microlitres of n-butanol (Merck Chemical, South Africa) was added to each sample as well as, 
50µL of saturated sodium chloride and vortexed for ten seconds.  
Hereafter, the samples were microfuged at 12000rpm for two minutes at 4°C. This separated 
the samples into a transparent, top-butanol phase and a bottom-phase containing the white 
protein pellets. Three hundred microliters of the butanol phase was pipetted into the wells 
of a UV readable, Greiner-96 well plate (Lasec, South Africa). The absorbance was read at 
532nm, with a micro plate data acquisition program (SoftMax® Pro 4.8) and the Beer-
Lamberts law was used to calculate the concentration of malonic dialdehyde in the samples 
with an extinction coefficient of 1.54x105 M-1/cm-1 313. The final values were expressed in 
µmol malonic dialdehyde/mL plasma (Figure 13). 
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1.4. Oxygen radical absorbance capacity assay 
The oxygen radical absorbance capacity (ORAC) assay is a method to assess the antioxidant 
capacity of biological samples 314,315. The assay determines the ability of plasma samples, to 
scavenge free radicals. With this assay, free radicals are generated from the thermal 
decomposition of 2, 2’-azobis-2-methyl-propanimidamide dihydrochloride (AAPH) (Sigma 
Aldrich, South Africa), on the signal intensity from the fluorescent probe (fluorescein, 3’, 6’-
dihydroxyspiro [isobenzofuran-1[3H], 9’ [9H]-xanthen-3]) (Sigma Aldrich, South Africa), in the 
presence of an oxygen radical absorbing substance. The stronger the absorbing capacity, the 
more the free radicals are scavenged, thus maintaining the intensity of the fluorescent signal 
observed. In order to obtain measurements, the area under the curve of the fluorescence 
intensity versus time is subtracted from that of the blank, to determine the antioxidant 
capacity of the blood plasma, in trolox equivalents. Trolox is a vitamin-E analogue that is used 
as the standard measure of antioxidant capacity. 
A trolox (6-OH-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid) (Sigma Aldrich, South Africa) 
standard curve was prepared by doing a range of dilutions. Firstly, 0.0050g of trolox was 
diluted in 200µL ethanol (100M) of which 100µL was added to 9.9mL of phosphate buffer 
(1000µM). Then, 1mL of this solution was added to 9mL of phosphate buffer (5nmol/L). We 
then took, 300µL of this solution and added it to 300µL of phosphate buffer (2.5nmol). 
Hereafter, 300µL was added to 300µL of phosphate buffer (1.25nmol/L). Similarly, further 
dilutions (0.625nmol/L, 0.313nmol/L, 0.156nmol/L and 0.078nmol/L) were prepared. The 
phosphate buffer contained K2HPO4·3H2O (0.75M) and NaH2PO4·H2O (0.75M) mixed to a final 
concentration of 0.75M, pH 7.4 (Figure 14). Fluorescein was prepared by making a range of 
dilutions. The first stock solution was prepared by adding 0.0225g fluorescein to 50mL of 
phosphate buffer (0.0012 mol/L), the second stock solution, by adding 50µL of stock number 
one to 10mL of phosphate buffer (5.98µmol/L) and the working solution was made by adding 
320µL of stock solution two to 20mL of buffer (95.7nmol/L)(Figure 15). 
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The AAPH solution was prepared by adding 0.087g of AAPH to 980µL of warm (37°C) 
phosphate buffer, to a final concentration of 0.33M. Fifty microlitres of AAPH was quickly 
added from wells A5 to well H12 and the timer was started. The amount of AAPH was 
dependent on the amount of samples analysed plus the number of wells used for the blanks 
and the trolox standard curve (Figure 16). 
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The plasma samples were deproteinized by adding 200µL of ice cold (4°C) ethanol (Merck 
Chemicals, South Africa) to 100µL of plasma. This was vortexed for ten seconds and 
microfuged at 12000rpm, for five minutes and the proteins precipitated at the bottom of the 
tube. The supernatant was pipetted into a new tube, to which 500µL of phosphate buffer 
(0.075M, pH 7.4) was added. Then, the supernatant (sample) was further diluted by first 
taking 160µL and adding it to 840µL of phosphate buffer. This was vortexed for 10 seconds 
and 100µL was added to 700µL of phosphate buffer and the final dilution was achieved by 
taking 200µL of the previous dilution and adding 200µL of buffer. This formed the final 
sample which was used for further experimentation (Figure 17 and 18). 
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Three hundred microliters of phosphate buffer was added to well A1 and A2 (blank), 200µL 
of phosphate buffer in A3 and A4 plus 100µL of fluorescein. To wells A5 and A6, 100µL of 
phosphate buffer was added and 100µL of fluorescein, into wells A7 and in A8 50µL of 
phosphate buffer and 50µL of fluorescein. In wells A7 to B8, 50µL of phosphate buffer was 
added as well as 50µL of fluorescein and 50µL of trolox (0.078nmol/L, 0.156nmol/L, 
0.313nmol/L, 0.625nmol/L, 1.25nmol/L, 2.5nmol/L and 0.078nmol/L respectively) (table 1). 
All the samples were then added into wells B9 until H12 (dependent on the amount of 
samples). Every component of this assay including the samples was added into the wells in a 
duplicated fashion. For the ORAC assay, the samples were loaded into a 96-well, white flat 
bottomed, micro titre plate Polysorp®-Nunc (Lasec, South Africa) and readings were recorded 
at an excitation wavelength of 485nm and emission wavelength of 520nm, with a micro plate 
data acquisition program (Advanced Reads®). 
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1.5. Catalase activity assay 
The catalase activity assay is based on the principle that catalase, an antioxidant enzyme, 
catalyses the reduction of hydrogen peroxide to water 316. For this assay, 30% hydrogen 
peroxide (Sigma Aldrich, South Africa) was diluted to a concentration of 12mM by adding 
150µL of hydrogen peroxide to 100mL of phosphate buffer. The phosphate buffer was 
prepared by adding KH2PO4 (50mM) to Na2HPO4 (50mM) to a final volume of one litre and a 
final concentration of 50mM (pH 7.0). All the samples were diluted to a ratio of one-in-ten. 
Into the first two wells (A1 and A2), 241µL of phosphate buffer was added and 241µL of 
hydrogen peroxide into wells A3 and A4. In the remainder of wells, 10µL of the diluted 
samples was added as well as 10µL of phosphate buffer.  
The Costar 96-well plate (Lasec, South Africa) was then inserted into the spectrophotometer 
(SPECTRAmaxPLUS-384) and a reading was recorded at 240nm to ascertain that the 
absorbance of the diluted hydrogen peroxide was approximately 0.523 ± 0.025. Hereafter, 
221µL of the diluted hydrogen peroxide was added to each well and the timer was started. 
A reading was recorded (at time point zero) and exactly one minute later another reading 
was recorded (Figure 19). The values were typed into a Microsoft Excel sheet, and the one 
minute reading was subtracted from the reading at time point zero. The difference between 
these two values was used to calculate the final catalase activity which was expressed as 
international units per milligram protein. 
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1.6. Superoxide dismutase assay 
Plasma superoxide dismutase (SOD) activity was measured by using a method adapted from 
Dalloz et al. 317. This assay is based on the principle that xanthine oxidase catalyses the 
oxidation of xanthine to uric acid and in the process ROS is produced. During this chemical 
reaction, cytochrome-C is reduced and this reduction rate as measured at 550nm 
wavelength317. The first step was to prepare all constituents of the assay including phosphate 
buffer, sodium azide, xanthine, ammonium sulphate, superoxide dismutase (stock solutions 
for the purpose of the standard curve), xanthine oxidase solution and the reaction solution 
(Figure 20). The second step was to determine the reaction slope (absorbance) of the 
xanthine oxidase solution, during which more or less xanthine oxidase was added to adjust 
the reaction slope (absorbance) to approximately 0.025±0.027. To do this, 290µL of the 
reaction solution was added to wells A1 and A2 of the Greiner 96-well plate, together with 
6µL of phosphate buffer. In wells A3 and A4 was added 290µL of reaction solution and 9.5µL 
of phosphate buffer. Then, 3.5µL of xanthine oxidase was only added to wells A1 and A2 and 
the timer was started for 3 minutes. The plate was inserted into the spectrophotometer (pre-
heated to 37°C) and the absorbance was read at 550nm, with a micro plate data acquisition 
program (SoftMax® Pro 4.8). This was considered the reading at time point zero and after 
exactly three minutes, another reading was recorded. The reaction slope of the xanthine 
oxidase was then calculated by subtracting the last reading from the first. Once, this slope 
(absorbance) was adjusted to approximately 0.025±0.027, the rest of the assay was 
performed (Figure 21). 
The third step was to prepare the range of SOD dilutions in order to generate the SOD 
standard curve. Here, the SOD stock solution was used to prepare five standards: zero IU/mL 
(0µL SOD in 5mL phosphate buffer), 10 IU/mL (10µL SOD in 4990µL phosphate buffer), 20 
IU/mL (20µL SOD in 4980µL phosphate buffer), 40I U/mL (40µL SOD in 4960µL phosphate 
buffer), 80 IU/mL (80µL SOD in 4920µL phosphate buffer). In a clean 96 well plate, 3.5µL of 
each standard was pipetted into wells A1 to A10 in a duplicate manner. In these wells were 
also added 290µL of reaction solution and 6µL of phosphate buffer. During the fourth step of 
the assay, 3.8µL of each blood plasma sample was added to the separate wells (dependant 
on the amount of samples assayed). After all the additions were made, 3.5µL of xanthine 
oxidase was added to all the wells containing the SOD and the plate was inserted into the 
spectrophotometer. A reading was recorded at time point zero with a micro plate data 
acquisition program (SoftMax® Pro 4.8) and exactly three minutes later another reading was 
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recorded (Figure 22).The final reaction slope was determined and the final plasma SOD 
activity was expressed in international units per milligram protein.  
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1.7. Protein determination of blood plasma samples 
Blood plasma protein concentrations were determined by using the Quant-iT fluorometer 
(Invitrogen, South Africa). The kit was very selective for proteins in a range of 0.25-5.0µg/mL 
and when purchased, it included protein buffer, three standards and a protein reagent 
(fluorophore). The fluorometer was calibrated with three standards and all dilutions were 
made as described by the manual provided by the manufacturer. One micro litre of plasma 
was diluted by adding 199µL working solution (protein reagent plus protein buffer) and left 
to incubate for 15 minutes at room temperature. The tubes containing the diluted plasma 
samples were inserted into the fluorometer and a reading was recorded at 470nm 
excitation/590nm emission. If the protein concentration of the samples were too high or out 
of range, the samples were further diluted by adding 100µL of the previous sample dilution 
to 100µL of protein buffer.  
 
2. Validation of the experimental model of pulmonary hypertension 
2.1. Housing of rats 
All experiments were conducted in male Long Evans rats, as housed by the University of Cape 
Town’s animal unit, in a 12 hour dark/light cycle. Room temperature was kept at 22°C and 
humidity at 40% and the rats had ad libitum access to food and drinking water. All protocols 
were carried out in compliance with the guide for the care and use of laboratory animals 
published by the United States National Institute for Health in 1996. All experimental 
protocols were approved by the Faculty of Health Sciences animal Ethics Committee, 
University of Cape Town (ethical number 011/033). A maximum of three rats were housed in 
a cage and their tails were marked with a permanent marker which ensured that we knew 
exactly which data was generated from which rat. This was important as rats may respond 
differently to treatment and allowed us to retrospectively analysed data of every individual 
rat.  
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2.2. Experimental model of monocrotaline-induced pulmonary hypertension 
Monocrotaline (MCT) an alkaloid that originates from the plant Crotalaria spectabilis, was 
found to be a constituent of herbal tea used by natives in the West Indies many years ago 
and has been reported to cause hepatotoxicity as well as PH 318-321. Initially, a model of PH 
was established by feeding rats the seeds of Crotalaria spectabilis or by injecting non-human 
primates with a suspension of MCT 322-324.  
The mechanism whereby MCT causes PH requires it to be metabolized in the liver by the 
enzyme cytochrome-P450 into pyrrolic derivatives which initiates endothelial injury in the 
lung 325. This leads to pulmonary vasculitis and obstructive pulmonary vascular remodelling 
characterized by narrowing/obliteration of the vascular lumen features that are seen in 
various manifestations of PH 324,325. This pulmonary vascular remodelling precipitates as PH 
and RV remodelling 324,325. It is now general practice to inject rats with a single subcutaneous 
dose of MCT (60-80mg/kg) to induce moderate to severe PH and RV remodelling after 21-28 
days following injection of MCT 208,326,327. 
In this project, the body weights of all the rats were measured every day during the treatment 
protocol (from day zero, which represents the day of injection, until day 28 or day minus five 
until day 28) when appropriate. The weights of the animals were recorded in monitoring 
sheets tailored specifically for this project (Table 2). In the monitoring sheet, a whole range 
of factors were assessed including abnormal feeding, lethargy, piloerection, cyanosis of lower 
extremities, dyspnoea, discomfort and stress and physical deterioration as well as injection 
with MCT or the treatment with melatonin. If any rat lost more than ten percent of its initial 
body weight (as documented on day zero) it was euthanized with an intraperitoneal injection 
of sodium pentobarbitone (160mg/kg). The carcase was concealed in a plastic bag; placed in 
a -20°C refrigerator and incinerated by a bio waste removal company. 
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The dose of MCT (Sigma-Aldrich, South Africa) consisted of a single subcutaneous injection 
of MCT at 80mg/kg and this dose was chosen based on a study done by Handoko et al. (2009) 
as this was the only study that used this particular dose of MCT and measured cardiac 
function with the isolated rat heart perfusion apparatus. The MCT injection resulted in RV 
remodelling in the third to fourth week after injection (approximately 28 days) 208. All control 
rats received one single subcutaneous injection of sterile saline (0.9% NaCl). The calculation 
and preparation of MCT, for example three rats (per cage), was done by weighing all three of 
the rats on day zero. On day zero, rats were dispatched by the animal unit staff according to 
the required range of body weight. As an example, for one set of experiments, a total of 24 
rats were received and randomly divided into six rats per group. Then for each group, three 
rats were kept in one cage which meant that each group had two cages with three rats per 
cage. In total, there were eight cages for such an experiment. The three rats in each cage 
were marked on the tail with a black permanent marker by means of black stripes (one to 
three). All the rats were weighed and the initial body weights were recorded in rat monitoring 
sheets (Table 2). 
 
2.3. Preparation of the monocrotaline solution 
The amount of 140mg MCT was then dissolved in approximately 500μL of hydrochloric acid 
(1N) and neutralized with 500μL of sodium hydroxide (10N) 328. This yielded a total of 1mL 
MCT, which was made up to 5mL with sterile saline (0.9%). The pH of this solution was then 
measured and set to a pH of 7.4-7.5 with either hydrochloric acid (1N) or sodium hydroxide 
(10N) (Jenway 3510 pH meter, Lasec, South Africa). After the pH was adjusted, the solution 
was made up to a volume of 8mL and the pH was checked again just to confirm the previous 
measurement. If the pH was correct, the solution was brought to final volume of 10mL and 
the final concentration of MCT was 14mg/mL. 
 
2.4. Echocardiography: Cardiac function 
Anaesthesia was induced with 4% isoflurane gas (SAFELINE Pharmaceuticals (pty) ltd.) and 
maintained at 2% isoflurane in room air supplemented with 100% O2 (Afrox, South Africa). 
Rats were laid in a supine position, with all legs taped to a heated pad. Body temperature 
was maintained at 36.5°C to 37.5°C using the heated pad and infrared lamp. The rat’s chest 
was shaved with an electrical hear removal machine to reduce ultrasound interference. To 
provide a coupling medium for the transducer, a warm ultrasound gel was spread over the 
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chest wall. Transthoracic 2-dimensional, B and M-mode imaging was performed with a high-
resolution imaging system equipped with a 10-MHz transducer (Vivid-E, GE Healthcare). A 
number of parameters were measured including LV-end diastolic volume, LV-ejection 
fraction; LV-fractional shortening and LV end diastolic volume. After the echocardiography 
procedure was performed on day zero, the rat was placed in a cage and allowed to regain 
consciousness. When the procedure was performed on the day of sacrifice (day 28), the rat 
was kept on isoflurane (4%) inhalation, to induce a deep unconscious state. 
 
2.5. Isolated rat heart perfusions: Cardiac function 
Directly after echocardiography, the isoflurane was kept at 4% and maintained for 
approximately 15 minutes which allowed the rat to become completely unconscious. The 
chest cavity was cut open with scissors; the heart was rapidly excised and placed in ice cold 
Krebs-Henseleit buffer. The final composition of the buffer was as follow: 118.5mM NaCl, 
25mM NaHCO3, 4.75mM KCl, 1.18mM MgSO4.7H2O, 1.2mM KH2PO4, 1.36mM CaCl2.2H20 and 
11.1mM Glucose. Within a few minutes, the heart was cannulated via the aorta onto the 
Langendorff isolated rat heart perfusion apparatus and perfused retrogradely.  
Perfusion was performed at a constant pressure of 100cm H20 at 37°C, with Krebs-Henseleit 
buffer (pH 7.4) equilibrated with oxygen/carbon dioxide ratio of 95:5% (Afrox, SA). A water-
filled, latex balloon which (was custom made) was connected to a pressure transducer and 
the data were recorded on a Powerlab, Lab chart computerized data acquisition program 
(ADI Instruments, South Africa). The balloon was inserted into the left ventricle via the left 
atrium. The temperature of the heart was measured with a fine thermocouple wire 
(Physitemp, NJ, USA) and monitored with a Digitron 2600T temperature sensor (Torquay, 
UK). The LV-end diastolic pressure was adjusted and maintained at 8-9mmHg and the heart 
was perfused for 30 minutes (with the latex balloon still in the LV). This served as stabilization 
period. After this, the heart was perfused for an additional 30 minutes upon which the 
balloon was removed and inserted into the RV. Once the balloon was in the RV, the heart 
was allowed to stabilize for 30 minutes and perfused for an additional 30 minutes (to obtain 
RV measurements) (Figure 23). 
The cardiac parameters that were measured in both ventricles included heart rate, coronary 
flow rate (mL/min) and ventricular developed pressure (LV and RV) [LV-developed pressure 
(LVDP) and RV-developed pressure (RVDP)]. The LVDP and RVDP were calculated by 
subtracting the systolic pressure from the diastolic pressure. Our exclusion criteria were (i) a 
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minimum LVDP of 80mmHg, (ii) a minimum coronary flow rate of 8mL/min and a maximum 
of 16mL/min, (iii) a minimum heart rate of 250 beats per minute and a maximum of 400 beats 
per minute.  
 
 
 
2.6. Blood sample collection 
Blood samples were collected from the thoracic cavity immediately after the heart was 
removed for perfusion. A squeezable plastic Pasteur pipette (Lasec, South Africa) was used 
to pipette the blood from the thoracic cavity into a BD vacutainer blood collection tube 
(containing EDTA) (Lasec, South Africa). The tube was gently tilted twice and immediately 
placed on ice. The tubes were then transferred to a precooled (4°C) bench centrifuge and 
centrifuged for 10 minutes at a rotor speed of 2500rpm. After centrifugation, the blood 
samples separated into two phases with the plasma phase on top. Aliquots of 300μL plasma 
were transferred to 2mL Eppendorf tubes (Lasec, South Africa). These tubes were marked 
with the number of the rat, the treatment group, melatonin dose and date. The aliquots were 
stored at -80°C until the measurement of the various assays including the protein 
concentration assay kit were performed.  
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2.7. Biometrical measurements 
After completion of the perfusion protocol, the heart was weighed and the RV separated 
from the LV plus septum. The weight of the whole heart, RV and LV plus septum was 
recorded. The right tibia of every rat was excised and its length was also measured and 
recorded. The weight of the RV was divided by the LV plus septum, or tibial length or the 
whole heart weight and these ratios were used as different indexes of RV hypertrophy 329. 
The liver and lungs were excised from the rat carcase, rinsed with 1% phosphate buffered 
saline, slightly dried with a paper towel and weighed. Other biometrical indexes included 
liver weight and lung weights divided by body weight which gave an indication of either loss 
of liver mass (liver atrophy) or pulmonary oedema 69. 
 
2.8. Blood plasma assays and protein determination 
The protocol for the determination of protein concentration of each blood plasma was the 
same as the protocol for the human blood plasma. The blood samples from each group were 
designated for the determination of oxidative stress levels with assays including the TBARS, 
ORAC, and catalase and superoxide dismutase activity (Figures 13 – 21 and Table 1), as 
previously described.  
 
2.9. Histology of hearts 
2.9.1. Cardiac interstitial fibrosis 
In a separate set of experiments, the hearts were perfused on the isolated apparatus, the RV 
was separated from the LV plus septum and washed with 1% phosphate buffered saline. The 
RV and LV plus septum were fixed with 4% paraformaldehyde (Sigma Aldrich, South Africa) 
for one day. The following day, the LV plus septum were sliced into four equally sized cross 
sections and the RV was kept unsliced. This sectioning procedure allowed for the proper 
fixation of all areas of the heart. The heart sections (RV and LV plus septum) were placed 
back into the 4% paraformaldehyde for another day. Thus, in total, the heart sections were 
fixed in 4% paraformaldehyde for two consecutive days.  
After the two days, the sections were washed with and placed in 70% ethanol and embedded 
in paraffin. Subsequently, the slices were sectioned (cross sectional and transverse) at a 
thickness of 3μm for histological analysis 329. The purpose of the 70% ethanol step was to 
stop the fixation process in order to detect collagen deposition. Furthermore, the RV and LV 
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sections were stained with 0.1% Sirius red in picric acid (Sigma Aldrich, South Africa) for the 
determination of collagen deposition (Table 3). Sections were examined with a Nikon Eclipse 
90i microscope using a 20 times objective and the images were captured with the use of NIS-
Elements Basic Research software (Nikon, Instech Co. Ltd, Japan). Further quantification, to 
determine the interstitial collagen fraction was done with the Visiopharm Integrator System 
(Leica Microsystem, Wetzlar, Germany). 
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3. Melatonin as a therapy in PH 
3.1. Melatonin dose calculation: Three different doses 
Melatonin (Sigma Aldrich, South Africa) was given orally in the drinking water at 75ng/L, 
4mg/kg or 6mg/kg. These doses of melatonin were based on studies previously published 
250,273,309. The concentration of 75ng/L is the same as the concentration of melatonin found 
in red wine and other foods/plants, while the higher doses of melatonin (4mg/kg and 
6mg/kg) are comparable to the doses found in pills available at pharmacies. The treatment 
with melatonin was started on day zero of the treatment protocol i.e. on the same day as 
that the MCT injection was given. Melatonin treatment continued until day 28.  
 
3.2. Preparation and administration of melatonin 
3.2.1. 75ng/L concentration of melatonin 
75mg of melatonin was dissolved in absolute ethanol at a final concentration of 0.05% (v/v) 
and made up to a final volume of 1L of distilled water (this was solution A). Two successive 
dilutions were prepared by firstly taking 1mL of solution A and adding it to 100mL of distilled 
water (solution B). Secondly, 100µL of solution B was added to 100mL of distilled water 
(solution C.) Solution C had a final melatonin concentration of 75ng/L and was used to treat 
the rats. Other researchers in the laboratory had previously performed preliminary studies 
to confirm that addition of melatonin in the drinking water does not change the drinking 
behaviour of the rats.  
 
3.2.2. 4mg/kg and 6mg/kg melatonin 
For the calculation of these doses of melatonin, two factors were taken into consideration 
including average daily water consumption and body weight. As three rats were housed in 
one cage, they shared a water bottle. The first factor taken into consideration was the 
average body weight, which was used to calculate the amount (grams) of melatonin 
necessary for three rats. It is known that a rat with a body weight of approximately 100g 
drinks approximately 14-15mL water per day. 330 However, during the 28 day treatment 
period, the rats either gained or lost weight and this was also taken into account. Thus, on 
average, a rat with a body weight of 100g drinks 15mL of water per day, a 200g rat 30mL and 
a 300g rat 45mL. If a cage had for example an average body weight of approximately 160g, 
then the daily water consumption was taken as 15mL. Thus, together, the average body 
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weight and daily water consumption was used to calculate the amount of melatonin each rat 
received per total amount of water drank per day.  
Usually, when the animal unit staff exchanged the cages and bedding, the water bottles were 
often moved or shaken and inevitably leaked. With this arose the possibility that some rats 
may not receive enough melatonin or the bottle may be empty before adequate amounts of 
melatonin were consumed by the rats. To prevent this, enough melatonin (a maximum of 
500mL per bottle) was prepared so that even in the event of accidental loss, the rats still had 
enough melatonin to last for the night. This was done, by multiplying the amount of 
melatonin by a certain factor (e.g. 6) in order to achieve a maximum volume of 500mL 
melatonin per bottle. The total amount of water and melatonin was multiplied with the same 
factor to ensure that the final concentration ratio remained correct. 
After the correct final amount of melatonin was calculated, it was dissolved in absolute 
ethanol (Sigma Aldrich, South Africa) at a final concentration of 0.05% (v/v) and then added 
it to the total amount of water for each cage 273. The water bottles containing the melatonin 
were covered with aluminium foil, because melatonin is light sensitive and the foil was 
replaced on a daily basis, if necessary. Melatonin was made up fresh every day, even if there 
was some melatonin left the next day.  
 
4. Data analyses: Statistical tests 
Unless stated otherwise, all data were expressed as mean ± standard error of the mean 
(SEM). For comparative studies, Student’s t-test (unpaired) or two-way ANOVA analyses 
(with Bonferroni post-test, if p< 0.05) were used respectively. All statistical test were 
performed using Graph Pad Prism-5. The experimental groups used for the fibrosis 
determination were statistically analysed by one-way ANOVA and Newman-Keuls post hoc 
test for multiple comparisons. A p<0.05 was considered as significant. 
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SECTION D 
EVALUATION OF OXIDATIVE STRESS IN A PATIENT POPULATION OF PULMONARY 
HYPERTENSION 
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1. Introduction 
Over the past few years, experimental and clinical studies suggest that PH is associated with 
an increase in oxidative stress in the lung, the heart as well as the plasma/serum 213,225-
227,229,331. Although it is believed that oxidative stress may play a role in the development and 
progression of PH and RV remodelling, its exact mechanism is not fully understood 30,210,211. 
In a recent study, oxidative stress was shown to be associated with increased pulmonary 
artery systolic pressure in patients with PH, displaying the ability of oxidative stress to be 
used a possible biomarker of PH progression 332. Currently, there is no effective treatment 
available for PH, in part, to the diversity and lack of knowledge of the mechanisms involved 
in the development of the disease. 145 A better understanding of the mechanisms involved 
with oxidative stress-induced cardiovascular damage associated with PH, may lead to the 
development of novel and effective therapies against the disease. In the present section, we 
aim to evaluate the presence of oxidative stress in a South African population suffering from 
PH. 
 
2. Materials and Methods 
In brief, patients were referred from a primary to a secondary health institution, with 
symptoms including shortness of breath, fatigue, peripheral oedema, and persistent cough 
at night. Ten of these patients underwent clinical investigation and examinations in order to 
confirm diagnosis of PH. Blood samples were collected from the ten PH patients and ten 
healthy individuals (used as controls). All the blood samples were used for the determination 
of lipid peroxidation, overall antioxidant capacity as well as the activity of antioxidant 
enzymes catalase and superoxide dismutase (Figure 24) as described in sections C.  
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3. Data analyses: Statistical tests 
All data were expressed as mean ± standard error of the mean (SEM). For comparative 
studies, a Student’s t-test (unpaired) was used performed. A p<0.05 was considered as 
statistically significant. 
 
4. Results 
4.1. Demographic and clinical profile of patients with pulmonary hypertension 
Table 4 summarizes the demographic data and clinical profile of the ten patients with PH who 
were included in our study. These data included mean age, history of smoking, body mass 
index (BMI), World Health Organisation functional classes (I-IV), mean heart rate, blood 
pressure (systolic and diastolic), haemoglobin levels and HIV status (human immune 
deficiency virus infection).  
 
Table 4. Demographic and clinical profile of patients with pulmonary hypertension 
 
PH: pulmonary hypertension, BMI: body mass index, WHO: World health organisation, HIV: 
Human immunodeficiency virus, RV: right ventricular.  All the values are expressed as the 
mean ± standard error of the mean (SEM).  
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4.2. Evaluation of oxidative stress in controls and patients with pulmonary hypertension 
Levels of blood plasma lipid peroxidation were measured by assessing the thiobarbituric acid 
reactive substances (TBARS) in patients with PH and healthy controls. PH patients had 
significantly higher levels of plasma lipid peroxidation compared to controls (1.23 ± 0.11 vs. 
0.89 ± 0.02 µmol/mL, p<0.008) (Figure 25).  
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Figure 25. Plasma lipid peroxidation (TBARS) in control (C) and PH patients, *p<0.008 (PH vs. 
C), n=10 per group. 
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Antioxidant capacity was measured using the ORAC assay. PH patients had a similar plasma 
antioxidant capacity compared to controls (10.86 ± 2.89 vs. 5.65 ± 0.94 nmol/L trolox 
equivalents) (Figure 26).  
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Figure 26. Plasma antioxidant capacity in control (C) and PH patients, n=10 per group. 
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Catalase activity of the PH patients was significantly higher compared to controls (9.03 ± 1.92 
vs. 3.56 ± 0.33 IU/mg protein, p<0.01) (Figure 27).  
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Figure 27. Plasma catalase activity in control (C) and PH patients, *p<0.01 (PH vs. C), n=10 
per group. 
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SOD activity of the PH patients was significantly higher compared to controls (14.41 ± 0.74 
vs. 11.87 ± 0.25 IU/mg protein, p<0.005) (Figure 28). 
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Figure 28. Plasma superoxide dismutase (SOD) activity in control (C) and PH patients, 
*p<0.005 (PH vs. C), n=10 per group. 
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5. Discussion 
PH and the resultant RV failure, enhances the production of ROS and may diminish 
antioxidant activity, resulting in oxidative damage to crucial cell components such as DNA, 
proteins and lipids 211. Oxidative damage elevates the breakdown by-products of these 
oxidative processes which can be detected in plasma, serum or urine samples of patients and 
is referred to as oxidative stress 211. In PH, oxidative stress is suspected to be involved in the 
initial “trigger” stages of the disease development where it may contribute to endothelial 
injury in the pulmonary vasculature 30,210,211. The potential role for oxidative stress in PH is 
even more likely as all cells in the lung can generate ROS mediated by alveolar macrophages, 
via nicotinamide adenine dinucleotide phosphate-(NADPH)-oxidase 212.  
In our study, we showed that plasma oxidative stress was increased in a South African 
patients with PH compared to healthy controls. These findings are corroborated by others 
who report similar findings 225,226,229. Irodova et al, showed that plasma of patients with 
idiopathic PH had higher concentrations of malonic dialdehyde (lipid peroxidation) than 
healthy volunteers 213. Also, urine levels of F2-isoprostane, another marker of oxidative stress 
were increased in PH patients in a mass spectrometry based study 227. Furthermore, 
immunohistochemical studies by Bowers et al, showed that lung tissue from patients with 
idiopathic PH increased 8- hydroxyguanosine staining which was an indication of oxidative 
damage to DNA 210. Preston et al, used high-performance liquid chromatography, and 
demonstrated that patients with idiopathic PH have lower levels of lipophilic plasma 
antioxidants such as alpha-tocopherol and beta-carotene 228. These studies demonstrate that 
PH is associated with an increase in oxidative stress. 
In our study, we also showed that the overall oxygen radical absorbance (antioxidant) 
capacity of the blood plasma of PH patients showed a trend towards decreased antioxidant 
capacity. However, this was not statistically different, which may have been due to 
considerable variation within the group and relatively small sample size for human samples. 
We also showed that plasma antioxidant enzyme (catalase and SOD) activity was increased 
in patients with PH compared to healthy controls. These findings are supported by others 
who reported similar findings 213,227,228. In particular, Iridova et al, that assessed plasma 
erythrocyte antioxidant enzyme activity in patients with PH 213. They showed that erythrocyte 
antioxidant enzyme (glutathione peroxidase, catalase and SOD) activity was increased in 
patients with PH. However, we are not aware of any study who investigated the antioxidant 
enzyme activities in blood plasma, as shown in our study.  
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6. Limitations of this section of the study 
 No detailed clinical profile has been provided for the healthy patients, as a proper 
clinical investigation was not performed and these patients were not appropriately 
matched with their PH counterparts. This was mainly because the purpose of this 
section was just to show that oxidative stress is elevated in PH compared and not to 
perform an in-depth clinical trial.  
 A large proportion of the PH patients were HIV positive in our patient sample. HIV is 
known to lead to oxidative stress and further studies will be required in order to 
delineate the exact role of HIV vs. PH in this increase of oxidative stress, observed in our 
patient sample.  
 
7. Conclusion 
In our experiments we were able to show that oxidative stress is increased in the blood 
plasma of our South African population with PH compared to controls. These patients’ blood 
plasma samples also showed a trend towards a decrease in antioxidant capacity and a 
definite increase in catalase and SOD activities. This suggests that oxidative stress is increased 
with PH, despite simultaneous increase in antioxidant enzyme activities. However, while 
many of the patients were HIV positive, confounding factors may also result in changes in 
antioxidant status.  
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SECTION E 
VALIDATION OF EXPERIMENTAL MODEL OF PULMONARY HYPERTENSION 
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1. Introduction 
In order to better understand the pathophysiology of PH and discover novel therapies to 
treat the disease, several animal models for PH have been developed 333. The rat model of 
PH using a single injection of MCT has been largely published in the literature and has been 
useful in better understanding the pulmonary vascular remodelling in PH 333. This was mostly 
shown by studies exploring the role of a genetic mutation in genes that are responsible for 
the regulation of endothelial cell and pulmonary arterial smooth muscle cell apoptosis and 
proliferation. Researchers discovered a mutation in the gene that encodes for bone 
morphogenetic protein receptor-2 (BMPR-2) and forms part of the transforming growth 
factor superfamily of proteins 58. Other studies done in the MCT model also highlighted the 
pivotal role of inﬂammatory cells (macrophages, dendritic cells, and mast cells) and cytokines 
(interleukin-6, interleukin-1) in the early stages of pulmonary vascular remodelling observed 
in PH. Macrophages and dendritic cells, both antigen-presenting cells, are believed to 
facilitate the inﬂammatory response in PH, thereby contributing to pulmonary vascular 
remodelling 333. 
In this model, a single injection of MCT induces endothelial injury to the small pulmonary 
arteries and leads to PH and RV remodelling within 28 days 208,326. The MCT model has been 
described in Sprague Dawley rats but unfortunately this particular rat strain is not available 
at our animal facility, which only breeds Long-Evans and Wistar rats. In the literature it has 
been shown that the strain can influence the pathological response to a stimulus 334. 
Therefore, to know whether the injection with MCT will recapitulate the full spectrum of PH 
markers (RV hypertrophy, increased RV systolic pressure and increased oxidative stress) as 
observed in Sprague Dawley rats, our aim was to validate this model in Long Evans rats.  
 
2. Materials and methods 
We induced PH with a single subcutaneous injection of MCT which should lead to severe PH 
and RV remodelling after 28 days. Control (C) rats received a single subcutaneous injection 
of sterile saline on the same day the other rats were injected with MCT. After 28 days, 
echocardiography was performed, the hearts were isolated for the isolated heart perfusions, 
blood samples were collected, biometrical measurements were done and hearts were 
processed for histological staining. Blood plasma samples were used for the oxidative stress 
and antioxidant enzyme activity assays (TBARS, ORAC, catalase and SOD activity) (Figure 29).  
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3. Data analyses: Statistical tests 
All data were expressed as mean ± standard error of the mean (SEM). For comparative 
studies, a Student’s t-test (unpaired) was used performed. The experimental groups used for 
the fibrosis determination were statistically analysed by one-way ANOVA and Newman-Keuls 
post hoc test for multiple comparisons. A p<0.05 was considered as significant. 
 
4. Results 
4.1. Biometric measurements 
Table 5 summarizes the biometric measurements including body weights, weights of organs 
and weight of these organs expressed as a ratio of body weight or tibial length. MCT rats had 
significantly lower body weights (218.80 ± 18.41 vs. 308.70 ± 7.50 g, p<0.0006) and higher 
heart weights (1.62 ± 0.07 vs. 1.36 ± 0.07 g, p<0.02). MCT rats had higher heart weight over 
body weight (0.57±0.02 vs. 0.36±0.02 g/g, p<0.0001) and similar heart weight over tibial 
length ratios (0.37 ± 0.02 vs. 0.32 ± 0.02 g/cm, p>0.05). MCT rats had significantly higher RV 
weights (0.55 ± 0.02 vs. 0.20 ± 0.01 g/g, p<0.0001) and lower LV weights compared to control 
rats (0.65 ± 0.01 vs. 0.80 ± 0.03 g/g, p<0.0001). MCT rats had higher lung weights compared 
to controls (3.59 ± 0.13 vs. 1.85 ± 0.17 g, p<0.0001) and lung weight over body weight ratio 
(1.12±0.04 vs. 0.49±0.03 g/g, p<0.0001). MCT rats had also higher liver weights (19.60 ± 1.22 
vs. 15.81 ± 0.59 g, p<0.01) and liver weight over body weight ratio (0.56 ± 0.03 vs. 0.42 ± 0.03 
g/g, p<0.05).  
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Table 5. Biometric measurements 
 
C: Control, MCT: Monocrotaline *p<0.0001 (MCT vs C, MCT+MEL vs. MCT), *p<0.05 (MCT vs 
C), *p<0.05 (MCT vs C), *p<0.0006 (MCT vs C, MCT+MEL vs. MCT), n≥ 6 per group. Values are 
mean ± standard error of the mean.  
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4.2. Echocardiography: left ventricular functional parameters 
Echocardiography measurements showed that LV fractional shortening was significantly 
higher in MCT rats compared to controls (69.37 ± 2.17 vs. 36.13 ± 1.08 %, p<0.0001) (Figure 
30).  
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Figure 30. Effect of monocrotaline on left ventricular fractional shortening, *p<0.0001 (MCT 
vs. C), n≥6 per group. 
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Furthermore, MCT rats had significantly lower LV end diastolic volumes compared to controls 
(0.19 ± 0.01 vs. 0.68 ± 0.05 vs. mL, p<0.0001) (Figure 31 A). Representative images of LV 
echocardiography (M-Mode) are shown below (Figure 31 B). 
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Figure 31 (A). Effect of monocrotaline on left ventricular end diastolic volume, *p<0.0001 
(MCT vs. C), n≥6 per group. 
 
 
Figure 31 (B). Representative M-mode echocardiography images, for control (C) and 
monocrotaline (MCT) groups.  
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MCT rats had higher LV ejection fractions compared to controls (96.05 ± 0.63 vs. 69.09 ± 1.57 
%, p<0.0001) (Figure 32).  
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Figure 32. Effect of monocrotaline on left ventricular ejection fraction, *p<0.0001 (MCT vs. 
C), n≥6 per group. 
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4.3. Isolated heart perfusions: Left ventricular function 
Isolated heart perfusions showed that MCT rats had similar LV developed pressures 
compared to controls (96.18 ± 5.24 vs. 96.08 ± 6.66 mmHg) (Figure 33). 
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Figure 33. Effect of monocrotaline on left ventricular developed pressure, (MCT vs. C), n≥6 
per group. 
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The LV systolic pressure was similar for MCT rats compared to controls (99.19 ± 6.63 vs. 
103.80 ± 4.11 mmHg) (Figure 34). 
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Figure 34. Effect of monocrotaline on left ventricular systolic pressure, (MCT vs. C), n≥6 per 
group. 
  
125 
 
The LV diastolic pressure was similar for MCT rats compared to controls (8.77 ± 0.25 vs. 8.42 
± 0.12 mmHg) (Figure 35). 
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Figure 35. Effect of monocrotaline on left ventricular diastolic pressure, (MCT vs. C), n≥6 per 
group. 
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The heart rate was similar for MCT rats compared to controls (318.70 ± 9.29 vs. 303.30 ± 
18.16 bpm) (Figure 36). 
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Figure 36. Effect of monocrotaline on heart rate, (MCT vs. C), n≥6 per group. 
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4.4. Isolated heart perfusions: Right ventricular function 
The RV developed pressure was higher in the MCT rats compared to controls (81.22 ± 2.75 
vs. 45.87 ± 2.11 mmHg, p<0.0001) (Figure 37).  
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Figure 37. Effect of monocrotaline on right ventricular developed pressure, *p<0.0001 (MCT 
vs. C), n≥6 per group. 
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The RV systolic pressure was higher in the MCT rats compared to controls (87.91 ± 5.48 vs. 
54.35 ± 2.28 mmHg, p<0.0001) (Figure 38).  
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Figure 38. Effect of monocrotaline on right ventricular systolic pressure, *p<0.0001 (MCT vs. 
C), n≥6 per group. 
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RV diastolic pressure was similar in the MCT rats compared to the controls (9.06 ± 0.32 vs. 
8.55 ± 0.09 mmHg) (Figure 39).  
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Figure 39. Effect of monocrotaline on right ventricular diastolic pressure, (MCT vs. C), n≥6 
per group. 
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4.5. Oxidative stress in an experimental model of pulmonary hypertension 
Levels of blood plasma lipid peroxidation was measured by assessing the thiobarbituric acid 
reactive substances (TBARS) in control rats and those with MCT induced PH. MCT rats had 
higher levels of plasma lipid peroxidation compared to controls (2.27 ± 0.22 vs. 0.84 ± 0.05 
µmol/mL, p<0.0001) (Figure 40).  
 
 
 
 
 
 
 
 
 
Figure 40. Effect of monocrotaline on plasma lipid peroxidation, *p<0.0001 (MCT vs. C), n≥6 
per group. 
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MCT rats was a significantly lower antioxidant capacity compared to controls (18.40 ± 2.29 
vs. 30.67 ± 3.89 nmol/L trolox equivalents p<0.02) (Figure 41).  
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Figure 41. Effect of monocrotaline on plasma antioxidant capacity, *p<0.02 (MCT vs. C), n≥6 
per group. 
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Catalase activity of the MCT rats was significantly higher than that of the controls (12.40 ± 
1.80 vs. 3.72 ± 0.40 IU/mg protein, p<0.0008) (Figure 42).  
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Figure 42. Effect of monocrotaline on plasma catalase activity, *p<0.0008 (MCT vs. C), n≥6 
per group. 
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SOD activity in the plasma of the MCT rats was significantly higher than that of the controls 
(9.97 ± 0.20 vs. 6.57 ± 0.83 IU/mg protein, p<0.003) (Figure 43).  
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Figure 43. Effect of monocrotaline on plasma superoxide dismutase activity, *p<0.003 (MCT 
vs. C), n≥6 per group. 
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4.6. Cardiac interstitial fibrosis in an experimental model of pulmonary hypertension 
The percentage of collagen deposition in the LV sections of the MCT hearts were higher 
compared to the controls (2.18 ± 0.23 vs. 1.13 ± 0.15 % area, p<0.009) (Figure 44 A). (Figure 
44 A). Representative images of all groups are shown below (Figure 44 B).  
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Figure 44 (A). Effect of monocrotaline on cardiac interstitial fibrosis, *p<0.009 (MCT vs. C for 
the LV sections), n=4 per group.  
 
 
 
 
 
 
Figure 44 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 44 C). 
Representative images of all groups are shown below (Figure 44 D).  
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Figure 44 (C). Effect of monocrotaline on cardiac interstitial fibrosis, *p<0.04 (MCT vs. C for 
the RV sections), n=4 per group.  
 
 
 
 
 
 
Figure 44 (D). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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5. Discussion 
The experimental model of MCT-induced PH has only been performed in Sprague Dawley rats 
but unfortunately, we do not have these rats available in our animal facilities Therefore, our 
goal was to validate whether PH can be induced in the Long Evans rat strain, with all 
characteristics of experimental PH. In our study, we showed that a single subcutaneous 
injection of 80mg/kg MCT induced PH and RV hypertrophy after 28 days in the Long Evans 
rat strain as seen by the biometric measurements. Our rats also displayed RV and LV 
dysfunction as seen with echocardiography and isolated rat heart perfusions. Furthermore, 
the blood plasma analyses showed increased lipid peroxidation, decreased antioxidant 
capacity and increased antioxidant enzymes (catalase & SOD) activities.  
 
Biometric measurements 
With this experimental model of PH, MCT Sprague Dawley rats are characterized with a lower 
body weight, higher lung weight and higher liver weight compared to controls 208,219. In our 
study, MCT had similar effects in Long Evans rats as seen in table 7. At the end of the 28 day 
period, MCT rats displayed severe weight loss or cachexia, while control rats were healthy. It 
appears that the increase in heart weight is mainly due to the increased RV weights or RV 
hypertrophy. During the 28 day period, we observed that MCT rats also had an obvious lack 
of physical activity, increased breathing rate (dyspnoea) and piloerection. It could be argued 
that the dose of 80mg/kg MCT was too high but this was chosen based on the study by 
Handoko et al, which was at the conception of our study, the only accessible paper where 
isolated rat heart perfusions to assess cardiac function were performed 208. These 
observations were also made by Hessel et al, who induced PH with the same dose of MCT 
and examined these rats for the same time period 326. Furthermore, the lung weights were 
significantly higher in MCT rats which could be a confirmation of extensive proliferative 
pulmonary response in oedema 326.  
Our MCT rats had significantly higher liver weights which are also corroborated by Handoko 
et al, The reason for this increase is not clear but it has been reported that MCT induces 
damage of sinusoidal endothelial cells, central venular endothelial cells and hepatic 
parenchymal cells 324. Although, these effects of MCT on the liver may not completely explain 
the increase in liver weights it does provide enough grounds for speculation that it may have 
caused hepatic damage associated with oedema.  
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RV hypertrophy 
MCT induces pulmonary arterial remodelling and lumen narrowing which increases the, 
pulmonary artery pressure, RV afterload, RV hypertrophy and eventually leads to RV failure 
324,325. Therefore, this model has been characterized by RV hypertrophy which is underlined 
by microtubule proliferation in RV-cardiomyocytes 335. An interesting finding in our study, 
was that MCT rats had higher RV weights (RV hypertrophy) but simultaneously, also lower LV 
weights than controls. This was also apparent in the study by Hessel et al, even though the 
changes weren’t statistically significant 326. However, this reduction in LV mass was 
completely visible in a study by Hardziyenka et al, who found that this reduction in LV mass 
was underlined by cardiomyocyte shrinkage due to atrophic remodelling 336.  
 
Echocardiography: LV function 
In our study, we assessed LV function with echocardiography and found that MCT rats had 
severely decreased LV end diastolic volumes. There is a paucity of publications that report 
the effects of MCT on both right and left ventricles. Nevertheless, Handoko et al, showed 
that MCT at a dose of 80mg/kg, caused both RV and LV dysfunction as assessed with cardiac 
magnetic resonance imaging 208. This was supported by Hardziyenka et al, who showed that 
already at a dose of 60mg/kg, MCT caused RV and LV dysfunction and LV atrophy as assessed 
with both echocardiography and cardiac magnetic resonance imaging 336.  
In our study, we also found that the LV fractional shortening and ejection fraction was 
increased in the MCT rats. There are not many available studies that report on these LV 
parameters for the MCT model but it does appear that these rats develop LV diastolic 
dysfunction and the changes in LV parameters may be due to severely altered LV filling. 
However, the increased LV fractional shortening does mean that the LV contractility is 
adversely affected by MCT-induced PH, as fractional shortening is a measure of the LV wall 
diameter during systole and diastole.  
MCT seems to cause atrophy of the LV with concomitant contractile dysfunction in an in vivo 
setting. The LV ejection fraction is severely increased in the MCT rats compared to controls. 
A possible way to explain this is by taking a mathematical approach and to revisit the basic 
principles of LV ejection fraction, which is calculated by dividing the stroke volume with by 
the LV end diastolic volume. In our study, the LV end diastolic volumes in the MCT rats were 
decreased, so therefore, if one assumes the stroke volumes remains constant, and simply 
divide by the now, lower end diastolic volumes, this would equate to a higher ejection 
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fraction. Therefore, one can speculate that the LV ejection fraction in the MCT rats is higher 
due to decreased LV end diastolic volume. Usually, the MCT model is characterised by RV 
dysfunction as assessed with echocardiographic measurements 329. This was seen in a study 
by Kosanovic et al, where MCT (60mg/kg) reduced RV function when it was assessed with 
echocardiography and right heart catheterisation 329. Unfortunately, we were not able to 
measure RV function with echocardiography in our setting due to low probe sensitivity. For 
this reason, we assessed both LV and RV function with the isolated heart perfusion 
apparatus.  
 
Isolated heart perfusions: LV and RV function 
Data from the isolated heart perfusions generated very interesting results as we could not 
observe LV dysfunction as seen with echocardiography. These results are corroborated by 
the findings of Handoko et al, who also assessed LV function with the isolated heart perfusion 
apparatus 208. Authors could not explain this phenomenon but this could be due to various 
reasons open to speculation. In our study, the hearts of MCT rats were bigger, the RV mass 
increased and the LV mass was smaller. It appears therefore, that the pressure overload with 
MCT-induced PH caused the RV to become hypertrophied and constitute a greater part of 
the actual heart. The LV mass was smaller in MCT rats and the LV function decreased when 
assessed with echocardiography. This could just mean that the isolated heart apparatus is 
not sensitive enough to pick up the LV functional changes as observed with the in vivo 
echocardiography. Furthermore, in our study we used the Langendorff, retrograde perfusion 
apparatus, which is not a true reflection of in vivo blood flow in a whole organism. Therefore, 
the better apparatus would have been the working heart perfusion apparatus and therefore 
the use of the Langendorff in our study could also account for the inability to pick up LV 
functional difference as with echocardiography.  
We have also found that RV function was compromised as assessed with the isolated rat 
heart perfusion system. These findings are in line with that of Handoko et al, who showed 
that MCT-induced PH leads to increased RV developed and systolic pressure with the isolated 
heart perfusion apparatus 208. This LV and RV dysfunction in the MCT model have been 
attributed to ventricular dyssynchrony and septal bulging 208. In our study, the experimental 
model of PH was associated with concomitant LV and RV dysfunction as previously described 
in the literature 325,335,337.  
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Blood plasma oxidative and antioxidant capacity 
Our study also showed that MCT increased plasma oxidative stress, decreased the total 
oxygen radical absorbance (antioxidant) capacity and increased antioxidant enzyme activity 
(catalase and SOD). Even though the antioxidant enzyme activities are increased in response 
to the oxidative stress, it is appears that this increase is not sufficient to limit the oxidative 
stress. This is supported by our findings that the total antioxidant capacity of the blood 
plasma was decreased in the MCT rats compared to control rats. 
These findings are in line with work by Dorfmuller et al, who showed that MCT rats who also 
underwent left pneumonectomy, had increased NADPH-oxidase-4 and oxidative stress-
induced lipid peroxidation 217. These rats also had increased activity of plasma antioxidant 
enzymes 217. On the other hand, Mohammadi et al, showed that rats only injected with MCT 
without an additional pathology such as pneumonectomy, had increased malonic dialdehyde 
levels and decreased plasma levels of catalase, superoxide dismutase and glutathione 
peroxidase 218. In the light of both of these studies, it appears in a severe model of PH, the 
oxidative stress is elevated as well as the plasma antioxidant enzyme activity. In our present 
study, we also had a very severe model of PH as we injected rats with a relatively high dose 
of MCT. Therefore, this could be a possible explanation for the increased antioxidant enzyme 
activity in the blood plasma of MCT rats.  
Furthermore, if one considers the generally accepted definition of oxidative stress, it holds 
that oxidants (such as ROS) are increased and the cell’s inherent antioxidant systems 
(catalase, SOD activity) are decreased 76,210. However, in either MCT-induced PH or that in 
humans, this is not always the case 213,225-229. As with our results, it is clear that the plasma 
oxidative stress (lipid peroxidation) is increased while the antioxidant enzyme activity is also 
increased. This could mean that the oxidative stress provokes an increase in the antioxidant 
enzyme activity as an adaptive response, but despite the increased activity, this is insufficient 
to prevent or at least stunt the oxidative stress. This was then confirmed when the overall 
antioxidant capacity of the blood plasma was lower than that of healthy control rats. All these 
data mimic our findings of the plasma of the patients in the previous section.  
  
140 
 
Cardiac interstitial fibrosis 
Our data show that MCT induced interstitial fibrosis exceeding control levels, in both the LV 
and RV. These data are corroborated by others who reported that a single injection of MCT 
induces interstitial fibrosis 12. In this particular study, authors showed that the amount of RV 
ﬁbrosis increased throughout the disease progression, reaching a peak when the RV starts to 
fail. They could not see an increase in LV fibrosis, as we did but this was most probably due 
to the differences in MCT dose as well as the degree of LV atrophy, which could have affected 
the degree of interstitial fibrosis 12. The mechanism underlying the collagen deposition is 
believed to be an angiotensin-II-induced fibrosis mediated via the growth factor pathways 
and activation of the angiotensin receptor-1 12. The work of Campian et al, is also supported 
by others who showed similar levels of collagen deposition in RV’s of MCT rats at the same 
dose 336.  
Work by Redout et al, corroborates our data that 80mg/kg MCT induces extensive ventricular 
interstitial fibrosis 219. In their study, the use of the antioxidant EUK-1, reduced fibrosis 
supporting the notion that matrix remodelling in the RV of MCT rats is at least partially due 
to ROS dependent activation of matrix metalloproteinases in PH-induced RV remodelling 219. 
Therefore, it is possible that this increased interstitial fibrosis, also contributes to the cardiac 
dysfunction in the MCT model.  
 
6. Conclusions 
Our data demonstrate that a single subcutaneous injection of MCT (80mg/kg) induced 
experimental PH with RV hypertrophy, cardiac dysfunction, increased plasma oxidative 
stress, decreased plasma antioxidant capacity and abnormal antioxidant enzyme activity in 
Long Evans rats. Taken together, these data validated our experimental model of PH in the 
Long Evans rat strain which we aim to use in order to test the cardioprotective effect of 
melatonin in PH.  
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SECTION F 
MELATONIN AS THERAPY IN PULMONARY HYPERTENSION 
 
 
 
 
 
 
 
  
142 
 
1. Introduction 
In the previous sections of this thesis (sections D and E), we have been able to demonstrate 
that PH is associated with oxidative stress in a South African population with PH and in a Long 
Evans rats model of PH, induced by injection with MCT. Oxidative stress has been suggested 
to be a major player in the development of PH 30,210,211.  
Melatonin is an endogenously produced hormone that is commonly available over the 
counter to regulate the sleeping pattern. It has powerful antioxidant properties by either 
directly scavenging ROS or indirectly stimulating the synthesis and activity of antioxidant 
enzymes. Experimental data have demonstrated that a chronic treatment of melatonin, at 
the concentration found in red wine (75ng/L) protects the heart against 
ischemia/reperfusion injury 250. This cardioprotective effect was mediated mainly via the 
activation of the survivor activating factor enhancement (SAFE) pathway 338. At much higher 
concentrations (4mg/kg corresponds approximately to 106 higher dose compared to the 
amount of melatonin absorbed via the drinking of red wine), melatonin presents antioxidant 
as well as antihypertensive properties, effects partly mediated via the nitric oxide pathway 
and scavenging superoxide ion 282.  
Therefore, our aim was to investigate whether a daily oral, melatonin treatment at a 
concentration of 75ng/L or doses of 4mg/kg and 6mg/kg could confer cardioprotection in the 
MCT model of PH.  
 
2. Materials and methods 
To test our hypothesis, we used the Long Evans rat model of PH, induced by a single injection 
of MCT as described in Section E. Subsequently, rats were designated for treatment with 
three doses of melatonin based on previous literature. 75ng/L, corresponding to the 
concentration of melatonin obtained through the chronic and regular consumption of red 
wine. Furthermore, also 4mg/g and 6mg/kg of melatonin, which represents a much higher 
concentration and would mimic better the amount of melatonin received with melatonin 
capsules available over the counter.  
Melatonin was given orally in the drinking water and the treatment started on day zero of 
the treatment protocol i.e. on the same day as that the MCT injection was given. Melatonin 
treatment continued until day 28. After the 28 day period, we assessed various endpoints 
including echocardiography, blood collection, isolated rat heart perfusions, biometric 
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measurements, blood plasma oxidative and antioxidant status assays (TBARS, ORAC, and 
catalase and SOD activity) and histology of hearts for fibrosis assessment (Figure 45).  
 
 
 
3. Data analyses: Statistical tests 
Unless stated otherwise, all data were expressed as mean ± standard error of the mean 
(SEM). For comparative studies a two-way ANOVA analysis was performed (with Bonferroni 
post-test, if p< 0.05). All statistical tests were performed using Graph Pad Prism-5. The 
experimental groups used for the fibrosis determination were statistically analysed by one-
way ANOVA and Newman-Keuls post hoc test for multiple comparisons. A p<0.05 was 
considered as significant. 
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4. Results: Effects of 75ng/L melatonin 
4.1. Biometric measurements 
Table 6 summarizes the biometric measurements including body weights, weights of organs and weight of these organs expressed as a ratio of body 
weight or tibial length. Melatonin treated MCT rats had significantly higher body weights (323.0 ± 5.46 vs. 218.80 ± 18.41 g, p<0.0001) while the 
heart weights were similar (1.64 ± 0.11 vs. 1.62 ± 0.07 g, p>0.05). Melatonin treated MCT rats had similar heart weights over body weights (0.58 ± 
0.03 vs. 0.57 ± 0.02 g/g, p>0.05) and higher heart weight over tibial length ratios (0.47 ± 0.03 vs. 0.37 ± 0.02 g/cm, p<0.09). Melatonin treated MCT 
rats had significantly lower RV weights (0.33 ± 0.03 vs. 0.55 ± 0.02 g/g, p<0.0001) and higher LV weights compared to MCT rats (0.82 ± 0.07 vs. 0.65 
± 0.01 g/g, p<0.09). Melatonin treated MCT rats had lower lung weights compared to untreated MCT rats (2.87 ± 0.17 vs. 3.59 ± 0.13 g, p<0.002) and 
similar lung weight over body weight ratios (1.06 ± 0.08 vs. 1.12 ± 0.04 g/g, p>0.05). Melatonin treated MCT had also lower liver weights (11.30 ± 
0.71 vs. 19.60 ± 1.22 g, p<0.004) and lower liver weight over body weight ratios (0.41 ± 0.02 vs. 0.56 ± 0.03 g/g, p<0.05).  
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Table 6. Biometric measurements 
 
C: Control, MCT: Monocrotaline, MEL: Melatonin. *p<0.0001 (MCT vs C, MCT+MEL vs. MCT), *p<0.05 (MCT vs C), *p<0.05 (MCT vs C),  
*p<0.0006 (MCT vs C, MCT+MEL vs. MCT), n≥ 6 per group. Values are mean ± standard error of the mean. 
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4.2. Echocardiography: LV functional parameters 
Echocardiography measurements showed that LV fractional shortening was significantly 
lower in the melatonin treated MCT rats compared to MCT rats (46.74 ± 4.44 vs. 69.37 ± 2.17 
%, p<0.001) (Figure 46). Control rats treated with melatonin had similar LV fractional 
shortening compared to normal controls (39.10 ± 0.984 vs. 36.13 ± 1.08 %, p>0.05) (Figure 
46). 
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Figure 46. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular 
fractional shortening in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.001 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had significantly higher LV end diastolic volumes compared to 
MCT rats (0.56 ± 0.06 vs. 0.193 ± 0.01 mL, p<0.0001) (Figure 47). Control rats treated with 
melatonin had higher LV end diastolic volumes (0.82 ± 0.05 vs. 0.68 ± 0.05 mL, p<0.04) 
compared to controls (Figure 47). 
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Figure 47. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular end 
diastolic volume in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.0001 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had significantly lower LV ejection fractions compared to MCT 
rats (80.74 ± 3.96 vs. 96.05 ± 0.63%, p<0.02) (Figure 48). Control rats treated with melatonin 
had similar LV ejection fractions compared to controls (72.90 ± 1.49 vs. 69.09 ± 1.57 %) 
(Figure 48).  
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Figure 48. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular ejection 
fraction in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.02 (MCT+MEL vs. 
MCT), n≥6 per group. 
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4.3. Isolated heart perfusions: Left ventricular function 
Isolated heart perfusions showed that melatonin treated MCT rats had similar LV developed 
pressures compared to MCT rats (96.18 ± 5.24 vs. 96.08 ± 6.66 mmHg) (Figure 49). Melatonin 
treated control rats had similar LV developed pressures compared to controls (106.30 ± 2.42 
vs. 96.18 ± 5.24 mmHg) (Figure 49).  
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Figure 49. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular 
developed pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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The LV systolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(99.19 ± 6.63 vs. 103.80 ± 4.11 mmHg) (Figure 50). Melatonin treated control rats had similar 
LV systolic pressures compared to controls (115.50 ± 2.46 vs. 103.80 ± 4.11 mmHg) (Figure 
50).  
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Figure 50. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular systolic 
pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per 
group. 
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The LV diastolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(8.77 ± 0.25 vs. 8.42 ± 0.12 mmHg) (Figure 51). Melatonin treated control rats had similar LV 
systolic pressures compared to controls (8.53 ± 0.11 vs. 8.42 ± 0.12 mmHg) (Figure 51).  
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Figure 51. Effect of a chronic treatment with melatonin (75ng/L) on left ventricular diastolic 
pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per 
group. 
  
152 
 
Melatonin treated MCT rats had similar heart rates compared to the MCT rats (299.40 ± 12.62 
vs. 283.90 ± 13.73 bpm) (Figure 52). Control rats treated with melatonin had similar heart 
rates compared to normal controls (274.90 ± 14.85 vs. 272.40 ± 14.04 bpm) (Figure 52).  
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Figure 52. Effect of a chronic treatment with melatonin (75ng/L) on heart rate in a rat model 
of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per group. 
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4.4. Isolated heart perfusions: Right ventricular function 
The RV developed pressure was lower in the melatonin treated MCT rats compared to MCT 
rats (71.95 ± 5.16 vs. 81.22 ± 2.75 mmHg, p<0.04) (Figure 53) Control rats treated with 
melatonin had similar RV developed pressures compared to normal controls (48.15 ± 2.21 vs. 
45.87 ± 2.11 mmHg) (Figures 53).  
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Figure 53. Effect of a chronic treatment with melatonin (75ng/L) on right ventricular 
developed pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.04 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had similar RV systolic pressures compared to the MCT rats 
(84.53 ± 4.83 vs. 87.91 ± 5.48 mmHg) (Figure 54). Control rats treated with melatonin had 
similar RV developed pressures compared to normal controls (50.44 ± 5.26 vs. 54.35 ± 2.28 
mmHg, p>0.05) (Figure 54).  
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Figure 54. Effect of a chronic treatment with melatonin (75ng/L) on right ventricular systolic 
pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), (MCT+MEL vs. MCT), 
n≥6 per group. 
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Melatonin treated MCT rats had similar RV diastolic pressures compared to the MCT rats 
(8.49 ± 0.14 vs. 9.06 ± 0.32 mmHg) (Figure 55). Control rats treated with melatonin had 
similar RV diastolic pressures compared to normal controls (8.51 ± 0.11 vs. 8.55 ± 0.09 mmHg) 
(Figure 55).  
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Figure 55. Effect of a chronic treatment with melatonin (75ng/L) on right ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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4.5. Plasma oxidative stress and antioxidant capacity 
Levels of blood plasma lipid peroxidation was measured by assessing the thiobarbituric acid 
reactive substances (TBARS) in all treated groups. Melatonin treated MCT rats had 
significantly lower levels of plasma lipid peroxidation compared to MCT rats (1.30 ± 0.05 vs. 
2.27 ± 0.22 µmol/mL, p<0.002) (Figure 56). Melatonin treated controls had similar levels of 
plasma lipid peroxidation compared to normal controls (0.87 ± 0.08 vs. 0.83 ± 0.05 µmol/mL) 
(Figure 56). 
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Figure 56. Effect of a chronic treatment with melatonin (75ng/L) on plasma lipid 
peroxidation in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.002 (MCT+MEL 
vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had a similar antioxidant capacity compared to MCT rats (20.23 
± 2.61 vs. 18.40 ± 2.29 nmol/L trolox equivalents) (Figure 57). Melatonin treated controls had 
a similar antioxidant capacity compared to normal controls (29.50 ± 2.37 vs. 30.67± 3.88 
nmol/L trolox equivalents) (Figure 57). 
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Figure 57. Effect of a chronic treatment with melatonin (75ng/L) on plasma antioxidant 
capacity in a rat model of MCT-induced PH, *p<0.02 (MCT vs. C), (MCT+MEL vs. MCT), n≥6 
per group. 
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Melatonin treated MCT rats had a significantly lower catalase activity compared to MCT (5.44 
± 0.75 vs. 12.40 ± 1.79 IU/mg protein, p<0.0008) (Figure 58). Melatonin treated controls had 
a similar catalase activity compared to controls (5.16 ± 0.87 vs. 3.72 ± 0.40 IU/mg protein 
(Figure 58). 
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Figure 58. Effect of a chronic treatment with melatonin (75ng/L) on plasma catalase activity 
in a rat model of MCT-induced PH, *p<0.0008 (MCT vs. C), #p<0.0008 (MCT+MEL vs. MCT), 
n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower SOD activity compared to MCT rats (8.75 
± 0.39 vs. 9.97 ± 0.20 IU/mg protein, p<0.02) (Figure 59). Melatonin treated control rats had 
a similar SOD activity compared to controls (7.69 ± 0.44 vs. 6.57 ± 0.83 IU/mg protein) (Figure 
59). 
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Figure 59. Effect of a chronic treatment with melatonin (75ng/L) on plasma superoxide 
dismutase (SOD) activity in a rat model of MCT-induced PH, *p<0.003 (MCT vs. C), #p<0.02 
(MCT+MEL vs. MCT), n≥6 per group. 
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4.6. Cardiac interstitial fibrosis: The effect of 75ng/L melatonin treatment 
The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 60 A). The 
percentage of collagen deposition in the RV sections of the MCT+MEL hearts were similar to 
the MCT rats (4.20 ± 0.26 vs. 4.68 ± 0.75 %) (Figure 60A). Representative images of all groups 
are shown below (Figure 60 B).  
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Figure 60 (A). Effect of a chronic treatment with melatonin (75ng/L) on cardiac interstitial 
fibrosis in a rat model of MCT-induced PH, *p<0.04 (MCT vs. C), (MCT+MEL vs. MCT), n=4 
per group.  
 
 
 
 
 
 
 
 
 
 
Figure 60 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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5. Results: Effects of 4mg/kg melatonin 
5.1. Biometric measurements 
Table 7 summarizes the biometric measurements including body weights, weights of organs and weight of these organs expressed as a ratio of body 
weight or tibial length. Melatonin treated MCT rats had significantly higher body weights (323.0 ± 5.46 vs. 218.80 ± 18.41 g, p<0.0002) while the 
heart weights were significantly lower (1.24 ± 0.15 vs. 1.62 ± 0.07 g, p>0.05). Melatonin treated MCT rats had similar heart weights over body weights 
(0.46 ± 0.05 vs. 0.57 ± 0.02 g/g, p>0.05) and similar heart weight over tibial length ratios (0.31 ± 0.04 vs. 0.37 ± 0.02 g/cm, p<0.09). Melatonin treated 
MCT rats had significantly lower RV weights (0.28 ± 0.04 vs. 0.55 ± 0.02 g/g, p<0.0001) and higher LV weights compared to MCT rats (0.71 ± 0.04 vs. 
0.65 ± 0.01 g/g, p<0.04). Melatonin treated MCT rats had lower lung weights compared to untreated MCT rats (1.80 ± 0.25 vs. 3.59 ± 0.13 g, p<0.0001) 
and lower lung weight over body weight ratios (0.70 ± 0.09 vs. 1.12 ± 0.04 g/g, p<0.002). Melatonin treated MCT had also lower liver weights (11.44 
± 1.15 vs. 19.60 ± 1.22 g, p<0.0002) and similar liver weight over body weight ratios (0.48 ± 0.08 vs. 0.56 ± 0.03 g/g, p>0.05).  
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Table 7. Biometric measurements 
 
C: Control, MCT: Monocrotaline, MEL: Melatonin. *p<0.0001 (MCT vs C, MCT+MEL vs. MCT), *p<0.0001 (MCT+MEL vs. MCT), *p<0.05  
(MCT vs C), *p<0.0006 (MCT vs. C), n≥ 6 per group. Values are mean ± standard error of the mean. 
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5.2. Echocardiography: LV functional parameters 
Echocardiography measurements showed that LV fractional shortening was significantly 
lower in the melatonin treated MCT rats compared to normal MCT rats (56.66 ± 4.65 vs. 69.37 
± 2.17 %, p<0.01) (Figure 61). Melatonin treated control rats had similar LV fractional 
shortening (39.69 ± 1.47 vs. 36.13 ± 1.08 %) (Figure 61). 
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Figure 61. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular 
fractional shortening in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.01 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had significantly higher LV end diastolic volumes compared to 
MCT rats (0.701 ± 0.05 vs. 0.193 ± 0.008 mL, p<0.0001) (Figure 62). Melatonin treated control 
rats had similar LV end diastolic volumes (0.76 ± 0.04 vs. 0.68 ± 0.05 mL) compared to normal 
controls (Figures 62).  
C MCT C+MEL MCT+MEL
0.0
0.5
1.0
1.5
Groups
L
V
 e
n
d
 d
ia
s
to
li
c
 v
o
lu
m
e
 (
m
L
)
 
Figure 62. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular end 
diastole volume in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.0001 
(MCT+MEL vs. MCT), n≥6 per group.  
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Melatonin treated MCT rats had significantly lower LV ejection fractions (89.32 ± 2.55 vs. 
96.05± 0.63 %, p<0.04) (Figure 63). Melatonin treated control rats had similar LV ejection 
fractions (72.90 ± 1.49 vs. 69.09 ± 1.57 %) (Figure 63).  
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Figure 63. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular 
ejection fraction in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.04 
(MCT+MEL vs. MCT), n≥6 per group. 
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5.3. Isolated heart perfusions: Left ventricular function 
Isolated heart perfusions showed that melatonin treated MCT rats had similar LV developed 
pressures compared to MCT rats (97.14 ± 3.47 vs. 96.08 ± 6.66 mmHg) (Figure 64). Melatonin 
treated control rats had similar LV developed pressures compared to controls (97.91 ± 1.86 
vs. 100.30 ± 7.38 mmHg) (Figure 64).  
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Figure 64. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular 
developed pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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The LV systolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(103.50 ± 1.25 vs. 106.10 ± 4.44 mmHg) (Figure 65). Melatonin treated control rats had 
similar LV systolic pressures compared to controls (107.00 ± 1.86 vs. 103.80 ± 4.11 mmHg) 
(Figure 65).  
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Figure 65. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular systolic 
pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per 
group. 
 
  
168 
 
The LV diastolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(8.27 ± 0.09 vs. 8.59 ± 0.08 mmHg) (Figure 66). Melatonin treated control rats had similar LV 
systolic pressures compared to controls (8.56 ± 0.12 vs. 8.56 ± 0.10 mmHg) (Figure 66).  
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Figure 66. Effect of a chronic treatment with melatonin (4mg/kg) on left ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
 
  
169 
 
The heart rate was similar for melatonin treated MCT rats compared to MCT rats (304.60 ± 
6.06 vs. 303.30 ± 18.16 bpm) (Figure 67). Melatonin treated control rats had similar heart 
rates compared to controls (307.1 ± 5.41 vs. 303.20 ± 14.77 bpm) (Figure 67).  
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Figure 67. Effect of a chronic treatment with melatonin (4mg/kg) on heart rate in a rat 
model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per group. 
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5.4. Isolated heart perfusions: RV function 
The RV developed pressure was lower in the melatonin treated MCT rats compared to MCT 
rats (57.18 ± 3.04 vs. 81.22 ± 2.75 mmHg, p<0.001) (Figure 68) Control rats treated with 
melatonin had similar RV developed pressures compared to normal controls (45.89 ± 0.54 vs. 
45.87 ± 2.11 mmHg) (Figures 68).  
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Figure 68. Effect of a chronic treatment with melatonin (4mg/kg) on right ventricular 
developed pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.001 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had lower RV systolic pressures compared to the MCT rats (68.40 
± 3.59 vs. 87.91 ± 5.48 mmHg, p<0.002) (Figure 69). Control rats treated with melatonin had 
similar RV developed pressures compared to normal controls (54.37 ± 0.57 vs. 54.35 ± 2.28 
mmHg) (Figure 69).  
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Figure 69. Effect of a chronic treatment with melatonin (4mg/kg) on right ventricular 
systolic pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.002 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had similar RV diastolic pressures compared to the MCT rats 
(8.49 ± 0.08 vs. 8.74 ± 0.04 mmHg) (Figure 70). Control rats treated with melatonin had 
similar RV diastolic pressures compared to normal controls (8.48 ± 0.13 vs. 8.51 ± 0.12 mmHg) 
(Figure 70).  
C MCT C+MEL MCT+MEL
0
2
4
6
8
10
R
V
 d
ia
s
to
li
c
 p
re
s
s
u
re
 (
m
m
H
g
)
Groups
 
Figure 70. Effect of a chronic treatment with melatonin (4mg/kg) on right ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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5.5. Plasma oxidative stress and antioxidant capacity  
Levels of blood plasma were measured by assessing the thiobarbituric acid reactive 
substances (TBARS) in all treated groups. Melatonin treated MCT rats had significantly lower 
levels of plasma lipid peroxidation compared to MCT rats (1.66 ± 0.07 vs. 2.27 ± 0.22 
µmol/mL, p<0.03) (Figure 71). Melatonin treated controls had similar levels of plasma lipid 
peroxidation compared to normal controls (0.88 ± 0.05 vs. 0.83 ± 0.05 µmol/mL) (Figure 71).  
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Figure 71. Effect of a chronic treatment with melatonin (4mg/kg) on plasma lipid 
peroxidation in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.03 (MCT+MEL 
vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had a higher antioxidant capacity compared to MCT rats (26.69 
± 1.84 vs. 18.40 ± 2.29 nmol/L trolox equivalents, p<0.02) (Figure 72). Melatonin treated 
controls had a similar antioxidant capacity compared to normal controls (23.23 ± 1.43 vs. 
30.6 7± 3.88 nmol/L trolox equivalents) (Figure 72). 
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Figure 72. Effect of a chronic treatment with melatonin (4mg/kg) on plasma antioxidant 
capacity in a rat model of MCT-induced PH, *p<0.02 (MCT vs. C), #p<0.02 (MCT+MEL vs. 
MCT), n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower catalase activity compared to MCT (7.27 
± 0.88 vs. 12.40 ± 1.79 IU/mg protein, p<0.006) (Figure 73). Melatonin treated controls had 
a similar catalase activity compared to controls (4.71 ± 0.97 vs. 3.72 ± 0.40 IU/mg protein 
(Figure 73). 
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Figure 73. Effect of a chronic treatment with melatonin (4mg/kg) on plasma catalase 
activity in a rat model of MCT-induced PH, *p<0.0008 (MCT vs. C), #p<0.006 (MCT+MEL vs. 
MCT), n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower SOD activity compared to MCT rats (8.20 
± 0.71 vs. 9.97 ± 0.20 IU/mg protein, p<0.04) (Figure 74). Melatonin treated control rats had 
a similar SOD activity compared to controls (6.80 ± 0.65 vs. 6.57 ± 0.83 IU/mg protein) (Figure 
74).  
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Figure 74. Effect of a chronic treatment with melatonin (4mg/kg) on plasma superoxide 
dismutase (SOD) activity in a rat model of MCT-induced PH, *p<0.003 (MCT vs. C), #p<0.04 
(MCT+MEL vs. MCT), n≥6 per group. 
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5.6. Cardiac interstitial fibrosis: The effect of 4mg/kg melatonin treatment 
The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 75 A). The 
percentage of collagen deposition in the RV sections of the MCT+MEL hearts were similar to 
the MCT rats (3.82 ± 1.02 vs. 4.68 ± 0.75 %) (Figure 75 A). Representative images of all groups 
are shown below (Figure 75 B).  
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Figure 75 (A). Effect of a chronic treatment with melatonin (4mg/kg) on cardiac interstitial 
fibrosis in a rat model of MCT-induced PH, *p<0.04 (MCT vs. C), (MCT+MEL vs. MCT), n=4 
per group.  
 
 
 
 
 
 
 
 
 
 
Figure 75 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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6. Results: Effects of 6mg/kg melatonin 
6.1. Biometric measurements 
Table 8 summarizes the biometric measurements including body weights, weights of organs and weight of these organs expressed as a ratio of body 
weight or tibial length. Melatonin treated MCT rats had significantly higher body weights (323.00 ± 5.46 vs. 218.80 ± 18.41 g, p<0.02) while the heart 
weights were similar (1.28 ± 0.09 vs. 1.62 ± 0.07 g, p<0.01). Melatonin treated MCT rats had similar heart weights over body weights (0.41 ± 0.02 vs. 
0.57 ± 0.02 g/g, p>0.05) and similar heart weight over tibial length ratios (0.28 ± 0.01 vs. 0.37 ± 0.02 g/cm, p>0.05). Melatonin treated MCT rats had 
significantly lower RV weights (0.30 ± 0.04 vs. 0.55 ± 0.02 g/g, p<0.0001) and higher LV weights compared to MCT rats (0.74 ± 0.04 vs. 0.65 ± 0.01 
g/g, p<0.04). Melatonin treated MCT rats had lower lung weights compared to untreated MCT rats (2.65 ± 0.3 vs. 3.59 ± 0.13 g, p<0.02) and similar 
lung weight over body weight ratios (1.03 ± 0.14 vs. 1.12 ± 0.04 g/g, p<0.03). Melatonin treated MCT had also lower liver weights (12.77 ± 0.97 vs. 
19.60 ± 1.22 g, p<0.0001) and lower liver weight over body weight ratios (0.39 ± 0.02 vs. 0.56 ± 0.03 g/g, p<0.0002).  
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Table 8. Biometric measurements 
 
C: Control, MCT: Monocrotaline, MEL: Melatonin. *p<0.0001 (MCT vs C), *p<0.0001 (MCT vs C, MCT+MEL vs. MCT), *p<0.05 (MCT vs. C),  
*p<0.0006 (MCT vs C, MCT+MEL vs. MCT), n≥ 6 per group. Values are mean ± standard error of the mean. 
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6.2. Echocardiography: LV functional parameters 
Echocardiography measurements showed that LV fractional shortening was significantly 
lower in the melatonin treated MCT rats compared to MCT rats (39.08 ± 5.19 vs. 69.37 ± 2.17 
%, p<0.0001) (Figure 76). Control rats treated with melatonin had similar LV fractional 
shortening compared to normal controls (36.52 ± 1.88 vs. 36.13 ± 1.08 %) (Figures 76).  
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Figure 76. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular systolic 
fractional shortening in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.0001 
(MCT+MEL vs. MCT), n≥6 per group. 
  
* 
# 
181 
 
Melatonin treated MCT rats had significantly higher LV end diastolic volumes compared to 
MCT rats (0.64 ± 0.15 vs. 0.19 ± 0.008 mL, p<0.0001) (Figure 77). Control rats treated with 
melatonin had similar LV end diastolic volumes (0.78 ± 0.06 vs. 0.68 ± 0.05 mL) compared to 
controls (Figure 77).  
C MCT C+MEL MCT+MEL
0.0
0.2
0.4
0.6
0.8
1.0
Groups
LV
 e
n
d
 d
ia
st
o
lic
 v
o
lu
m
e 
(m
L)
 
Figure 77. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular end 
diastole volume in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.0001 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had significantly lower LV ejection fractions compared to MCT 
rats (80.74 ± 3.96 vs. 96.05 ± 0.63%, p<0.02) (Figure 78). Control rats treated with melatonin 
had similar LV ejection fractions compared to controls (72.83 ± 5.21 vs. 69.09 ± 1.57 %) 
(Figure 78).  
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Figure 78. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular 
ejection fraction in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.02 
(MCT+MEL vs. MCT), n≥6 per group. 
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6.3. Isolated heart perfusions: Left ventricular function 
Isolated heart perfusions showed that melatonin treated MCT rats had similar LV developed 
pressures compared to MCT rats (107.50 ± 1.53 vs. 98.41 ± 3.87 mmHg) (Figure 79). 
Melatonin treated control rats had similar LV developed pressures compared to controls 
(105.50 ± 2.75 vs. 104.20 ± 5.08 mmHg) (Figure 79).  
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Figure 79. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular 
developed pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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The LV systolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(109.70 ± 2.20 vs. 104.10 ± 5.82 mmHg) (Figure 80). Melatonin treated control rats had 
similar LV systolic pressures compared to controls (113.30 ± 2.70 vs. 110.00 ± 3.51 mmHg) 
(Figure 80).  
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Figure 80. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular systolic 
pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per 
group. 
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The LV diastolic pressure was similar for melatonin treated MCT rats compared to MCT rats 
(8.59 ± 0.09 vs. 8.62 ± 0.11 ± 0.12 mmHg) (Figure 81). Melatonin treated control rats had 
similar LV systolic pressures compared to controls (8.39 ± 0.07 vs. 8.44 ± 0.15 mmHg) (Figure 
81).  
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Figure 81. Effect of a chronic treatment with melatonin (6mg/kg) on left ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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The heart rate was similar for melatonin treated MCT rats compared to MCT rats (318.40 ± 
16.22 vs. 284.40 ± 13.23 bpm) (Figure 82). Melatonin treated control rats had similar heart 
rates compared to controls (312.90 ± 17.99 vs. 303.20 ± 14.77 bpm) (Figure 82).  
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Figure 82. Effect of a chronic treatment with melatonin (6mg/kg) on heart rate in a rat 
model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per group. 
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6.4. Isolated heart perfusions: Right ventricular function 
The RV developed pressure was lower in the melatonin treated MCT rats compared to MCT 
rats (60.38 ± 3.10 vs. 81.22 ± 2.75 mmHg, p<0.009) (Figure 83) Control rats treated with 
melatonin had similar RV developed pressures compared to normal controls (48.72 ± 5.18 vs. 
45.87 ± 2.11 mmHg) (Figures 83).  
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Figure 83. Effect of a chronic treatment with melatonin (6mg/kg) on right ventricular 
developed pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.009 
(MCT+MEL vs. MCT), n≥6 per group.  
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Melatonin treated MCT rats had lower RV systolic pressures compared to the MCT rats (64.34 
± 2.55 vs. 87.91 ± 5.48 mmHg, p<0.0004) (Figure 84). Control rats treated with melatonin had 
similar RV systolic pressures compared to normal controls (54.50 ± 3.73 vs. 54.35 ± 2.28 
mmHg) (Figure 84).  
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Figure 84. Effect of a chronic treatment with melatonin (6mg/kg) on right ventricular 
systolic pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.0004 
(MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had similar RV diastolic pressures compared to the MCT rats 
(8.44 ± 0.05 vs. 8.73 ± 0.08 mmHg) (Figure 85). Control rats treated with melatonin had 
similar RV diastolic pressures compared to normal controls (8.51 ± 0.10 vs. 8.55 ± 0.10 mmHg) 
(Figure 85).  
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Figure 85. Effect of a chronic treatment with melatonin (6mg/kg) on right ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), 
n≥6 per group. 
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6.5. Plasma oxidative stress and antioxidant capacity 
Levels of blood plasma were measured by assessing the thiobarbituric acid reactive 
substances (TBARS) in all treated groups. Melatonin treated MCT rats had significantly lower 
levels of plasma lipid peroxidation compared to MCT rats (1.65 ± 0.12 vs. 2.27 ± 0.22 
µmol/mL, p<0.005) Figure 86). Melatonin treated controls had similar levels of plasma lipid 
peroxidation compared to normal controls (0.93 ± 0.05 vs. 0.83 ± 0.05 µmol/mL) (Figure 86).  
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Figure 86. Effect of a chronic treatment with melatonin (6mg/kg) on plasma lipid 
peroxidation in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.005 (MCT+MEL 
vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had a higher antioxidant capacity compared to MCT rats (29.32 
± 1.35 vs. 18.40 ± 2.29 nmol/L trolox equivalents, p<0.004) (Figure 87). Melatonin treated 
controls had a similar antioxidant capacity compared to normal controls (32.20 ± 3.31 vs. 
30.6 7 ± 3.88 nmol/L trolox equivalents) (Figure 87). 
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Figure 87. Effect of a chronic treatment with melatonin (6mg/kg) on plasma antioxidant 
capacity in a rat model of MCT-induced PH, *p<0.02 (MCT vs. C), #p<0.004 (MCT+MEL vs. 
MCT), n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower catalase activity compared to MCT (4.98 
± 0.68 vs. 12.40 ± 1.79 IU/mg protein, p<0.0009) (Figure 88). Melatonin treated controls had 
a similar catalase activity compared to controls (4.90 ± 1.04 vs. 3.72 ± 0.40 IU/mg protein, 
p>0.05) (Figure 88). 
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Figure 88. Effect of a chronic treatment with melatonin (6mg/kg) on plasma catalase 
activity in a rat model of MCT-induced PH, *p<0.0008 (MCT vs. C), #p<0.0009 (MCT+MEL vs. 
MCT), n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower SOD activity compared to MCT rats (6.15 
± 0.73 vs. 9.97 ± 0.20 IU/mg protein, p<0.01) (Figure 89). Melatonin treated control rats had 
a similar SOD activity compared to controls (7.44 ± 0.52 ± 0.44 vs. 6.57 ± 0.83 IU/mg protein) 
(Figure 89). 
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Figure 89. Effect of a chronic treatment with melatonin (6mg/kg) on plasma superoxide 
dismutase (SOD) activity in a rat model of MCT-induced PH, *p<0.003 (MCT vs. C), #p<0.01 
(MCT+MEL vs. MCT), n≥6 per group. 
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6.6. Cardiac interstitial fibrosis: The effect of 6mg/kg melatonin treatment 
The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 90 A). The 
percentage of collagen deposition in the RV sections of the MCT+MEL hearts were similar to 
the MCT rats (3.89 ± 0.99 vs. 4.68 ± 0.75 %) (Figure 90 A). Representative images of all groups 
are shown below (Figure 90 B).  
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Figure 90 (A). Effect of a chronic treatment with melatonin (6mg/kg) on cardiac interstitial 
fibrosis in a rat model of MCT-induced PH, *p<0.04 (MCT vs. C), (MCT+MEL vs. MCT), n=4 
per group.  
 
 
 
 
 
 
 
 
 
 
 
Figure 90 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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7. Discussion for the effects of the different doses of melatonin 
In the previous sections, we were able to show that oxidative stress is increased in the plasma 
of patients with PH and controls, as well as in the experimental model of MCT-induced PH. 
Our next goal was to test whether melatonin, a powerful antioxidant, could confer 
cardioprotection in experimental PH. In order to do this, we administered three different 
doses of melatonin (75ng/L, 4m/kg and 6mg/kg) in the drinking water of the experimental 
rats. Melatonin treatment commenced on the same day as the induction of experimental PH 
(i.e. day zero) and continued until the last day of the experimental protocol (i.e. day 28). Our 
results showed that melatonin treatment reduced RV hypertrophy, oxidative stress and 
improved cardiac function in the MCT model of PH.  
 
Biometric measurements 
Melatonin treatment for 28 days resulted in increased body weights compared to the MCT 
rats. There are currently no reports in the literature reporting similar findings, as melatonin 
has not been tested in this experimental model of PH. From the literature, it is clear that MCT 
causes weight loss due to a combination of factors including, growth retardation, and lack of 
physical activity, reduced food consumption, skeletal muscle wasting and heart failure 
associated cachexia 208,326,339. Melatonin treatment may have modulated these factors to 
result in higher body weights. However, it’s imperative to keep in mind that we started 
melatonin treatment on the same day as the induction of MCT-PH, which may have 
interfered with the disease induction and thus modulated pathological processes that 
normally cause body weight loss.  
In the light of the above argument, it’s possible that melatonin inhibited the disease 
induction, development and progression, at least partially, and by doing so, prevented 
further weight loss as would occur in the absence of melatonin. Thus, when melatonin 
treated MCT rats were weighed on day 28, they had higher body weights than untreated MCT 
rats. This effect of melatonin was achieved by all three doses of melatonin in our 
experiments.  
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The 75ng/L dose of melatonin had no effect on the heart weights while the higher doses 
(4mg/kg and 6mg/kg) decrease these measurements back to normal values. This was also 
reflected in the ratios of heart weight over body weight and heart weight over tibial length. 
As mentioned previously, it seems that the higher heart weights are mainly due to the 
marked RV hypertrophy and therefore, a reduction in the heart weight measurements 
reflects reduced RV hypertrophy caused by melatonin treatment. It is clear, that the 75ng/L 
dose of melatonin corresponding to nutritional values is not sufficient to modulate heart 
weights compared to the higher doses.  
All of the doses of melatonin reduced lung weights and lung weight over body weight ratios. 
This could mean that melatonin treatment attenuated pulmonary oedema or damage, 
underlined by endothelial injury, oxidative stress and inflammation; however this was not 
assessed in our study. The protective effects of melatonin against lung injury and damage are 
widely reported for animal models of cigarette smoke exposure-induced lung damage, 
ventilator induced lung injury, hyperbaric oxygen exposure-induced lung injury and allergic 
lung inflammation 302-304. Therefore, the reduction of lung weight by melatonin may have 
occurred because melatonin had direct pulmonary protective effects. Lastly, all doses of 
melatonin normalised liver weight and liver weight over body weight ratios. This suggests 
that melatonin also had a protective effect on the livers of MCT rats.  
As melatonin has been shown to have antihypertensive properties, it could be argued that 
we should have measured the blood pressures of the melatonin treated rats. The blood 
pressure lowering effects of melatonin has been shown in healthy women and men in three 
classic studies in the literature 340-342. These studies looked at the acute effects of melatonin, 
within 90 minutes post-administration and they used carotid atery pulsatility as an index of 
vasodilation. An interesting observation in these studies was that individuals who had higher 
baseline values, had greater reduction in pulsatility and lower blood pressures. Therefore, 
these data does not necessarily mean that melatonin reduces blood pressure of healthy 
individuals, but at the time, rather suggested that melatonin could reduce blood pressure in 
individuals perhaps already predisposed to hypertension. If these findings are extrapolated 
to our animal study, it becomes highly unlikely that laboratory bred rats would have varying 
baseline blood pressures or carotid artery pulsatility. Another interesting observation, is that 
in these three classic studies, these individuals were placed a “low light” room. These low 
light conditions could have contributed to the reduced blood pressure, as different types of 
light have been shown to affect plasma/saliva melatonin levels 343. Furthermore, these 
investigators administered 1mg of melatonin to the individuals, which is three times lower 
197 
 
than the dose of melatonin available at pharmacies for jetlag or 5 times lower than the doses 
tested in healthy volunteers, yet without any reported effect on blood pressure 255-257,295. Xia 
et al, have shown that melatonin causes a slight decrease in blood pressure in normotensive 
rats but this effect lasted for only 15 minutes, after which blood pressure returned to normal 
levels 344. It is therefore clear that one should cautiously interpret these data of melatonin on 
blood pressure in healthy individuals or healthy animals. Nevertheless, it would have been 
relevant to measure the blood pressures in our animals in order to explore the possible 
effects of melatonin on blood pressure.  
 
RV hypertrophy 
In our experiments, RV hypertrophy was prevalent as displayed by the increased RV weight 
over LV weight plus septal weight ratios in the MCT rats. With this experimental model of PH, 
the RV hypertrophy is solely due to PH or increased RV afterload. Together with these 
findings, all three doses of melatonin reduced the RV hypertrophy. Therefore suggesting that 
melatonin reduced RV hypertrophy by attenuating PH, however, we can only assume its 
effects of PH as we did not measure pulmonary haemodynamic parameters. In line with this 
notion, melatonin’s antihypertensive properties may also have come into play in our study. 
This is highly likely as melatonin can cause vasodilation by increasing plasma L-arginine levels 
(a substrate used by nitric oxide synthase to produce nitric oxide) and decreasing asymmetric 
dimethyl arginine (a natural inhibitor of nitric oxide) 251,252. Furthermore, the 
antihypertensive effects of melatonin are also achieved by activation of its receptors, 
reduction of intracellular calcium, elevation of cyclic-GMP levels and consequent vasodilation 
290. However, these mechanisms would require further investigation in our study.  
With this experimental model of PH, there are also direct oxidative stress-induced adverse 
effects on the RV which could also have been stunted with melatonin treatment. There are 
three interesting studies, where melatonin was administered at 10mg/kg or 30mg/kg for 
either four or 6 weeks to spontaneously hypertensive rats 294,345,346. In all three these studies, 
spontaneous hypertensive rats developed LV hypertrophy and had marked systemic 
hypertension. Melatonin reduced systemic blood pressure in the rats with heart disease, but 
did not affect LV hypertrophy and these studies, concluded that melatonin did not have a 
direct effect on the hypertrophic process despite a reduction of systemic blood pressure. 
However, this phenomenon could have been due to the fact that in these studies, melatonin 
only achieved minimal effect on systemic blood pressure. In a rat model of hyperthyroid-
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induced cardiac hypertrophy, melatonin treatment ameliorated cardiac hypertrophy 292. 
Yeung et al, gave rats a daily intraperitoneal injection of 10mg/kg melatonin and 
subsequently exposed these rats to chronic hypoxia (10% oxygen) for 28 days 347. Melatonin 
reduced RV hypertrophy compared to the vehicle treated rats. It appears therefore that the 
anti-hypertrophic effects of melatonin are achieved by attenuating the underlying disease 
and depends on the aetiology of the cardiac hypertrophy.  
 
Echocardiography and Isolated heart perfusions: LV and RV function 
Our echocardiography data showed that all three doses of melatonin increased LV fractional 
shortening and ejection fraction and also increased LV end diastolic volumes towards control 
levels. LV dysfunction in the MCT model, as measured with echocardiography, has been 
attributed to LV atrophy caused by the MCT toxin. 336 Melatonin attenuates the LV atrophy 
as seen by the normalised LV weight ratios, which could be the reason for the improved LV 
function. 
We did not find any cardiac functional abnormalities when we assessed LV function with 
isolated heart perfusions. Therefore, also no effects were seen with melatonin treatment. 
We ascribe this to the insensitivity of the Langendorff isolated heart perfusion apparatus to 
detect up functional changes which echocardiography can detect. Nevertheless, the ability 
of melatonin to improve cardiac function has been shown in other models of cardiac 
dysfunction 250,273. The mechanisms underlining these cardioprotective effects of melatonin 
have been ascribed to its direct antioxidant properties, antiadrenergic and receptor 
mediated effects 273. Furthermore, melatonin has also been shown to confer 
cardioprotection by activating the RISK pathway, which is an inherent, cellular pro-survival 
signalling pathway 273. Melatonin also improves cardiac function, by improving calcium 
handling at the level of the sarcoplasmic reticulum in the setting of ischemia/reperfusion 347. 
Lastly, Lamont et al, demonstrated that melatonin confers cardioprotection via the activation 
of the survivor activating factor enhancement (SAFE) pro-survival signalling pathway that 
involves the activation of tumour necrosis factor alpha and the signal transducer and 
activator of transcription 3 (STAT3) 250. It is possible that all these functions of melatonin 
could have contributed to improvement of cardiac function seen in our study.  
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Blood plasma oxidative stress and antioxidant capacity 
All three doses of melatonin reduced plasma lipid peroxidation, increased plasma antioxidant 
capacity and normalised plasma catalase and SOD activity. Melatonin is well known for its 
powerful antioxidant effect in various animal models of cardiovascular disease 288. This 
antioxidant effect of melatonin is either achieved by increasing the activity of antioxidant 
enzymes via promoting a preferable reduced state or by increasing antioxidant enzyme 
expression 282. In our study it became apparent that despite an increase in catalase and SOD 
activity, oxidative stress (lipid peroxidation) was still increased in the MCT rats. Therefore, 
the fact that oxidative stress was reduced in the plasma of melatonin treated MCT rats means 
that melatonin might have had a direct effect on the oxidative stress by scavenging free 
radicals either independent or in concert with antioxidant enzymes. Melatonin can directly 
bind hydroxyl radical to the C-2 position of its indole ring and interact with hydrogen peroxide 
and form water as a by-product and N-acetyl-n-formyl-5-methoxy-kenuramine (AFMK) 284,285. 
These antioxidant abilities of melatonin are even further amplified by its by-products which 
have also been shown to scavenge oxygen free radicals more effectively than melatonin itself 
284,285. It has been demonstrated by Venegas et al, that high doses of melatonin (10mg/kg- 
200mg/kg) seem necessary to reach subcellular concentrations suﬃcient and exert 
pharmacological therapeutic eﬀects 348. However, our data show clearly that even the low 
concentration of melatonin (75ng/L) can modulate antioxidant capacity and enzyme activity.  
It is possible that the antioxidant properties of melatonin, its metabolites and by-products 
could be responsible for the antioxidant and cardioprotective effects seen in our study. Other 
antioxidant effects could also be mediated via activation of the melatonin receptors 1, 2 and 
3 282. With these receptor mediated effects, melatonin can bind to its membrane bound, G-
protein coupled receptors, activate cytoplasmic molecules, which translocate to the nucleus 
and increase the expression of antioxidant enzymes 288. However, we did not assess 
antioxidant enzyme expression and furthermore, the increase in enzyme expression does not 
necessarily mean increased activity. Nevertheless, the receptor mediated effects of 
melatonin could also be involved in the cardioprotective effects in our study.  
 
Cardiac interstitial fibrosis 
The involvement of melatonin in the process of cardiac remodelling, is supported by findings 
of Simko et al, who showed that pinealectomized rats and constant exposure to light reduced 
circulating melatonin levels and led to the development of LV interstitial fibrosis 349. It is 
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suggested that the anti-fibrotic effect of melatonin is mediated via its antioxidant effects and 
modulation of the sympathetic nervous and renin-angiotensin systems 349. However, in our 
study, none of the three doses of melatonin affected cardiac interstitial fibrosis. One would 
assume that improved cardiac function after melatonin treatment would also be due to 
improved interstitial fibrosis, but the fact the melatonin treatment did not affect fibrosis 
could mean otherwise. It is possible that cardiac dysfunction in the MCT model of PH is mainly 
due to the pressure overload, RV hypertrophy, oxidative stress and the adverse 
consequences of all these parameters. 
The fact that these three doses of melatonin did not modulate interstitial fibrosis may mean 
that starting melatonin treatment on the same day as the induction of PH, does either not 
have an effect on fibrosis or the effects is not seen due to a small sample size. The latter 
argument is very likely as all three doses showed a trend towards a decrease. The fact that 
we only measured fibrosis in only 5 fields of each heart section could also be a reason we did 
not see statistically significant differences in the effect of melatonin on fibrosis. More fields 
could have yielded more significant results. Furthermore, Simko et al, demonstrated the anti-
fibrotic effect of melatonin at a dose of 10mg/kg per day for 6 weeks, while we used much 
lower doses for shorter time periods 349. 
 
8. Conclusions 
In this section, our data suggest that melatonin given at a concentration similar to nutritional 
values (75ng/L) or at doses similar to the dose received with pills (4mg/kg or 6mg/kg) confers 
cardioprotection. This cardioprotective effect was validated by reduction of RV hypertrophy, 
improved cardiac function, antioxidant capacity and antioxidant enzyme activity. Our 
findings are important as even the low concentration of melatonin was found to cause 
substantial improvement of cardiac parameters. The data suggest that cardioprotection 
could be offered via a diet consisting of food enriched with melatonin. Our data also 
demonstrate that the higher doses of melatonin, conferred greater cardioprotective benefit 
as seen by their greater effect on cardiac parameters and plasma antioxidant parameters. 
Our data therefore suggest that melatonin could be used as a simple therapy for 
cardioprotection in PH.  
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SECTION G 
MELATONIN AS A THERAPEUTIC OF PREVENTIVE TREATMENT IN PH 
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1. Introduction 
In section F, we were able to demonstrate that all three doses of melatonin conferred 
cardioprotection against PH, as seen with reduced RV hypertrophy, improved cardiac 
function, decreased oxidative stress, normalised antioxidant capacity and antioxidant 
enzyme activity. Melatonin treatment was started on the same day as the induction of 
experimental PH, which poorly mimics the clinical situation. Furthermore, one could argue 
that administration of melatonin on the same day as the induction of experimental PH may 
interfere with the disease development and this may display the true efficacy of melatonin 
in PH. Therefore, in order to truly test the efficacy of melatonin as a cardioprotective agent 
in PH, we proposed to take two different approaches including therapeutic (melatonin 
treatment started fourteen days after the induction of experimental PH, when the disease 
already manifests) and preventive (melatonin treatment started five days before the 
induction of experimental PH). For these protocols, we used 6mg/kg of melatonin as our 
previous data suggested that this dose conferred the greatest degree of cardioprotection  
 
2. Materials and methods 
In order to assess the efficacy of melatonin treatment in a protocol that better mimics the 
clinical setting, we started melatonin treatment fourteen days after the induction of PH or 
five days before. For these experiments, we used 6mg/kg of melatonin which corresponds to 
the range of melatonin absorbed via pills. Echocardiography was done on the first day of 
experiments, day 14 and day 28.  
After the melatonin treatment protocols, rats were sacrificed on day 14 and 28 for the 
therapeutic approach or day 28 for the preventive approach. Hereafter, we assessed cardiac 
function with echocardiography, isolated heart perfusions, we collected blood samples, 
performed biometric measurements and assessed oxidative/antioxidant status with blood 
assays for lipid peroxidation (TBARS), antioxidant capacity (ORAC), and catalase and 
superoxide dismutase (SOD) activity. Lastly, hearts were collected for histology (Figure 91). 
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3. Data analyses: Statistical tests 
Unless stated otherwise, all data were expressed as mean ± standard error of the mean 
(SEM). For comparative studies two-way ANOVA analyses (with Bonferroni post-test, if 
p<0.05) were used respectively. All statistical tests were performed using Graph Pad Prism-
5. The experimental groups used for the fibrosis determination were statistically analysed by 
one-way ANOVA and Newman-Keuls post hoc test for multiple comparisons. A p<0.05 was 
considered as significant. 
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4. Results: Effects of therapeutic treatment with 6mg/kg melatonin 
To test the cardioprotective effect of melatonin as therapeutic treatment, daily oral treatment of melatonin (6mg/kg) was given fourteen days after the 
induction of experimental PH and treatment continued until the end of the 28 days protocol.  
 
4.1. Biometric measurements 
Table 9 summarizes the biometric measurements including body weights, weights of organs and weight of these organs expressed as a ratio of body weight 
or tibial length. MCT rats at day 14 had lower body weights and LV+septal weight over heart weight ratios compared to the control rats at day 14. MCT rats at 
day 14 also had higher heart weight over body weight, RV weight over LV+septal weight over heart weight, heart weight over tibial length ratios. Furthermore, 
MCT rats at day 14 had higher lung weights, liver weight over body weights and live weights over body weight ratios. Melatonin treated MCT rats had 
significantly higher body weights (297.30 ± 11.31 vs. 218.80 ± 18.41 g, p<0.0001) while the heart weights were similar (1.64 ± 0.11 vs. 1.62 ± 0.07 g, p>0.05). 
Melatonin treated MCT rats had similar heart weights over body weights (0.58 ± 0.03 vs. 0.57 ± 0.02 g/g, p>0.05) and higher heart weight over tibial length 
ratios (0.47 ± 0.03 vs. 0.37 ± 0.02 g/cm, p<0.09). Melatonin treated MCT rats had significantly lower RV weights (0.33 ± 0.03 vs. 0.55 ± 0.02 g/g, p<0.0001) and 
higher LV weights compared to MCT rats (0.75 ± 0.07 vs. 0.65 ± 0.01 g/g, p<0.09). Melatonin treated MCT rats had lower lung weights compared to untreated 
MCT rats (2.87 ± 0.17 vs. 3.59 ± 0.13 g, p<0.002) and similar lung weight over body weight ratios (1.06 ± 0.08 vs. 1.12 ± 0.04 g/g, p>0.05). Melatonin treated 
MCT had also lower liver weights (11.30 ± 0.71 vs. 19.60 ± 1.22 g, p<0.004) and lower liver weight over body weight ratios (0.41 ± 0.02 vs. 0.56 ± 0.03 g/g, 
p<0.05).  
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Table 9. Biometric measurements 
 
C: Control, MCT: Monocrotaline, MEL: Melatonin, n≥ 6 per group. Values are mean ± standard error of the mean. 
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4.2. Echocardiography: LV functional parameters 
Echocardiography measurements showed that LV fractional shortening was higher in the 
MCT rats at day 14 compared to the controls rats at day 14 (60.29 ± 5.41 vs. 48.02 ± 1.28 
%, p<0.001) (Figure 92 A). LV fractional shortening was also higher in the MCT+MEL group 
(who was designated to receive melatonin treatment on day 14) compared to the controls 
on day 14 (62.65 ± 5.10 vs. 48.02 ± 1.28, p<0.001). The LV fractional shortening was similar 
between melatonin treated control rats (50.98 ± 3.40 %) and the untreated controls (48.14 ± 
1.28 %) (Figure 92 A).  
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Figure 92 (A). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
systolic fractional shortening measured at day 14 in a rat model of MCT-induced PH, 
*p<0.001 (MCT at day 14 vs. C at day 14), #p<0.001 (MCT+MEL vs. MCT), n≥6 per group.  
  
* # 
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LV fractional shortening was significantly higher in the melatonin treated MCT rats compared 
to MCT rats at day 28 (36.61 ± 1.31 vs. 69.37 ± 2.17 %, p<0.0001) (Figure 92 B). Control rats 
treated with melatonin had similar LV fractional shortening compared to normal controls at 
day 28 (39.78 ± 1.14 ± 0.98 vs. 32.95 ± 1.08 %) (Figures 92 B). 
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Figure 92 (B). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
systolic fractional shortening measured at day 28 in a rat model of MCT-induced PH, 
*p<0.0001 (MCT vs. C at day 28), #p<0.0001 (MCT+MEL vs. MCT at day 28), n≥6 per group.  
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LV end diastolic volumes were similar in the MCT rats at day 14 compared to the controls rats 
at day 14 (0.57 ± 0.03 vs. 0.64 ± 0.07 mL) (Figure 92 C). The melatonin treated MCT rats had 
similar LV end diastolic volumes at day 14 (0.55 ± 0.04 vs. 0.57 ± 0.03 mL). (Figure 92 C). 
Furthermore, the melatonin treated controls had similar LV end diastolic volumes compared 
to the untreated controls at day 14 (0.64 ± 0.04 vs. 0.64 ± 0.07 mL) (Figure 92 C). 
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Figure 92 (C). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
end diastolic volume measured at day 14 in a rat model of MCT-induced, (MCT at day 14 vs. 
C at day 14), (MCT+MEL vs. MCT at day 14), n≥6 per group.  
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Melatonin treated MCT rats had significantly higher LV end diastolic volumes compared to 
MCT rats at day 28 (0.65 ± 0.08 vs. 0.193 ± 0.01 mL, p<0.0001) (Figure 92 D). Control rats 
treated with melatonin had higher LV end diastolic volumes (0.73 ± 0.05 vs. 0.68 ± 0.05 mL, 
p<0.04) compared to controls at day 28 (Figure 92 D).  
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Figure 92 (D). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
end diastolic volume measured at day 28 in a rat model of MCT-induced PH, *p>0.0001 
(MCT at day 28 vs. C at day 28), *p>0.0001 (MCT+MEL vs. MCT at day 28), n≥6 per group.  
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LV ejection fractions were similar in the MCT rats at day 14 compared to the controls rats at 
day 14 (91.01 ± 2.73 vs. 84.24 ± 1.15 %) (Figure 93 A). LV ejection fractions were similar 
between the melatonin treated MCT rats and controls at day 14 (86.00 ± 2.61 vs. 91.01 ± 
2.731 %) (Figure 93 A). 
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Figure 93 (A). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
ejection fraction measured at day 14 in a rat model of MCT-induced PH, (MCT at day 14 vs. 
C at day 14), (MCT+MEL vs. MCT at day 14), n≥6 per group. 
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Melatonin treated MCT rats had significantly lower LV ejection fractions compared to MCT 
rats at day 28 (72.14 ± 1.68 vs. 96.05 ± 0.63%, p<0.002) (Figure 93 B). Control rats treated 
with melatonin had similar LV ejection fractions compared to controls at day 28 (67.25 ± 1.67 
vs. 69.09 ± 1.57 %) (Figure 93 B).  
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Figure 93 (B). Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
ejection fraction measured at day 28 in a rat model of MCT-induced PH, *p<0.0001 (MCT at 
day 28 vs. C at day 28), #p<0.002 (MCT+MEL vs. MCT at day 28), n≥6 per group. 
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4.3. Isolated heart perfusions: Left ventricular function 
LV developed pressure was similar in the MCT rats at day 14 compared to control rats at day 
14 (92.62 ± 2.33 vs. 87.39 ± 1.67 mmHg) (Figure 94). Isolated heart perfusions showed that 
melatonin treated MCT rats had similar LV developed pressures compared to MCT rats at day 
28 (92.62 ± 5.04 vs. 85.93 ± 0.99 mmHg) (Figure 94). Melatonin treated control rats had 
similar LV developed pressures compared to controls at day 28 (94.70 ± 3.78 ± 2.42 vs. 92.73 
± 3.25 mmHg) (Figure 94).  
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Figure 94. Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
developed pressure in a rat model of MCT-induced PH, (MCT at day 14 vs. C at day 14), 
(MCT+MEL vs. MCT), n≥6 per group. 
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LV systolic pressure was similar in the MCT rats at day 14 compared to control rats at day 14 
(99.15 ± 3.51 vs. 93.15 ± 2.61 mmHg) (Figure 95). The LV systolic pressure was similar for 
melatonin treated MCT rats compared to MCT rats at day 28 (107.80 ± 2.39 vs. 98.24 ± 6.75 
mmHg) (Figure 95). Melatonin treated control rats had similar LV systolic pressures 
compared to controls at day 28 (109.20 ± 1.97 vs. 103.60 ± 4.37 mmHg) (Figure 95).  
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Figure 95. Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
systolic pressure in a rat model of MCT-induced PH, (MCT at day 14 vs. C at day 14), 
(MCT+MEL vs. MCT), n≥6 per group. 
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LV diastolic pressure was similar in the MCT rats at day 14 compared to control rats at day 
14 (8.53 ± 0.17 vs. 8.713 ± 0.04 mmHg) (Figure 96). The LV diastolic pressure was similar for 
melatonin treated MCT rats compared to MCT rats at day 28 (8.48 ± 0.12 vs. 8.62 ± 0.13 
mmHg) (Figure 96). Melatonin treated control rats had similar LV systolic pressures 
compared to controls at day 28 (8.30 ± 0.09 vs. 8.38 ± 0.08 mmHg) (Figure 96).  
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Figure 96. Effect of a therapeutic treatment with melatonin (6mg/kg) on left ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT at day 14 vs. C at day 14), 
(MCT+MEL vs. MCT), n≥6 per group. 
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Heart rate was similar in the MCT rats at day 14 compared to control rats at day 14 (279.20 
± 18.24 vs. 337.90 ± 19.80 bpm) (Figure 97). The heart rate was similar for melatonin treated 
MCT rats compared to MCT rats at day 28 (293.60 ± 5.80 vs. 296.30 ± 14.25 bpm) (Figure 97). 
Melatonin treated control rats had similar heart rates compared to controls at day 28 (284.80 
± 11.41 vs. 271.20 ± 8.79 bpm) (Figure 97).  
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Figure 97. Effect of a therapeutic treatment with melatonin (6mg/kg) on heart rate in a rat 
model of MCT-induced PH, (MCT at day 14 vs. C at day 14), (MCT+MEL vs. MCT), n≥6 per 
group. 
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4.4. Isolated heart perfusions: Right ventricular function 
RV developed pressure was significantly higher in the MCT rats at day 14 compared to control 
rats at day 14 (56.57 ± 2.47 vs. 37.95 ± 2.34 mmHg, p<0.0009) (Figure 98). The RV developed 
pressure was lower in the melatonin treated MCT rats compared to MCT rats at day 28 (71.39 
± 0.57 vs. 86.28 ± 2.61 mmHg, p<0.0002) (Figure 98) Control rats treated with melatonin had 
similar RV developed pressures compared to normal controls at day 28 (42.62 ± 4.13 vs. 45.87 
± 2.11 mmHg) (Figures 98).  
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Figure 98. Effect of a therapeutic treatment with melatonin (6mg/kg) on right ventricular 
developed pressure in a rat model of MCT-induced PH, *p<0.0009 (MCT at day 14 vs. C at 
day 14), #p<0.0002 (MCT+MEL vs. MCT), n≥6 per group. 
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RV systolic pressure was significantly higher in the MCT rats at day 14 compared to control 
rats at day 14 (96.18 ± 5.24 vs. 96.08 ± 6.66 mmHg, p<0.005) (Figure 99). Melatonin treated 
MCT rats had lower RV systolic pressures compared to the MCT rats at day 28 (79.82 ± 0.51 
vs. 95.00 ± 7.07 mmHg, p<0.005) (Figure 99). Control rats treated with melatonin had similar 
RV developed pressures compared to controls at day 28 (50.95 ± 4.16 vs. 54.35 ± 2.28 mmHg) 
(Figure 99).  
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Figure 99. Effect of a therapeutic treatment with melatonin (6mg/kg) on right ventricular 
systolic pressure in a rat model of MCT-induced PH, *p<0.005 (MCT at day 14 vs. C at day 
14), #p<0.005 (MCT+MEL vs. MCT), n≥6 per group. 
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RV diastolic pressure was similar in the MCT rats at day 14 compared to control rats at day 
14 (8.53 ± 0.19 vs. 8.59 ± 0.30 mmHg) (Figure 100).Melatonin treated MCT rats had similar 
RV diastolic pressures compared to the MCT rats at day 28 (8.48 ± 0.10 vs. 8.47 ± 0.15 mmHg) 
(Figure 100). Control rats treated with melatonin had similar RV diastolic pressures compared 
to normal controls at day 28 (8.33 ± 0.07 vs. 8.58 ± 0.11 mmHg) (Figure 100).  
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Figure 100. Effect of a therapeutic treatment with melatonin (6mg/kg) on right ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT at day 14 vs. C at day 14 and 
MCT+MEL vs. MCT), n≥6 per group. 
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4.5. Plasma oxidative stress and antioxidant capacity 
Levels of blood plasma were measured by assessing the thiobarbituric acid reactive 
substances (TBARS) in all treated groups. Plasma lipid peroxidation was significantly higher 
in the MCT rats at day 14 compared to control rats at day 14 (1.60 ± 0.15 vs. 0.74 ± 0.12 
mmHg, p<0.0009) (Figure 101). Melatonin treated MCT rats had significantly lower Levels of 
plasma lipid peroxidation compared to MCT rats at day 28 (1.48 ± 0.07 vs. 2.19 ± 0.26 
µmol/mL, p<0.006) (Figure 101). Melatonin treated controls had similar levels of plasma lipid 
peroxidation compared to normal controls at day 28 (0.97 ± 0.04 vs. 0.84 ± 0.05 µmol/mL) 
(Figure 101). 
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Figure 101. Effect of a therapeutic treatment with melatonin (6mg/kg) on plasma lipid 
peroxidation in a rat model of MCT-induced PH, *p<0.0009 (MCT at day 14 vs. C at day 14), 
#p<0.006 (MCT+MEL vs. MCT), n≥6 per group. 
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Plasma antioxidant capacity was significantly lower in the MCT rats at day 14 compared to 
control rats at day 14 (18.01 ± 2.64 vs. 25.77 ± 1.94 mmHg, p<0.04) (Figure 102). Melatonin 
treated MCT rats had a higher antioxidant capacity compared to MCT rats at day 28 (42.10 ± 
1.28 vs. 18.40 ± 2.29 nmol/L trolox equivalents, p<0.0001) (Figure 102). Melatonin treated 
controls had a similar antioxidant capacity compared to normal controls at day 28 (25.77 ± 
1.94 vs. 30.67 ± 3.88 nmol/L trolox equivalents) (Figure 102). 
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Figure 102. Effect of a therapeutic treatment with melatonin (6mg/kg) on plasma 
antioxidant capacity in a rat model of MCT-induced PH, *p<0.04 (MCT at day 14 vs. C at day 
14), #p<0.0001 (MCT+MEL vs. MCT), n≥6 per group. 
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Plasma catalase activity was significantly higher in the MCT rats at day 14 compared to 
control rats at day 14 (8.19 ± 0.90 vs. 5.11 ± 0.61 mmHg, p<0.02) (Figure 103). Melatonin 
treated MCT rats had a significantly lower catalase activity compared to MCT at day 28 (6.81 
± 0.68 vs. 12.40 ± 1.80 IU/mg protein, p<0.004) (Figure 103). Melatonin treated controls had 
a similar catalase activity compared to controls at day 28 (2.62 ± 0.60 vs. 3.72 ± 0.40 IU/mg 
protein) (Figure 103). 
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Figure 103. Effect of a therapeutic treatment with melatonin (6mg/kg) on plasma catalase 
activity in a rat model of MCT-induced PH, *p<0.02 (MCT at day 14 vs. C at day 14), #p<0.004 
(MCT+MEL vs. MCT), n≥6 per group. 
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Plasma SOD activity was similar in the MCT rats at day 14 compared to control rats at day 14 
(8.68 ± 0.31 vs. 9.20 ± 0.40 mmHg) (Figure 104). Melatonin treated MCT rats had a 
significantly lower SOD activity compared to MCT rats at day 28 (8.19 ± 0.52 vs. 9.97 ± 0.20 
IU/mg protein, p<0.02) (Figure 104). Melatonin treated control rats had a similar SOD activity 
compared to controls at day 28 (6.94 ± 0.30 vs. 6.57 ± 0.83 IU/mg protein) (Figure 104). 
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Figure 104. Effect of a therapeutic treatment with melatonin (6mg/kg) on plasma 
superoxide dismutase (SOD) activity in a rat model of MCT-induced PH, (MCT at day 14 vs. 
C at day 14), #p<0.02 (MCT+MEL vs. MCT), n≥6 per group.  
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4.6. Cardiac interstitial fibrosis: The effect of 6mg/kg therapeutic melatonin treatment 
The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 105 A). The 
percentage of collagen deposition in the RV sections of the MCT+MEL hearts was significantly 
lower than in the MCT rats (2.23 ± 0.43vs. 4.68 ± 0.75 %, p<0.03) (Figure 105 A). 
Representative images of all groups are shown below (Figure 105 B).  
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Figure 105 (A). Effect of a therapeutic treatment with melatonin (6mg/kg) on cardiac 
interstitial fibrosis in a rat model of MCT-induced PH, *p<0.04 (MCT vs C), #p<0.03 
(MCT+MEL vs. MCT), n=3-4 per group.  
 
 
 
 
 
 
 
 
 
 
Figure 105 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis.
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5. Results: Effects of preventive treatment with 6mg/kg melatonin 
In these experiments, the daily, oral melatonin treatment was started five days prior to the induction of experimental PH with a single subcutaneous 
injection of MCT and was continued until day 28.  
 
5.1. Biometric measurements 
Table 10 summarizes the biometric measurements including ratios of the heart weight over body weight, lung weight over body weight, liver weight 
over body weight and body weight respectively. Compared to the MCT group, preventive melatonin treatment (6mg/kg) did not affect the heart 
weight over body weight (0.52 ± 0.04 vs. 0.57 ± 0.02 g/g, p<0.0001) but decreased the lung weight over body weight (0.84 ± 0.06 vs. 1.12±0.04 g/g, 
p<0.0001). Preventive melatonin treatment decreased liver weight over body weight compared to the MCT group (0.47 ± 0.03 vs. 0.56 ± 0.03 g/g, 
p<0.05). Furthermore, preventive melatonin treatment increased the body weight compared to the MCT group (301.2 ± 28.24 vs. 218.8 ± 18.41 
gram, p<0.0006). 
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Table 10. Biometric measurements 
 
C: Control, MCT: Monocrotaline, MEL: Melatonin. *p<0.0001 (MCT vs C), *p<0.0001 (MCT+MEL vs. MCT), *p<0.05 (MCT vs C), *p<0.0006  
(MCT vs C, MCT+MEL vs. MCT), n≥ 6 per group. Values are mean ± standard error of the mean. 
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5.2. Echocardiography: LV functional parameters 
Echocardiography measurements showed that LV fractional shortening was significantly lower in 
the melatonin treated MCT rats compared to MCT rats (51.18 ± 2.34 vs. 69.37 ± 2.17 %, p<0.0001) 
(Figure 106). Control rats treated with melatonin had similar LV fractional shortening compared 
to normal controls (36.45 ± 1.74 vs. 36.13±1.08 %) (Figures 106).  
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Figure 106. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular 
systolic fractional shortening in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), 
#p<0.0001 (MCT+MEL vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had significantly higher LV end diastolic volumes compared to MCT 
rats (0.39 ± 0.03 ± 0.06 vs. 0.19 ± 0.01 mL, p<0.0001) (Figure 107). Control rats treated with 
melatonin had similar LV end diastolic volumes (0.55 ± 0.06 vs. 0.68± 0.05 mL, p<0.04) compared 
to controls (Figure 107).  
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Figure 107. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular end 
diastolic volume in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.004 (MCT+MEL 
vs. MCT), n≥6 per group.  
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Melatonin treated MCT rats had significantly lower LV ejection fractions compared to MCT rats 
(86.50 ± 1.80 vs. 96.05± 0.63 %, p<0.003) (Figure 108). Control rats treated with melatonin had 
similar LV ejection fractions compared to controls (71.78 ± 2.14 vs. 69.09± 1.57 %) (Figure 108).  
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Figure 108. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular 
ejection fraction in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.003 (MCT+MEL 
vs. MCT), n≥6 per group. 
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5.3. Isolated heart perfusions: Left ventricular function 
Isolated heart perfusions showed that melatonin treated MCT rats had similar LV developed 
pressures compared to MCT rats (108.80 ± 3.32 vs. 102.30 ± 7.86 mmHg) (Figure 109). Melatonin 
treated control rats had similar LV developed pressures compared to controls (115.60 ± 3.06 vs. 
104.20 ± 5.08 mmHg) (Figure 109).  
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Figure 109. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular 
developed pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 
per group. 
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The LV systolic pressure was similar for melatonin treated MCT rats compared to controls (99.19 
± 6.63 vs. 103.80 ± 4.11 mmHg) (Figure 110). Melatonin treated control rats had similar LV 
systolic pressures compared to controls (106.20 ± 1.84 vs. 110.00 ± 3.51 mmHg) (Figure 110).  
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Figure 110. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular 
systolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per 
group. 
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The LV diastolic pressure was similar for melatonin treated MCT rats compared to controls (8.68 
± 0.10 vs. 8.42 ± 0.12 mmHg) (Figure 111). Melatonin treated control rats had similar LV diastolic 
pressures compared to controls (8.50 ± 0.09 vs. 8.42 ± 0.12 mmHg) (Figure 111).  
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Figure 111. Effect of a preventive treatment with melatonin (6mg/kg) on left ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 
per group. 
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The heart rate was similar for melatonin treated MCT rats compared to controls (318.70 ± 9.29 
vs. 303.30 ± 18.16 bpm) (Figure 112). Melatonin treated control rats had similar heart rates 
compared to controls (302.60 ± 14.87 vs. 303.20 ± 14.77 bpm) (Figure 112).  
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Figure 112. Effect of a preventive treatment with melatonin (6mg/kg) on heart rate in a rat 
model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 per group. 
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5.4. Isolated heart perfusions: Right ventricular function 
The RV developed pressure was lower in the melatonin treated MCT rats compared to MCT rats 
(59.85 ± 3.77 vs. 81.22 ± 2.75 mmHg, p<0.005) (Figure 113) Control rats treated with melatonin 
had similar RV developed pressures compared to normal controls (49.04 ± 3.34 vs. 45.87 ± 2.11 
mmHg) (Figures 113).  
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Figure 113. Effect of a preventive treatment with melatonin (6mg/kg) on right ventricular 
developed pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.005 
(MCT+MEL vs. MCT), n≥6 per group.  
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Melatonin treated MCT rats had lower RV systolic pressures compared to the MCT rats (68.65 ± 
3.82 vs. 87.91 ± 5.48 mmHg, p<0.03) (Figure 114). Control rats treated with melatonin had similar 
RV developed pressures compared to normal controls (57.80 ± 3.51 vs. 54.35 ± 2.28 mmHg) 
(Figure 114).  
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Figure 114. Effect of a preventive treatment with melatonin (6mg/kg) on right ventricular 
systolic pressure in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.03 (MCT+MEL 
vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had similar RV diastolic pressures compared to the MCT rats (8.80 ± 
0.08 vs. 8.73 ± 0.08 mmHg) (Figure 115). Control rats treated with melatonin had similar RV 
diastolic pressures compared to normal controls (8.60 ± 0.33 vs. 8.55 ± 0.10 mmHg) (Figure 115).  
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Figure 115. Effect of a preventive treatment with melatonin (6mg/kg) on right ventricular 
diastolic pressure in a rat model of MCT-induced PH, (MCT vs. C and MCT+MEL vs. MCT), n≥6 
per group. 
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5.5. Plasma oxidative stress and antioxidant capacity 
Levels of blood plasma were measured by assessing the thiobarbituric acid reactive substances 
(TBARS) all treated groups. Melatonin treated MCT rats had significantly lower levels of plasma 
lipid peroxidation compared to MCT rats (1.66 ± 0.09 vs. 2.27 ± 0.22 µmol/mL, p<0.002) (Figure 
116). Melatonin treated controls had similar levels of plasma lipid peroxidation compared to 
normal controls (0.95 ± 0.06 vs. 0.83 ± 0.05 µmol/mL) (Figure 116). 
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Figure 116. Effect of a preventive treatment with melatonin (6mg/kg) on plasma lipid 
peroxidation in a rat model of MCT-induced PH, *p<0.0001 (MCT vs. C), #p<0.002 (MCT+MEL 
vs. MCT), n≥6 per group. 
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Melatonin treated MCT rats had a higher antioxidant capacity compared to MCT rats (44.67 ± 
2.33 vs. 18.40 ± 2.29 nmol/L trolox equivalents, p<0.0001) (Figure 117). Melatonin treated 
controls had a higher antioxidant capacity compared to normal controls (61.42 ± 2.63 vs. 30.67± 
3.88 nmol/L trolox equivalents, p<0.0001) (Figure 117). 
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Figure 117. Effect of a preventive treatment with melatonin (6mg/kg) on plasma antioxidant 
capacity in a rat model of MCT-induced PH, *p<0.02 (MCT vs. C), #p<0.0001 (MCT+MEL vs. MCT), 
n≥6 per group, (CON+MEL vs. CON), n≥6 per group. &p<0.0001 
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Melatonin treated MCT rats had a significantly lower catalase activity compared to MCT (3.19 ± 
0.73 vs. 12.40 ± 1.79 IU/mg protein, p<0.0008) (Figure 118). Melatonin treated controls had a 
similar catalase activity compared to controls (4.75 ± 0.65 vs. 3.72 ± 0.40 IU/mg protein) (Figure 
118). 
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Figure 118. Effect of a preventive treatment with melatonin (6mg/kg) on plasma catalase 
activity in a rat model of MCT-induced PH, *p<0.0008 (MCT vs. C), #p<0.0008 (MCT+MEL vs. 
MCT), n≥6 per group. 
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Melatonin treated MCT rats had a significantly lower SOD activity compared to MCT rats (6.71 ± 
0.48 vs. 9.97 ± 0.20 IU/mg protein, p<0.001) (Figure 119). Melatonin treated control rats had a 
similar SOD activity compared to controls (5.95 ± 0.34 vs. 6.57 ± 0.83 IU/mg protein) (Figure 119). 
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Figure 119. Effect of a preventive treatment with melatonin (6mg/kg) on plasma superoxide 
dismutase (SOD) activity in a rat model of MCT-induced PH, *p<0.003 (MCT vs. C), #p<0.001 
(MCT+MEL vs. MCT), n≥6 per group. 
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5.6. Cardiac interstitial fibrosis: The effect of 6mg/kg preventive melatonin treatment 
The percentage of collagen deposition in the RV sections of the MCT hearts were higher 
compared to the controls (4.68 ± 0.75 vs. 2.54 ± 0.36 % area, p<0.04) (Figure 120 A). The 
percentage of collagen deposition in the RV sections of the MCT+MEL hearts was significantly 
lower than the MCT rats (2.61 ± 0.5 vs. 4.68 ± 0.75 %, p<0.04) (Figure 120 A). Representative 
images of all groups are shown below (Figure 120 B).  
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Figure 120 (A). Effect of a preventive treatment with melatonin (6mg/kg) on cardiac interstitial 
fibrosis in a rat model of MCT-induced PH, *p<0.04 (MCT vs. C), #p<0.04 (MCT+MEL vs. MCT), 
n=4 per group.  
 
 
 
 
 
 
 
 
 
Figure 120 (B). Histology sections of hearts stained with picro-sirius red to assess interstitial 
fibrosis. 
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6. Discussion of the effects of melatonin as a therapeutic and preventive intervention 
Our data demonstrate that a daily administration of melatonin either given as a therapeutic or 
preventive intervention attenuated the adverse effects of experimental PH on the heart. Hence, 
therapeutic and preventive melatonin treatment reduced RV hypertrophy, improved cardiac 
function, reduced oxidative stress, increased antioxidant capacity and normalised antioxidant 
enzyme activity in a rat model of MCT-induced PH.  
 
Biometric measurements 
The therapeutic approach has generated very important findings, as the rats were first injected 
with MCT, allowed to develop PH to a reasonably far progressed stage and then melatonin was 
administered. As seen from the biometric measurements, RV hypertrophy was already evident 
at day 14. Rats also displayed body weight loss and changes in heart weight, lung and liver 
weights. It has been shown that MCT rats have muscularization of the pulmonary arteries which 
leads to increased medial thickness and therefore PH, detectable as early as three to seven days 
after the MCT injection 350. This pulmonary arterial remodelling and cardiac alterations are 
significantly increased between day ten and fourteen after MCT injection 350. Therefore, this 
cardioprotective effect of melatonin seen in our study, means when melatonin was administered 
on day fourteen, it was able to stunt the RV hypertrophy, possibly by modulating pulmonary 
vascular pathology. In our study, the most striking effects of melatonin were seen on body 
weight, where it caused animals to not lose weight as those without treatment. This is striking, 
as even though melatonin was administered for a shorter period of time and only started when 
the disease is far progressed, it can still cease further body weight loss and reduce cachexia 
similar to the other melatonin treatment protocols. Similar effects were seen with the preventive 
melatonin treatment, where melatonin improved biometric measurements such as body weight, 
heart, lung and liver weight ratios as well as RV hypertrophy. There are a number studies that 
investigated the anti-hypertrophic effects of melatonin and possible mechanisms include the 
binding of melatonin to its receptors (MT-1 and 2), activation of anti-hypertrophic pathways and 
modulation of gene cardiac transcription 288.  
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Echocardiography and isolated heart perfusions: LV and RV function 
Both the therapeutic and preventive treatments of melatonin improved cardiac function as seen 
with echocardiography and the isolated heart perfusions. These cardioprotective effects are 
attributed to the antioxidant properties of melatonin, which may have either attenuated PH or 
directly improved cardiac function. The direct effects of melatonin on cardiac function could have 
been achieved by either directly scavenging oxygen radicals in the heart or by binding to the 
melatonin receptors which have been shown to be present on ventricular cardiomyocytes 247. 
These cardioprotective effects of melatonin were shown in hypertensive heart disease, 
ischemia/reperfusion, hyperthyroidism-induced cardiac hypertrophy and obesity associated 
myocardial dysfunction 273,294,347. In a very interesting study by Ersahin et al, melatonin reduced 
oxidative stress and cardiac tissue, pathological remodelling and improve systolic function as 
assessed with echocardiography 351. These desirable effects of melatonin on cardiac function 
were also ascribed to its antioxidant and anti-fibrotic properties. Melatonin may therefore, also 
employ similar functions in our study in order to improve cardiac function.  
 
Blood plasma oxidative stress and antioxidant capacity 
Both melatonin treatment protocols reduced plasma oxidative stress, increased antioxidant 
capacity and normalised antioxidant enzyme activities. A very important observation in the 
therapeutic protocol was that, at day fourteen, an increase in oxidative stress and a decrease in 
antioxidant capacity was already observed, while the catalase activity was increased but not the 
SOD activity. This is important, as the SOD activity does eventually increase at day 28 and the 
fact that only certain antioxidant enzymes increase their activity, may be the reason why 
oxidative damage far surpasses the antioxidant defence.  
Furthermore, one need to acknowledge that other antioxidant enzymes such as glutathione 
peroxidase or non-enzymatic antioxidant molecules such as ascorbate, alpha-tocopherol and uric 
acid can also be employed to target ROS 352,353. However, even if they did play a role in our study, 
oxidative stress is still increased which could mean that the antioxidant defence mechanisms of 
the body are not enough to counteract the damage caused by free radicals. Nevertheless, 
melatonin treatment reduced oxidative stress and normalized antioxidant status, despite the 
fact that the disease was far progressed.  
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Preventive melatonin treatment had similar effects on blood plasma oxidative stress and 
antioxidant status. A very interesting finding here was that preventive melatonin treatment also 
increased the blood plasma antioxidant capacity of the melatonin treated controls, to more than 
double the levels of control rats. This is an important observation, as it means that melatonin 
has the ability to increase the antioxidant capacity of the healthy blood plasma, which could 
potentially protect against future disease. Similar finding were generated by Piechota et al, who 
also administered 6mg of melatonin orally to healthy individuals 295. These individuals, received 
melatonin treatment for two weeks after which blood samples were collected, plasma 
antioxidant ferric reducing ability was shown to be increased. These effects of melatonin were 
maintained even ten days after discontinuation of melatonin treatment 295. On the other hand, 
this one should also be cautious about increasing antioxidant status too much, as this might also 
be detrimental 76,237.  
As mentioned previously in this dissertation, Piantadosi et al, showed that ROS plays a crucial 
role in antioxidant-induced cardiac mitochondrial biogenesis by liberating, stabilizing and 
translocation of nuclear respiratory factor-2 to the nucleus 237. Upon activation by ROS, nuclear 
respiratory factor-2 subsequently binds to multiple antioxidant-response-element motifs which 
bring about regulation of mitochondrial biogenesis, in conjunction with peroxisome proliferator-
activated receptor-gamma coactivator-1-alpha 237. Therefore suggesting that ROS may enable 
cardiomyocytes, to “sense” ROS-induced damage, employ its inherent antioxidant systems and 
counteract the damage as an adaptive response 76,237. The maintenance of an intricate balance 
between scavenging detrimental free radicals and preserving some free radicals for physiological 
stimulus remains imperative. Nevertheless, in our study, preventive melatonin treatment 
eloquently reduced oxidative stress and normalized antioxidant capacity and antioxidant enzyme 
activity in MCT rats.  
 
Cardiac interstitial fibrosis: The effect of therapeutic and preventive melatonin treatment 
Both therapeutic and preventive melatonin reduced cardiac interstitial fibrosis compared to the 
MCT rats without treatment. Our data are supported by other who showed that melatonin can 
either reduce or prevent fibrosis in models of LV hypertrophy 271,354. It is believed that the cardiac 
remodelling is dependent on the interaction between pro-proliferative neurohumoral factors 
such as catecholamines, angiotensin-II, endothelin, free radicals, cytokines or growths factors 
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and anti-proliferative factors including nitric oxide, prostacyclin, atrial natriuretic peptides or 
antioxidants 271. In a recent publication it was shown that melatonin reduced interstitial fibrosis 
in a rat model of isoproterenol induced heart failure, where the mechanisms included increased 
nitric oxide levels and reduced angiotensin-II 271. Another publication also showed that melatonin 
treatment reduced fibrosis in a rat model of L-arginine-methyl-ester (L-NAME) induced 
hypertensive heart disease 354. Here, melatonin did not affect the nitric oxide synthase 
expression and activity but completely prevented oxidative stress in the form of conjugated 
dienes in the LV. Exploring the effects of melatonin on the nitric oxide pathway in our model 
would be of interest to understand the mechanisms involved in the melatonin-induced 
modulation of fibrosis in our model.  
All the different melatonin treatments improved cardiac function with a concomitant reduction 
of oxidative stress. However, only the therapeutic and preventive melatonin treatments reduced 
interstitial fibrosis. Therefore, one cannot say that reduction of fibrosis was the main reason for 
the improved cardiac function but this reduction together with the reduction of oxidative stress 
may be the reason why we see better cardiac function and health benefit with the therapeutic 
and preventive treatments. We did not measure the cardiac interstitial fibrosis for all the 
melatonin treated MCT and control groups. This we will consider for investigation at a later stage.  
 
7. Conclusions 
In conclusion our data strongly sugggest that melatonin treatment is cardioprotective in the 
experimental model of PH by reducing oxidative stress and increasing antioxidant capacity. From 
these experiments it is clear that all three doses of melatonin conferred cardioprotection and 
6mg/kg appeared to be the most efficacious dose. Furthermore, both therapeutic and preventive 
treatment with melatonin conferred cardioprotection, reduced oxidative stress and normalized 
antioxidant capacity and antioxidant enzyme activities. Lastly, melatonin treatment also reduced 
cardiac interstitial fibrosis, which together with reduced oxidative stress may be the mechanism 
for greater benefit seen with the therapeutic and preventive interventions. The data from the 
therapeutic melatonin treatment is of particular interest as this better reflects the clinical setting 
where patients usually present with PH and RV remodelling/dysfunction. Thus, our data suggest 
that melatonin could be a possible therapy for patients who already have cardiac pathology.  
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SECTION H 
CONCLUSIONS 
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1. Summary - Conclusions 
In this present dissertation we set out to establish the presence of oxidative stress and assessed 
antioxidant capacity in patients with PH and compared these to healthy controls. We then 
validated an experimental model of PH in the Long Evans rat strain and assessed RV hypertrophy 
with biometric measurements and cardiac function with echocardiography and the isolated 
heart perfusion apparatus. Furthermore, we assessed and established blood plasma levels of 
oxidative stress and antioxidant capacity. Hereafter, we tested whether melatonin, a powerful 
antioxidant, is cardioprotective in this model of PH by testing three different doses of melatonin 
(75ng/L, 4mg/kg and 6mg/kg). Upon completion of these experiments, we administered 
melatonin either fourteen days after the induction of experimental PH (therapeutic approach) 
or five days before the induction (preventive approach). In all these experiments, we assessed 
biometric measurements, cardiac function with echocardiography or isolated heart perfusions 
and oxidative stress and antioxidative capacity with blood plasma assays.  
 
The main findings of our study: 
Section D: 
Oxidative stress in the form of lipid peroxidation was increased in the blood plasma of patients 
with PH compared to healthy controls. The antioxidant capacity of the plasma showed a trend 
towards a decrease and the antioxidant enzyme (catalase and SOD) activities were increased in 
response to the oxidative stress (Figure 121).  
 
Section E: 
We validated the MCT model of experimental PH in the Long Evans rat strain and showed the 
presence of both LV and RV dysfunction, RV hypertrophy and plasma oxidative stress. 
Furthermore, we showed this model displays plasma reduced antioxidant capacity and increased 
antioxidant enzyme (catalase and SOD) activities in response to the oxidative stress. These 
findings were the same as in the blood plasma of the PH patients (Figure 121).  
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Section F: 
In this section of the study, we tested the three different doses of melatonin and showed that all 
doses were cardioprotective by reducing RV hypertrophy, cardiac function, reducing plasma 
oxidative stress, improving antioxidant capacity and normalising antioxidant enzyme activities. 
Here we also ascertained the 6mg/kg dose as the most efficacious dose and continued further 
experimentation with it (Figure 121).  
 
Section G: 
In this last section of the study, we administered melatonin (6mg/kg) as a therapeutic and 
preventive treatment. Melatonin conferred cardioprotection, reduced oxidative stress, 
improved antioxidant capacity and normalised antioxidant enzyme activities (Figure 121).  
 
 
248 
 
 
 
 
249 
 
2. Limitations of the study 
Although commonly used, the MCT model of PH has been widely criticised in the literature and 
it has been questioned whether it truly fully models PH as observed in patients 355 324. This is due 
to the fact that the MCT toxin has other effects on the myocardium which often resembles 
myocarditis and does not develop plexogenic vasculopathy as humans with PH do. According to 
the literature, other models of PH are better options which include the rat model of sugen-5416 
plus either MCT or chronic hypoxia 333. Nevertheless, these models are not available or 
established in South Africa and because the MCT model is highly reproducible and does not 
require technical skill, it provides a perfect platform for “proof of concept” studies.  
A major limitation in our study was the low sensitivity of the echocardiography probe. We were 
not able to ascertain sufficient acoustic window to either visualize the RV properly or determine 
RV wall dimensions and filling pressures, as an echocardiography machine dedicated for animal 
use such as the Vevo 2100 (Visual Sonics) is not yet available in South Africa. Due to this, we 
could also not measure the haemodynamic measurements that are required to diagnose PH. 
These include mean pulmonary artery pressure and tricuspid valve annular plane excursion 
(TAPSE) 329.  
The use of the isolated rat heart perfusion system gave valuable information regarding the 
contractility of the heart but does not reflect changes obtained with echocardiography. This 
technique is perhaps more relevant to pathologies such as ischemia/reperfusion but not in RV 
hypertrophy due to PH.  
Another limitation in our study was that we only measured oxidative stress and antioxidant 
capacity in the blood plasma and not in the heart and lung tissue. These measurements may have 
given much more crucial information regarding the cardioprotective effects of melatonin. Also, 
we did not assess classic signalling pathways either involved in the cardiac hypertrophic response 
or pulmonary vascular remodelling that underline PH.  
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3. Future directions 
We would like to complete further investigations into the mechanisms underlining the 
cardioprotective effects of melatonin in this model. We want to treatment more animals with 
MCT and melatonin and collect heart and lung samples for immunohistochemistry analyses of 
pro-hypertrophic and prosurvival signalling pathways such as calcineurin, calmodulin, NFAT, 
STAT-3, Akt, ERK, eNOS, smad-1 – 5 and smad-8. Furthermore, we are in the process of 
purchasing a more sensitive probe for the echocardiography machine and will conduct 
experiments to assess the necessary pulmonary and RV parameters. Lastly, we would also like to 
test melatonin in the pulmonary artery banding model of RV hypertrophy. With this model, PH 
is not present but increased RV afterload is created by placing a hemoclip around the main 
pulmonary artery in the heart. These rats develop RV hypertrophy in three to four weeks and it 
will allow us to assess the direct effects of melatonin on the heart, independent of the pulmonary 
system. These experiments will allow us to further characterize the cardioprotective effects of 
melatonin treatment, especially on the RV.  
In conclusion, there are a number of treatments currently developed for PH in European 
countries but unfortunately, none of these treatments are currently available in South Africa, 
with the exception of the vasodilator sildenafil. PH is a terrible disease, with symptoms ranging 
from shortness of breath, fatigue, syncope and inability to do daily tasks such as climbing stairs 
or carrying heavy objects. Most patients in developing countries such as South Africa, are poor, 
have low income and cannot afford expensive treatments such as sildenafil and supplementary 
oxygen therapy to ease the management of the disease. Most patients, die rapidly due to the 
current absence of an effective treatment. There is thus a desperate need for new treatments 
for PH, especially treatments which are affordable and effective. Based on data from our study, 
melatonin could be used as an effective treatment for PH, if confirmed in humans/patients, as it 
evidently has a powerful cardioprotective effect and it presents the advantage of no reported 
side effects. 
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